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Abstract 
 
In the last decade, the huge decreasing of sequencing cost due to the development of high-
throughput technologies completely changed the way for approaching the genetic 
problems. In particular, whole exome and whole genome sequencing are contributing to the 
extraordinary progress in the study of human variants opening up new perspectives in 
personalized medicine. Being a relatively new and fast developing field, appropriate tools 
and specialized knowledge are required for an efficient data production and analysis.  
In line with the times, in 2014, the University of Padua funded the BioInfoGen Strategic 
Project with the goal of developing technology and expertise in bioinformatics and 
molecular biology applied to personal genomics. The aim of my PhD was to contribute to 
this challenge by implementing a series of innovative tools and by applying them for 
investigating and possibly solving the case studies included into the project.  
I firstly developed an automated pipeline for dealing with Illumina data, able to sequentially 
perform each step necessary for passing from raw reads to somatic or germline variant 
detection. The system performance has been tested by means of internal controls and by its 
application on a cohort of patients affected by gastric cancer, obtaining interesting results. 
Once variants are called, they have to be annotated in order to define their properties such 
as the position at transcript and protein level, the impact on protein sequence, the 
pathogenicity and more. As most of the publicly available annotators were affected by 
systematic errors causing a low consistency in the final annotation, I implemented VarPred, 
a new tool for variant annotation, which guarantees the best accuracy (>99%) compared to 
the state-of-the-art programs, showing also good processing times. To make easy the use of 
VarPred, I equipped it with an intuitive web interface, that allows not only a graphical result 
evaluation, but also a simple filtration strategy. 
Furthermore, for a valuable user-driven prioritization of human genetic variations, I 
developed QueryOR, a web platform suitable for searching among known candidate genes 
as well as for finding novel gene-disease associations. QueryOR combines several innovative 
features that make it comprehensive, flexible and easy to use. The prioritization is achieved 
by a global positive selection process that promotes the emergence of the most reliable 
variants, rather than filtering out those not satisfying the applied criteria.  
 
 
 
QueryOR has been used to analyze the two case studies framed within the BioInfoGen 
project. In particular, it allowed to detect causative variants in patients affected by 
lysosomal storage diseases, highlighting also the efficacy of the designed sequencing panel. 
On the other hand, QueryOR simplified the recognition of LRP2 gene as possible candidate 
to explain such subjects with a Dent disease-like phenotype, but with no mutation in the 
previously identified disease-associated genes, CLCN5 and OCRL. 
As final corollary, an extensive analysis over recurrent exome variants was performed, 
showing that their origin can be mainly explained by inaccuracies in the reference genome, 
including misassembled regions and uncorrected bases, rather than by platform specific 
errors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sommario 
 
Nell’ultimo decennio, l’enorme diminuzione del costo del sequenziamento dovuto allo 
sviluppo di tecnologie ad alto rendimento ha completamente rivoluzionato il modo di 
approcciare i problemi genetici. In particolare, il sequenziamento dell’intero esoma e 
dell’intero genoma stanno contribuendo ad un progresso straordinario nello studio delle 
varianti genetiche umane, aprendo nuove prospettive nella medicina personalizzata. 
Essendo un campo relativamente nuovo e in rapido sviluppo, strumenti appropriati e 
conoscenze specializzate sono richieste per un’efficiente produzione e analisi dei dati. 
Per rimanere al passo con i tempi, nel 2014, l’Università degli Studi di Padova ha finanziato il 
progetto strategico BioInfoGen con l’obiettivo di sviluppare tecnologie e competenze nella 
bioinformatica e nella biologia molecolare applicate alla genomica personalizzata. Lo scopo 
del mio dottorato è stato quello di contribuire a questa sfida, implementando una serie di 
strumenti innovativi, al fine di applicarli per investigare e possibilmente risolvere i casi 
studio inclusi all’interno del progetto. 
Inizialmente ho sviluppato una pipeline per analizzare i dati Illumina, capace di eseguire in 
sequenza tutti i processi necessari per passare dai dati grezzi alla scoperta delle varianti sia 
germinali che somatiche. Le prestazioni del sistema sono state testate mediante controlli 
interni e tramite la sua applicazione su un gruppo di pazienti affetti da tumore gastrico, 
ottenendo risultati interessanti.   
Dopo essere state chiamate, le varianti devono essere annotate al fine di definire alcune 
loro proprietà come la posizione a livello del trascritto e della proteina, l’impatto sulla 
sequenza proteica, la patogenicità, ecc. Poiché la maggior parte degli annotatori disponibili 
presentavano errori sistematici che causavano una bassa coerenza nell’annotazione finale, 
ho implementato VarPred, un nuovo strumento per l’annotazione delle varianti, che 
garantisce la migliore accuratezza (>99%) comparato con lo stato dell’arte, mostrando allo 
stesso tempo buoni tempi di esecuzione. Per facilitare l’utilizzo di VarPred, ho sviluppato 
un’interfaccia web molto intuitiva, che permette non solo la visualizzazione grafica dei 
risultati, ma anche una semplice strategia di filtraggio. 
Inoltre, per un’efficace prioritizzazione mediata dall’utente delle varianti umane, ho 
sviluppato QueryOR, una piattaforma web adatta alla ricerca all’interno dei geni causativi, 
 
 
 
ma utile anche per trovare nuove associazioni gene-malattia. QueryOR combina svariate 
caratteristiche innovative che lo rendono comprensivo, flessibile e facile da usare. La 
prioritizzazione è raggiunta tramite un processo di selezione positiva che fa emergere le 
varianti maggiormente significative, piuttosto che filtrare quelle che non soddisfano i criteri 
imposti.   
QueryOR è stato usato per analizzare i due casi studio inclusi all’interno del progetto 
BioInfoGen. In particolare, ha permesso di scoprire le varianti causative dei pazienti affetti 
da malattie da accumulo lisosomiale, evidenziando inoltre l’efficacia del pannello di 
sequenziamento sviluppato. Dall’altro lato invece QueryOR ha semplificato l’individuazione 
del gene LRP2 come possibile candidato per spiegare i soggetti con un fenotipo simile alla 
malattia di Dent, ma senza alcuna mutazione nei due geni precedentemente descritti come 
causativi, CLCN5 e OCRL. 
Come corollario finale, è stata effettuata un’analisi estensiva su varianti esomiche ricorrenti, 
mostrando come la loro origine possa essere principalmente spiegata da imprecisioni nel 
genoma di riferimento, tra cui regioni mal assemblate e basi non corrette, piuttosto che da 
errori piattaforma-specifici.  
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1. Introduction 
 
1.1.  A survey on sequencing: 40 years of development 
1.1.1.  First Generation Sequencing 
Nucleic acid sequencing is a powerful technique developed for solving the specific order of 
nucleotides within a DNA or RNA molecule, which have met the interest of many branches 
of medicine and biology. Although several methodologies had already been proposed at 
that time [1–3], the advent of sequencing can be found in the middle of the 1970s, when 
Maxam and Gilbert (1977) [4] and Sanger and Coulson (1975) [5] proposed in parallel two 
different sequencing approaches, called the “chemical sequencing method” and the “chain-
termination method”, respectively.  
Briefly, in the first system, DNA fragments were labelled with a radioactive compound 
(usually ɣ-32P) at one 5’ end and then purified. The following chemical treatments triggered 
to a partial modification of the bases causing specific pattern of cleavage, depending on the 
chosen reaction (G, A+C, C, C+T). The obtained marked DNA chunks were separated by 
electrophoresis and revealed using autoradiography. The sequence could be deduced from 
presence and absence of specific fragments [6].  
Instead, the chain-termination approach, also called Sanger sequencing, was based on DNA 
elongation, mediated by DNA-polymerase, which was blocked when a modified di-
deoxynucleotidetriphosphates (ddNTPs) was incorporated. In this way, four parallel 
reactions, in which only one of the four radiolabeled-ddNTPs (ddATP, ddCTP, ddGTP and 
ddTTP) was added, were enough to easily obtain all fragments, necessary to inferred the 
sequence, after their electrophoresis on a thin acrylamide gel and corresponding bands 
revelation by autoradiography [7, 8].  
Although at the beginning chemical sequencing had become more popular, since purified 
DNA could be directly handled, it was soon replaced by the Sanger sequencing, as it was less 
hazardous, less complex and more scalable, so resulting more prone to be automatized and 
scaled up [9]. In particular, the advent of capillary electrophoresis for DNA separation [10, 
11] and the introduction of fluorescent ddNTPs (dye-terminator sequencing) [12] allowed to 
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sequence DNA in a single reaction, boosting the speed and simultaneously dropping the 
costs.  
In this way, the automated Sanger sequencing became the gold standard of the first 
generation sequencing (FGS) methods, dominating the scenario for more than two decades 
and leading to extraordinary progresses in life sciences, including the publication of an initial 
draft [13, 14] in 2001 and then the complete sequence of the human genome in 2004 [15]. 
Nevertheless, the Human Genome Project (HGP), which at that time was the largest 
collaborative biological project, had also elucidated the limitations of FGS, highlighting in 
particular two huge aspects: the time spent (~13 years), directly linked to the low 
throughput, and the costs (US$3 billion) [16]. These problems were widely discussed by 
scientific community, identifying the urgency of decreasing the cost of DNA sequencing in 
order to reach the goal of $1000 for a genome. For this purpose, in 2004 the National 
Human Genome Research Institute (NHGRI) began to fund projects focused on the 
development of new technologies capable of reducing by four to five orders of magnitude 
the sequencing expenditure, committing more than $100 million to 50 research teams [17]. 
 
1.1.2. Second Generation Sequencing 
The request of faster and cheaper sequencing approaches triggered the development of 
second-generation sequencing (SGS) methods, referred also as next-generation sequencing 
(NGS). NGS has overcome Sanger sequencing through at least three substantial 
improvements: first, the huge increasing of the throughput, thanks to the parallelization of 
sequencing reactions which allow the concurrent reading of millions of DNA fragments 
belonging to a single sample; second, the dramatic reduction of the sequencing cost, 
directly linked to the massive parallelization; and third, the drop of the required sequencing 
time, as bacterial cloning was replaced by library preparation and the output detection, 
performed cyclically and in parallel, has become direct, thus avoiding the electrophoresis 
step. On the other hand, the big number of produced reads and their relatively short length 
raised novel issues mainly regarding data analysis and data interpretation, constituting the 
pitfalls of NGS technologies [16–18]. 
The NGS revolution began in 2005 with the commercialization of Roche 454’s 
pyrosequencing method, directly followed by the appearing on the market of the 
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Solexa/Illumina Genome Analyzer platform based on the sequencing-by-synthesis approach 
in 2006 and the Sequencing by Oligo Ligation Detection (SOLiD) system released by Applied 
Biosystems (now Life Technologies) in 2007. The last SGS method was proposed in 2010 by 
the Ion Torrent (now Life Technologies) through the sale of the Personal Genome Machine 
(PGM) based on the semiconductor sequencing [16–19].  
The different kinds of platform have shown several innovations not only in the way in which 
the sample is sequenced, but also in how the templates should be prepared. The specific 
aggregation of the various protocols allows to discriminate one technology from another 
and it directly influences also the type of data produced. All the previously mentioned SGS 
platforms require an initial step of template preparation, where DNA is randomly broken 
into small sizes and common adaptor sequences are added to generate either mate-pair 
templates or fragment templates. This cell-free system has the advantage of avoiding the 
arbitrary loss of genomics portions, typical of cloning-based procedures [20, 21]. The 
templates are usually fixed or blocked on a support in order to be spatially separated, 
allowing in this way the simultaneous execution of a huge number, from thousands to 
billions, of sequencing reactions [21]. The sequencing is preceded by an amplification step 
where several copies of each template are generated, forming clusters: this passage is 
necessary as the majority of detectors have been designed to collect multiple fluorescent 
signals, but at the same time it permits a high signal magnification. Solid-phase amplification 
(i.e. bridge PCR, solid-phase PCR, asymmetric solid phase PCR) (Figure 1B) [22] and emulsion 
PCR (emPCR) (Figure 1A) [23] have been the two most chosen protocols for clonally 
amplified template preparation [21], even if other methods such as in situ polonies [24], in 
situ rolling circle amplification (RCA) [25, 26], and picotiter PCR [27] have been proposed 
[28].  
Bridge PCR (Figure 1B) is the solid-phase amplification protocol integrated in its sequencers 
by Illumina, which is applied to create on a slide a series of randomly spread, clonally 
amplified clusters derived from both fragment and mate-pair templates. The slide is coated 
with a certain density of forward and reverse primers attached to the surface at their 5’ 
ends through a flexible linker. When a ssDNA template is added, it binds one kind of adaptor 
blocked on the surface, which is then elongated by polymerase creating a double-stranded 
DNA (dsDNA). The dsDNA is denatured and the original template is washed away. The 
remaining strand, which now contains on the top the second type of adapter, bends over 
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and hybridizes to a complementary oligonucleotide on the flow cell. The synthesis of the 
complementary strand creates a dsDNA bridge which results, after denaturation, in two 
single stranded copies of the molecule, that are tethered to the slide. The process is then 
repeated several times and it occurs concurrently for millions of clusters, triggering to the 
clonal amplification of all the fragments. Each cluster contains an average of 1000 copies of 
a single member of the library. To avoid overcrowding and to maximize the cluster density, 
it is necessary to accurately measure the concentration of the starting template library [16, 
19–21, 29–31].  
A 
 
B 
 
Figure 1|Common template immobilization 
strategies for NGS systems. A|EmPCR 
begins with the creation of an oil–aqueous 
emulsion to encapsulate bead–DNA 
complexes into single aqueous droplets. PCR 
is performed to amplify the template within 
these droplets and finally beads are 
attached to a glass slide. B|Solid-phase 
amplification requires two basic steps: initial 
priming and extending of the denatured 
template (ssDNA), and amplification via 
bridge PCR of the immobilized template 
with immediately adjacent primers for 
forming clusters. Figures adapted from [22]. 
On the other hand, emPCR (Figure 1A) is adopted by almost all other platforms, including 
SOLiD, Ion Torrent and Roche/454. In this method, NGS library is captured on micron-scale 
beads, tethering on the surface one of the PCR primers linked via the 5’ end [20, 21, 32]. 
Theoretically, each bead should host only one fragment if the template concentration is 
correctly established. However, due to the usual low template concentration chosen, it is 
more frequent having the formation of unbounded beads, which then will be unproductive 
PCR reactors, rather than obtaining multi-bounded particles, associated with by-products 
production [33]. A water-in-oil emulsion including PCR reagents and one bead per droplet is 
generated to amplify each template individually, producing up to 107 copies per bead [31, 
32]. The dsDNAs, formed after PCR, are denatured and the emulsion is then broken, in order 
to distribute each bead in a single well of a fiber-optic slide (Roche/454, Ion Torrent) or on a 
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glass surface (SOLiD). Each bead carries on its surface the amplification products deriving 
from only one fragment of the library [16, 20, 32, 34]. 
The NGS library preparation has surely overcome the cloning methods applied in FGS. 
However, it is not free from biases, which are mainly derived from the step involving the 
PCR process. To improve the yield of PCR, various adjustments have been performed 
including a deep assessment of the less noisy DNA polymerases and the best conditions at 
which they work [35]. Instead, to reduce the losing of sample, some specific protocol which 
integrates DNA fragmentation, end-polishing and adaptor-ligation in a single reaction, as in 
the Nextera technology [36], have been developed. These progresses directly influence the 
amount of DNA required: currently, few nanograms of starting material are enough for 
completing the whole sequencing process [37].  
Although different approaches for sample preparation have been proposed, the main 
differences among the SGS platforms can be appreciated at the sequencing level. Here, I will 
describe only the four methods (Roche/454 pyrosequencing, Ion Torrent semiconductor 
sequencing, SOLiD sequencing-by-ligation and Illumina sequencing-by-synthesis) implement 
in the most widely spread sequencers (Figure 2); however, other methodologies such as the 
combinatorial probe anchor ligation (cPAL) sequencing, exploited by the Polonator G.007 of 
Complete Genomics [26], and the single molecule sequencing  (SMS), adopted by the 
HeliScope of Helicos BioSciences [38], have found a remarkable interest not only in the 
scientific community, but also on the market [30].  
Pyrosequencing technology (Figure 2A) is the methodology used by Roche/454 sequencers 
[32]. It is a non-electrophoretic, bioluminescence method. The DNA polymerase derived 
from Bacillus stearothermophilus and a single-stranded binding protein are preincubated 
together with the beads coated with the amplified template, produced after the emPCR. 
The solution is then deposited on a PicoTiterPlate (PTP) in order to have only a single bead 
within each well. Wells are also loaded with smaller beads bearing the other enzymes 
necessary for the reactions (ATP sulfurylase and luciferase) and with the remaining 
reagents, including primer, luciferin and adenosine 5’ phosphosulfate (APS). The PTP wells 
are exposed on the top to the flow of 2’-deoxyribonucleoside-triphosphate (dNTPs), while 
on the bottom they are linked to a fiber-optic bundle which is directly bound to a high-
resolution charge-coupled device (CCD) camera. 
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A 
  
B 
C 
 
 
D 
Figure 2|NGS sequencing approaches. A|Pyrosequencing used by Roche/454 platforms. The incorporation 
of a known dNTP causes the release of a PPi which is converted by sulfurylase into ATP, using APS. Luciferin 
consume ATP, producing a burst of light, detected by a CCD camera. The signal is proportional to number of 
dNTPs incorporated. As the dNTP added at each cycle is known, the template sequence can be established. 
B|Sequencing by ligation used by SOLiD platforms. Labeled octamers, whose fluorochrome changes 
depending on an internal dinucleotide (interrogation bases), are ligated to the primed-template by a DNA-
ligase. Signal is detected and the last three nucleotides chemically cleaved. Other cycles are performed until 
the end of the sequence. The extended primer is then stripped and four more ligation rounds are 
performed, changing the initial reading position (n-1). C|Sequencing by synthesis used by Illumina 
platforms. Primers annealed to the immobilized templates are elongated using four different fluorescent 
reversible terminators. The propagation of polymerization is inhibited by the blocking element, which is 
removed and washed away together with the dye after the image acquisition, allowing the incorporation of 
a further nucleotide. D|Semiconductor sequencing used by Ion Torrent platforms. The method is really 
similar to pyrosequencing, but a changing in pH is detected by a transistor (pHFET), when a nucleotide is 
incorporated. Figures A, B, C adapted from [21], D from [39]. 
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This apparatus permits the detection of the light emitted by the PTP wells after the 
pyrosequencing reaction [20, 21, 30]. The latter begins when a dNTP is incorporated on the 
complementary strand of the template, causing the release of an inorganic pyrophosphate 
(PPi). PPi is combined with APS by sulfurylase producing ATP, which is used by luciferase to 
convert luciferin in oxyluciferin, triggering to the emission of a burst of light [40]. The flash is 
detected by the CCD, recording the coordinate of the specific well and the intensity of the 
signal: the peak height will be proportional to the number of nucleotides incorporated [41]. 
The free dNTPs are degraded by apyrase and the by-products washed away. Then, another 
dNTP is added into the flow cell repeating the pyrosequencing reaction. As the nucleotide 
added at each cycle is known, the sequence of the template can be established [19, 40]. 
The semiconductor sequencing (Figure 2D) can be seen as an improvement of 
pyrosequencing, because the chemistry of the sequencing reaction is very similar, but the 
signal detected regards the release of a proton (H+) instead of a pyrophosphate when a 
nucleotide is incorporated [16]. Nevertheless, semiconductor sequencing, proposed by Ion 
Torrent division of Life Technologies, differs from the other SGS platform as it has replaced 
the use of the complex optical systems based on CCD cameras with an ion-sensitive field 
effect transistor (ISFET), working as pH field effect transistor (pHFET), produced using 
standard complementary metal-oxide-semiconductor (CMOS) processes [34]. The 
introduction of such type of chip putting sequencing definitely into the framework of 
Moore’s Law, to the extent that the Ion Torrent chips have been classified by the 
International Technology Roadmap for Semiconductors (ITRS) as “More-than-Moore”, 
because they have proposed a “functional diversification” to the original applications of 
CMOS chips [39]. To have a briefly focus on the chemistry, the amplicon-bearing beads are 
distributed on 3.5 µm diameter wells, specifically designed to host at maximum a single 
bead. dsDNA is denatured, then primed and finally loaded with the DNA polymerase [34]. A 
first trial solution containing one type of dNTP flows over the wells. If the dNTP is 
complementary to the template sequence, it will be incorporated causing a release of a 
pyrophosphate and a H+, which triggers to a pH changing (ΔpH = 0.02). Such variation is 
detected by pHFET, converted to a voltage and digitized [39]. Otherwise, no pH 
modifications are collected when the nucleotide is not incorporated. After each trial flow, 
unbound dNTPs and by-products are washed away. A different dNTP is then made flowing 
and the process is repeated until all the templates are sequenced. When homopolymeric 
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(HP) tracts are present, more than one nucleotide is incorporated by polymerase, causing an 
higher release of H+ ions. The associated amplitude of the incorporation signal is applied to 
evaluate the length of HP region [34]. As for the pyrosequencing, this kind of estimation 
constitutes the greater source of error, even if other biases related to the sequencing of AT-
rich genomes have been reported [42]. The magnitude of these problems seems to be 
reduced after the introduction of new chips and the improvements of PCR chemistry and 
base-calling software.  
Another method preceded by emPCR is the sequencing-by-ligation (Figure 2B) developed for 
the SOLiD platforms [28, 43]. It is driven by a DNA-ligase, rather than the polymerase [44]. 
The first step of the ligation-based sequencing corresponds to the hybridization of a 
universal primer, exposing a free 5’-PO4, to the SOLID-specific adaptors, which are captured 
on the surface of paramagnetic beads and linked to the template molecules [20, 45]. Each 
cycle of the process involves the ligation of a degenerate octamers population, which 
contains a ligation site (first nucleotide), a cleavage site (phosphorothiolate linkage between 
fifth and sixth nucleotides), a fluorescent dye attached to the eighth nucleotide, and 
inosines in the last three positions to reduce the probe complexity [21]. The color of the dye 
depends on the sequence of a specific dinucleotides (interrogation bases) which can 
correspond to the first two nucleotides or nucleotides in position 4 and 5, depending on the 
cycle number [45]. After the ligation of the proper probe (interrogation bases must be 
complementary to template) and the signal detection, a cleavage step mediated by silver 
ions [43, 45] removes the last three nucleotides and consequently also the fluorophore, 
enabling a subsequent round of ligation. The process of probe ligation is repeated more 
times in order to reach the end of the template and it triggers to the reading of a certain 
combination of dinucleotides. The synthesized reads are removed by denaturation and 
washed away. A further lap of sequencing starts with the hybridization of a second universal 
primer in position n-1, followed by another cycle of probes ligation. Five ligation rounds 
allow to complete the reading of the whole template. Although the method is quite slow, 
the accuracy is really high, as each base of the template is read twice (2 base encoding), 
allowing an easier identification of miscalling [20, 45]. 
The last SGS technology discussed in this section is the sequencing-by-synthesis (Figure 2C) 
approach implemented by Illumina, which is based on the four-color cyclic reversible 
terminator (CRT) chemistry [29]. After bridge PCR, the several million clusters, each 
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containing ~1000 copies of the same fragment, represent both the forward and the reverse 
strand of the template. To prevent issues derived from steric hindrance or from unintended 
complementary base pairing, one of the two strands (usually reverse) is removed exploiting 
the different adaptor by which the templates are kept on the slide [30]. Linearized 
amplicons are primed exploiting the adaptor located at the top of the template and then 
loaded with a mutant DNA polymerase, able to incorporate modified nucleotides. The latter 
are called 3’-blocked reversible terminators, because their 3’-OH end is protected by a 
blocking element [46], as for example the 3’-O-allyl [47] or the 3’-O-azydomethyl [29, 48], 
linked via an etheric bond. This group inhibits the propagation of the polymerization, but at 
the same time it should be easily cleaved by chemical agents, after the signal detection. 
Reversible terminators present also a fluorescence dye connected to the base. Such 
modification, in addition to the possibility to be removed, does not have to hugely modify 
the base structure, in order to keep its capability to be recognized by DNA polymerase [46]. 
Sequencing process begins when a mixture of four labelled nucleotides flows over the slide. 
Primers bound to the template are extended by only a single-base, thanks to the presence 
of termination group, while the remaining unincorporated nucleotides are washed away. 
The image acquisition is performed using a CCD camera and two lasers, which are able to 
excite couples of nucleotides (A/C and G/T), allowing the correct base recognition through a 
set of optical filters, working on emission spectra. After imaging, both groups, the 
terminator and the dye, are chemically cleaved. Finally, a further step of washing is carried 
out, before starting another CRT cycle. The number of cycles depends on the desired read 
length, which depends on the way in which the library was built [20, 21, 29, 31]. When the 
first strand is completed, few bridge PCR cycles are performed for second strand synthesis 
(usually reverse). The first strand is then removed and the second strand is sequenced. This 
approach is called “paired-end” sequencing and it is widely used also by other technologies, 
even if it is extensively applied by Illumina sequencers [30].  
 
1.1.3. Third Generation Sequencing 
Nowadays, the SGS technologies are still dominating the sequencing market, even if in the 
last decade a variety of new systems overcoming in many aspects the NGS methods have 
been proposed [49]. This new category of platforms has been classified as third generation 
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sequencing (TGS) because they promised higher throughput, shorter run time (real time 
detection), smaller quantities of starting material (theoretically a single molecule), longer 
reads (several Kb), higher consensus accuracy for rare variant discovery and, finally, lower 
cost, reaching the goal of a high coverage genome for less than $100 [50].  
Currently, none method has achieved all these targets. In addition, for a couple of 
platforms, it is even difficult to understand if they should be included into SGS or into TGS 
group. Among these transitioning technologies, Ion Torrent and HeliScope devices are the 
two main examples [50]. In fact, the first one has removed the need of scanning system 
thanks to the introduction of the CMOS pHFET chip; otherwise it still requires PCR for the 
initial amplification and the washing of byproducts between one cycle and the following 
[34]. The HeliScope instead has been the first system based on SMS, but the use of virtual 
terminators nucleotides, whose dyes have to be cleaved after the signal detection, heavily 
influences the speed of sequencing [38].  
Nevertheless, in the TGS technologies, all such platforms able to perform fast SMS in real-
time, could be included. They can be divided into three approximate categories [50]: 1) 
direct observation of single DNA molecules through cutting edge microscopy systems, as for 
example the aberration-corrected scanning transmission electron microscopy (TEM) [51] or 
the scanning tunneling microscope (STM) [52]; 2) single molecule real-time SBS, where the 
processing of DNA polymerase is detected, exploiting the zero-mode waveguide (ZMW) 
technology [53] or the fluorescence resonance energy transfer (FRET) [21, 54]; 3) nanopore 
sequencing [49].  
The two most successful TGS methods can be found in the last two groups, corresponding to 
the single-molecule real-time (SMRT) sequencing, developed by Pacific Biosciences (PacBio) 
and the nanopore sequencing, proposed by Oxford Nanopore Technologies (ONT). Both 
systems still require a library preparation which is usually quite simple to prepare and not 
time-consuming. The PacBio template is called SMRTbell (Figure 3A) and it consists in a 
single stranded circular DNA, produced by ligating hairpin adaptors, which provide the 
primer binding site, to both ends of a dsDNA fragment [55]. The nanopore template 
preparation (Figure 3B), instead, requires a common genomic DNA fragmentation, followed 
by end-repairing and dA-tailing to add an adenosine to 3’ end of the fragment. Then two 
adaptors are ligated: the leader adaptor, also referred as “Y adaptor” for its “Y” shape, 
where the sequencing process begins, and the “HP adaptor” with a hairpin-like structure, 
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binding site of the hairpin protein. Finally, a purification step using His-beads is performed 
for removing nucleotides and enzymes. To allow a 2D base calling, before loading the library 
is briefly incubates (30 min) with the motor protein and the HP [56].   
A 
 
B 
 
Figure 3|Template preparation for 
TGS systems. A|PacBio SMRTbell 
template. Circular ssDNA is created 
by ligating hairpin adaptors to both 
ends of a dsDNA fragment. Adaptors 
provide primer binding site. 
B|Nanopore template preparation 
starts with a common genomic DNA 
fragmentation, followed by end-
repairing and dA-tailing. Two 
adaptors, the “Y adaptor” and the 
“HP adaptor”, are then ligated. A 
final purification step using His-beads 
is performed. A further incubation 
with the motor protein and the HP 
allows a 2D base calling. Figure A 
adapted from [57], B from [56]. 
In the PacBio SMRT sequencing (Figure 4A), when the SMRTbell library is ready, it is loaded 
into a chip, named SMRT cell. Each SMRTbell diffuses into a nanophotonic structure, the 
zero-mode waveguide (ZMW), which constitutes the smallest available volume for light 
detection [57]. On the bottom of each ZMW, a single molecule of engineered Φ29 DNA 
polymerase, chosen for its favorable properties [58], is bound using streptavidin/biotin 
interaction. When all polymerases are loaded with primed SMRTbell, a mixture of four 
different colored γ-labeled phospho-nucleotides, generating distinctive spectra, are flowing 
within the SMRT cell [53]. The structure of ZMW does not allow laser light penetration along 
the hole, avoiding the excitation of labeled nucleotides during their migration, unless it 
diffuses through the bottom 30 nm of the ZMW. Nevertheless, as the diffusion is really fast 
(µs), the emitted fluorescence results in a signal background [21]. Instead, when the right 
nucleotide is incorporated by DNA polymerase, it is blocked over the laser light for a longer 
time (ms), creating a high signal-to-noise ratio, which is distinctly detected as a pulse. The 
released labeled byproduct rapidly diffuses far [21, 50]. As soon as the next cognate 
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nucleotide reaches the polymerase binding site, the subsequent pulse is recorded. Thanks to 
the SMRTbell circular structure and the high processivity of polymerase, both strands of the 
fragment can be sequenced several times, producing a continuous long read (CLR), which is 
finally splitted in subreads after the adaptors recognition [57].    
Differently from PacBio, Oxford Nanopore technology does not apply any imaging systems 
to detect nucleotide incorporation. This process is revealed by measuring a change in the 
ion current when DNA passes through a pore (Figure 4B) [59]. The system is constituted by a 
lipid double layer, necessary to separate the different concentrations of KCl between the 
two sides of the membrane, where an engineered staphylococcal α-hemolysin protein pore 
is also inserted. The protein pore modifications not only regard some amino acidic 
substitutions in the heptamers (M113R/N139Q)6(M113R/N139Q/L135C)1, but also the 
covalent ligation within the barrel structure of a complex β-cyclodextrin (am6amPDP1βCD), 
working as sensor for base detection [60]. The sequencing process starts when the motor 
enzyme, usually a polymerase or a helicase, loaded with the DNA is attracted towards the 
pore by the application of a voltage on the two Ag/AgCl electrodes [61]. The motor enzyme, 
Φ29 DNA polymerase, provides multiple functions, as in addition to the DNA carrier activity 
it is also able to separate the two strands of the loaded DNA, regulating in this way the 
speed of DNA translocation through the pore. The latter feature is fundamental, because if 
the zip opening is too fast, the nucleotide reading could not be performed [62]. Once 
reached the top of the pore, the motor enzyme begins to unzip the dsDNA, causing the DNA 
translocation into the pore. When the nucleotide approaches the sensor, a perturbation in 
the current is measured, whose pattern and magnitude are used to decodify the base. Thus, 
the data streams are elapsed to a microchip named the application-specific integrated 
circuit (ASIC) and finally processed by the MinKNOW software [56, 63]. Thanks to the 
introduction of HP into the protocol, the complementary strand can also be sequenced, 
triggering to a 2D base calling. In this way, the information of both strands is included 
allowing a higher base quality [56].  
Since the beginning the nanopore technology raised enthusiastic interest in the scientific 
community. For this reason, a lot of work has been recently done in order to exploit new 
kind of pores, not only biological (α-hemolysin [60], MspA [64], Φ29 [65]), but also solid-
state nanopores or nanogap electrodes [66]. In particular, the solid-state pores can be 
manufactured in a wide range of shape and size, offering also the compatibility with CMOS 
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technology and thus a great cost reduction, due to the industrial scalability [67]. So, the 
significant improvements achieved have greatly simplified the experimental process, 
allowing the diffusion of these new nanopore technologies in many fields of DNA 
sequencing, creating a perspective for a rapid and low-cost fourth-generation DNA 
sequencing methods [66]. 
A 
 
B 
 
Figure 4|TGS sequencing approaches. A|SMRT 
sequencing used by PacBio platforms. The reduced 
observation volume of ZMW allows the entrance of 
a small number of stray fluorescently labelled 
molecules, limiting the background signal. When a 
modified nucleotide is incorporated by the 
anchored DNA polymerase, the dye remains near 
the bottom of the well for a longer time, causing the 
detection of a fluorescence pulse. The signal type is 
used for distinguishing the various nucleotides. 
B|Nanopore sequencing used by Oxford Nanopore 
platforms. When the motor enzyme reclines on the 
top of the pore, it starts to denature the dsDNA, 
causing the entrance of a strand into the hole. The 
perturbation of the ion current, whose pattern and 
magnitude are used to decodify the base, is 
detected by a sensor within the pore and is 
transmitted to the ASIC microchip. Figure A adapted 
from [21], B from [49]. 
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Platform Generation Library Template 
preparation Chemistry Time/run 
Read 
Length 
Read 
Number 
Output 
(Gb) Output Type Pros Cons 
Biological 
Application 
Release 
Date 
Sanger 3730xl 1 Frag PCR, cloning Dideoxy chain 
terminator 20 m - 3 h 
400 bp - 
900 bp - 
1.9 - 84 
Kb Chromatogram 
High quality, 
long reads, low 
cost for very 
small studies 
Low 
throughput, 
very high cost 
for large data 
amount 
Mutation 
detection, 
NGS 
validation 
2002 
Roche/ 454’s 
GS FLX 
Titanium 
2 Frag, MP emulsion PCR Pyrosequencing 24 h 
400 bp 
up to 
1000 bp 
1 M 0.7 
Standard 
Flowgram 
Format (SFF) 
Longer reads 
than other SGS 
High error rate, 
high cost of 
reagents, low 
throughput, no 
support since 
2016 
Small 
genomes 
assembly 
2009 
SOLiD 5500xl  2 Frag, MP, 
PE emulsion PCR 
Sequencing by 
Ligation 
1 w for frag, 
2-3 w for 
MP and PE 
1 x 75 bp 
Frag, 2 x 
50 bp for 
MP & PE 
1.2-1.4 G ~160  eXtensible 
SeQuence (XSQ) 
High accuracy 
due to double 
reading of each 
base, high 
throughput 
Short reads, 
long run times, 
almost retired 
small WGS, 
WES, 2010 
Illumina 
MiSeq 2 PE 
solid-phase 
bridge-PCR 
Sequencing by 
synthesis 4-55 h 
2 x 300 
bp 25 M 15 
Binary Base Call 
(BCL) 
Moderate cost 
instrument and 
per Mb, fast, 
longest Illumina 
read lengths 
Relatively few 
reads and 
Higher cost per 
Mb compared 
to NextSEq or 
HiSeq 
Targeted 
sequencing, 
16S 
metagenomic
s, small WGS 
2011 
Illumina 
NextSeq 2 PE 
solid-phase 
bridge-PCR 
Sequencing by 
synthesis 12-30 h 
2 x 150 
bp 400 M 120 
Binary Base Call 
(BCL) 
Easy to use, 
moderate 
instrument and 
run costs 
Version 2 of 
new chemistry 
not yet as good 
as older 
chemistry 
small WGS, 
WES, WTS 2014 
 
Illumina 
HiSeq 4000 2 PE 
solid-phase 
bridge-PCR 
Sequencing by 
synthesis 24 – 84 h 
2 x 150 
bp 5 G 1500 
Binary Base Call 
(BCL) 
Low cost per 
read and per 
MB 
High instrument 
cost, high cost 
per run, 
requires highly 
trained 
personnel  
WES, WTS 2015 
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Illumina 
NovaSeq 
6000 
2 PE solid-phase 
bridge-PCR 
Sequencing by 
synthesis 19 – 40 h 
2 x 150 
bp 20 G 6000 
Binary Base Call 
(BCL) 
Most powerful 
Illumina 
sequencer, very 
high 
throughput, 
current lowest 
cost per read or 
per MB  
High instrument 
cost, high cost 
per run, 
requires highly 
trained 
personnel, high 
data storage  
Large WGS, 
WES, WTS, 
methylation 
sequencing 
2017 
Ion Torrent 
PGM 2 Frag emulsion PCR 
Semiconductor 
sequencing 
4.4 h /  
7.3 h 
200 bp / 
400 bp 4-5.5 M 
0.6 - 1 / 
1.2 - 2 
Binary sequence 
Alignment Map 
(BAM) 
Low cost 
instrument, 
three chips 
available, very 
simple machine  
More hands-on 
time and fewer 
reads at higher 
cost per Mb 
relative to 
MiSeq 
Targeted 
sequencing,1
6S 
metagenomic
s, small WGS 
2010 
Ion Proton 2 Frag emulsion PCR Semiconductor 
sequencing 2 - 4 h 200 bp 60-80 M 10 
Binary sequence 
Alignment Map 
(BAM) 
Moderate cost 
instrument for 
medium 
throughput 
applications, 
fast run times 
More hands-on 
time and fewer 
overall bases of 
data than 
Illumina, smaller 
user community 
small WGS, 
WES, WTS 2012 
Ion S5 2 Frag emulsion PCR Semiconductor 
sequencing 
2.5 h / 
4 h / 
4 h 
200 bp / 
400 bp / 
600 bp /  
60-80 M 
3 - 4 / 
6 - 8 / 
1.5 - 4.5 
 
Binary sequence 
Alignment Map 
(BAM) 
Cost-
competitive vs. 
MiSeq and 
potentially 
NextSeq, fast 
run times 
More hands-on 
time and fewer 
reads at higher 
cost per Mb 
relative to 
MiSeq 
small WGS, 
WES, WTS 2015 
Oxford 
MinIon 3 Frag 
Single 
molecule 
Real Time 
Sequencing 1 m - 48 h 
10 kb up 
to 1 Mb 4.4 M 40 FAST5 
Portable 
instrument, USB 
device, 
extremely low-
cost instrument, 
extremely long 
reads 
High cost per 
read, quite high 
error rate 
de novo 
genome 
assemblies, 
WTS, 
structural 
variations 
discovery  
2015 
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Oxford 
PromethION 
(48 Flow 
Cells) 
3 Frag Single 
molecule 
Real Time 
Sequencing 1 m - 48 h 
10 kb up 
to 1 Mb 1.25 G 11000 FAST5 
Very high 
throughput, 
extremely long 
reads 
Similar to 
MinION, 
available only 
joining the 
PromethION 
Early Access 
Programme 
Large WGS, 
WES, WTS, 
epigenetics, 
CNV, 
structural 
variations 
discovery  
2017 
PacBio RS II 
(16 SMRT 
cells) 
3 Frag Single 
molecule 
Real Time 
Sequencing 8 h - 96 h > 20 kb 0.9 M 16 HDF5 
Extremely long 
reads, ability to 
detect base 
modifications, 
short run time, 
random error 
profile  
High error rates 
at high 
coverage, low 
total reads 
number, high 
cost per Mb, 
high capital cost  
de novo 
assemblies, 
WGS, WTS, 
haplotype 
detection, 
methylation 
profiles 
2013 
PacBio Sequel 
(16 SMRT 
cells) 
3 Frag Single 
molecule 
Real Time 
Sequencing 8 h - 160 h > 20 kb 5.84 M 120 HDF5 
Similar to RSII 
but with lower 
cost 
High cost per 
Mb and per 
read relative to 
other platforms 
de novo 
assemblies, 
WGS, WTS, 
epigenetic 
detection 
2015 
Table 1|Sequencing platforms comparison. Technical information, advantages, drawbacks and biological applications of the most diffused sequencing platforms are reported. Frag: 
fragment; MP: mate-pair; PE: paired-end. 
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1.1.4. Application and comparison of high-throughput sequencing 
technologies 
Clear differences among the various series of the sequencing technologies are appreciable, 
in particular regarding costs, limitations and advantages [20]. Considering these three 
features is necessary for designing the experimental flow in order to choose the best 
sequencer for achieving the planned objectives. For this purpose, a detailed comparison 
among the several platforms now available on the market or which have covered an 
important role in the NGS revolution is reported in Table 1. For example, the Sanger 
sequencing is yet confined to small projects, where few kilobases have to be analyzed, or 
thanks to its high accuracy it can be applied to mutation detection on a specific gene or 
more frequently to validate a variation found using NGS methodologies. The latter can be 
used for a various range of applications, although the heavy differences regarding 
throughput and read number between small benchtop platforms (Illumina MiSeq or Ion 
Torrent PGM) and the most powerful sequencers (Illumina NovaSeq and Illumina HiSeq) 
directly influence the main usage of the machinery. The NGS platforms have found use in 
variant discovery, metagenomics, transcriptomics and small RNA analysis, epigenetics and 
chromatin immunoprecipitation sequencing (ChIP-Seq) and finally small genome assembly 
[21]. In particular, the genome resequencing for the comprehensive polymorphisms and 
variant discovery in human genomes has been probably the most successful NGS 
application, due to its direct implication on the study of genetic diseases. At the same time 
in these projects, also the human DNA variability was evaluated, triggering to the 
development of population allele frequency databases, such as ExAC [68], ESP6500 [69] or 
dbSNP [70], exploited by clinicians and geneticists to understand if mutations under analysis 
are rare or not.  
Remaining in the field of human genetic variation detection, it is important to notice that 
although the sequencing cost has fallen very fast in the last decade, when high coverages 
are required, the whole genome sequencing (WGS) could still be too expensive [71]. Thus, 
as the majority of Mendelian diseases are associated with mutations in the coding regions 
[72], in many cases WGS can be replaced by the whole exome sequencing (WES), where 
only exons are analyzed. This method is cheaper than WGS, as the region covered is near to 
1.5% of the entire genome [18], but it requires an intermediate step where exons are 
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extracted from the whole DNA sequence, referred as target enrichment. A lot of work has 
been performed to optimize the enrichment process, for achieving the best values of 
sensitivity, specificity, uniformity, reproducibility and design coverage [73]. The nature of 
the mechanism involved in the process is used to separate the current techniques, dividing 
them into three groups [74]: I) hybrid capture, where the sample DNA is hybridized with 
specific probes, complementary to the target region, either in solution or on a solid support, 
allowing the physical capturing and the following purification of the sequences of interest 
[75]; II) molecular inversion probes (MIP) or selective circularization, where universal ssDNA 
molecules incorporating on their edges segments complementary to the boundaries of the 
target regions are firstly hybridized against sample DNA, then gap-filled and finally ligated, 
resulting in circularized DNA molecules containing the target sequence in addition to other 
features useful for downstream analyses [76]; III) PCR amplification, where a huge number 
of couple of primers (up to 20000) is designed to amplify specific target regions through a 
highly multiplexed PCR [34].  
The same enrichment techniques can be applied for targeted sequencing, where a limited 
set of genes (gene panel) or genomic regions are taken into account. This approach 
guarantees very high coverages (>1000X) at affordable costs and should be the first choice 
for studying disorders in which a middle heterogeneity is recognizable [77]. Gene panels for 
analyzing variants in patients affected by cardiomyopathy [78, 79], lysosomal storage 
disease [80] and epilepsy [81, 82] are only a few examples of the medical fields in which 
targeted sequencing has been employed [83].  
The platforms eligible for resequencing projects depend on the amount of data required. 
Surely, for targeted sequencing or WES, all Life Technologies platforms, the Illumina 
benchtop apparatus (MiSeq and NextSeq) and the SOLiD system can be used, while the 
Illumina HiSeq or NovaSeq sequencers are mostly prone for WGS [19]. Nevertheless, the 
performance in variant discovery among the various technologies is quite comparable [42], 
with a more precise single nucleotide polymorphism (SNP) calling for Ion Torrent platforms, 
at the expense of a higher rate of error in homopolymeric segment [34], where SOLiD or 
Illumina systems seems to keep a very high accuracy [84]. On the other hand, due to their 
high error rate, TGS methods are not prone for discovering short nucleotide variants (SNVs). 
However, exploiting the very long reads produced, they are really suitable for detecting full-
length gene isoforms, which instead are scarcely found by SGS, and structural variations 
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[57], such as copy-number variations (CNVs), inversion, translocation and segmental 
uniparental disomy [85], whose characterization is really crucial, because they cover an 
average of 18.4 Mbp in a diploid genome [86].  
 
1.2. NGS data analysis: from raw reads to variant prioritization 
Since 2005, the introduction of the high throughput technologies caused a huge decreasing 
of sequencing cost leading to the breaking of the $1000 threshold for an entire genome. 
Anyway, if it is now relatively easy to sequence the genome of a patient, it is instead really 
troublesome giving the correct meaning to the obtained data. Other challenges derived 
from the needing of working with large datasets, as terabytes of data are produced every 
day from big sequencing centers. In this way, also biologists have now joined the big-data 
club, encountering issues with handling, processing and transferring all such information 
[87]. For this reason, if during the FGS years the main bottleneck was constituted by 
sequencing, now it is moved downstream in the pipeline, as the most time wasteful and 
expensive step has surely become the data analysis [88].  
As described in the previous paragraphs, the applications of NGS are very widespread, and 
although some parts are shared between the various data analysis pipelines, it is extremely 
long giving a plenty information for each of them. For this reason, as the whole thesis in 
centered on different types of variant analysis and manipulation, this section of introduction 
will be dedicated to the description of the main steps involved in this process (read 
preprocessing, alignment, variant calling, variant annotation and prioritization) and the 
associated data formats. 
 
1.2.1. Read preprocessing and FASTQ format 
Table 1 shows the various data format used by sequencers to provide their outputs. 
Although quite different, almost all these formats can be converted to a simple extension of 
FASTA, called FASTQ, that has become the widest used interchange read file format, thanks 
to its simplicity [89]. An exception is constituted by Ion Torrent which directly returns the 
reads aligned on the reference genome, rather than raw reads. The FASTQ format, as 
frequently happened in biology, has suffered of a lack of formal definition, starting from a 
Sanger FASTQ, passing through different kinds of Solexa/Illumina format, and reaching the 
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current solution, which is almost the same of the first proposed. Thus, the quality of each 
base called is encoded by a PHRED quality score from 0 to 93 using ASCII characters from 33 
to 126 [89]. The PHRED quality score is defined as the estimated probability of error: 
QPHRED = 10 x log10(Pe)  
FASTQ format describes each read using four rows (Box 1). The first line begins with the @ 
character followed by the read identifier and an optional description. The second row 
displays the raw sequence of the read. The third line starts with + character and can 
optionally contain again the read information. The last row contains the quality values of 
the bases and must have the same length of the sequence expressed in line 2. 
Box 1|Example of FASTQ format. 
1) Identifier 
2) Raw Sequence 
3) Optional Info 
4) Quality 
@Lactobacillus_493302_495389_1_1_0_0_0:3:0_0:3:1_12cb59/1 
ATAGCAGTTTAAGCACGGTTCTTGTTCTGAAAAAGTTTGCGATAG 
+ 
?:8755433221110000////......--------,,,,,,,,, 
Before being processed, FASTQ data are usually briefly analyzed to understand if reads can 
be used for the following analysis. For this reason, several tools for viewing, manipulating 
and summarizing FASTQ data before the pre-processing step have been developed over the 
years. Among them, the most widely used are fastx-toolkit [90], fastq-tools [91], seqtk [92] 
and the newer fqtools [93], efficiently designed for working also with the very long TGS 
reads. 
Once FASTQ files have passed this sort of validation, they undergo to a set of processes 
which are commonly referred as the preprocessing step [94]. In this phase, read adaptors or 
primer portions kept within the sequence are recognized and thus removed [95, 96]. Then 
low-quality bases are usually trimmed out depending on the threshold chosen by the user 
[97, 98] and so the resulting reads can be discarded if too short [99]. Other programs based 
on various approaches, including maximum expected error (MEE) [100] or overlapping 
analysis [101], have also been implemented for a complete preprocessing step. Moreover, 
at the end of the preprocessing, a summary of read statistics (mean length, mean quality, 
GC content, etc.) is usually calculated using software like FastQC [102]. Concluding, some 
protocols such as the best practices of Broad Institute [103] suggest converting the final 
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FASTQ files into an unmapped BAM (uBAM) as it can store more information including all 
metadata. 
 
1.2.2. Read alignment and SAM format 
The read alignment is probably the most complex process at computational level in a 
common pipeline for variant detection. Considering a read of length m and a genome of 
length n, a common dynamic programming algorithm solves the approximate string 
matching with indels using a quantity of memory and time that grows proportionally to m × 
n. Filtering and indexing are two different ways proposed to address the problem of large 
input sizes, regarding both the huge number of reads and the length of complex genome 
(3.2 Gbp for a human) [104]. 
In the filtering methods, wide reference regions, where no approximate match can be 
found, are rapidly excluded. Several approaches exploiting filtration have been developed, 
but almost all of them are based on a hash table exploiting the q-gram index (or k-mers 
index). These seeding-based methods identify short portions of the reference, called k-mers, 
which constitute the keys of the hash table, sharing a small piece of the read with no error 
(seed). The seed is then extended allowing or not the presence of gap (spaced seed) [105]. 
The remaining regions, where no association is found, are filtered out. To choose which 
regions of the reference can be rejected as not presenting any approximate match, the 
applied filters are usually based on two main principles: the pigeonhole [106] or the q-gram 
[107]. Both establish a minimal length or number of perfect q-grams that a read with a 
definite count of mismatches shares with the reference sequence [104]. 
In the easiest form of the pigeonhole lemma, assuming that we want to find all approximate 
matches of a read with at most k errors, if the read is divided in k + 1 seeds, at least one 
piece appears without error [108]. Thus, for each read, k + 1 non-overlapping seeds of 
almost the same length are obtained applying a pigeonhole filter. Their matches are then 
found in parallel by scanning the hash table of the genome. Widely spread read mappers are 
based on different variants of the pigeonhole lemma, such as SeqMap [109], SOAP [110] and 
MAQ [111], where reads are broken into more seeds (e.g. k + 2) and at least two matches 
seeds are searched, or on the other hand splitting reads into fewer pieces, thus allowing a 
fews errors, including Bowtie2 [112] and Masai [113].  
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A potential issue associated with these seed-based approaches regards lack of gaps within 
the seeds. To overcome this problem, other software including SHRiMP [114] and RazerS 
[115] adopted the q-gram filter which supports an index that natively permits gaps. The q-
gram principle takes into account all overlapping q-grams (substrings of length q) of a read 
and provides a bottom limit for the number of substrings that a k-error match in the 
reference shares with the read. With these premises, a q-gram counting filter looks for 
genomic regions where at least a lower bound number of q-grams of a read can be 
detected, returning them as a possible match. The remaining regions can be securely 
eliminated [104].  
Moreover, in some new aligners as mrsFAST [116], mrsFAST-ultra [117] and Masai [113], the 
indices are made on the genome and the reads, which are then scanned in parallel for 
finding matches with the same q-gram. 
More recent software, instead of using filters and the q-gram index, implement a powerful 
data structure, referred as suffix tree, which straight searches reads with gap or 
mismatches. This approach is advantageous as multiple identical copies of a substring 
collapse into a single path in the tree and so they are aligned only once, while each copy 
should be singularly aligned if a common hash table is used [105]. The suffix tree of a certain 
string is made by all suffixes of such text and a linear time is required to build it. All 
occurrences of a read can be looked for in optimal time. In the native definition proposed by 
Weiner in 1973 [118], the suffix tree is a rooted tree, where from each internal node depart 
at least two edges, labeled with different substrings, deriving from the original text. The 
external leaves contain the starting index of the associated suffix. As the suffix tree requires 
a lot of space and it does not allow an efficient use of the cache memory, it has been firstly 
replaced by the suffix array [119], which still suffered of low performance in searching time, 
and then by two other methods, the enhanced suffix array [120] and the Ferragina-Manzini 
index (FM-index) [121].  
All these approaches have been implemented into published read mappers. In particular, 
the suffix tree is used in MUMmer [122] and OASIS [123], Segemehl [124] and Vmatch [125] 
exploit the enhanced suffix array, while BWA [126], SOAP2 [127] and Bowtie [128] 
implement the FM-index. 
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Although the read aligners are based on different methods, the final output follows the 
specifications indicated by the Sequence Alignment/Map (SAM) format [129]. SAM is a 
general tab-delimited alignment format capable of storing information regarding aligned 
and not aligned reads with a maximum length of 128 Mbp independently by the sequencing 
platform used. It usually contains a header block before the alignments, where each line 
starts with a @ character, followed by two letters representing the record types, such as the 
header line (HD), the reference sequence dictionary (SQ), the read group (RG), the program 
used (PG) and the one-line text comment (CO). Each record has also predefined tags: for 
example, the format version (VN), the sorting order of alignments (SO) and the grouping of 
alignments (GO) for the HD type. Below the header section, the various alignments are 
listed, each of them contains 11 mandatory columns, as explained in Table 2. Almost all 
fields are self-explanatory. However, FLAG and CIGAR are quite complex and need a more 
exhaustive description. For the CIGAR, I remand to the SAM format documentation [130], 
while the FLAG is briefly explained in Box 2 using information collected in Table 3.  
 
 
 
Column  Field Type Example Description 
1 QNAME Str Lactobacillus_3072417 Query template NAME 
2 FLAG Int 4, 67, 163 Bitwise FLAG 
3 RNAME Str chr1, 1 Reference sequence NAME 
4 POS Int 3070108, 1274308 1-based leftmost mapping POSition 
5 MAPQ Int 0, 22, 40 MAPping Quality [−10 log10 Pe✶] 
6 CIGAR Str 75M2D25M, 100M CIGAR string 
7 RNEXT Str =, * Ref. name of the mate/next read 
8 PNEXT Int 3072347, 1334817 Position of the mate/next read 
9 TLEN Int -2240, 1941 Observed Template LENgth 
10 SEQ Str GCCGTTTATTTCTCA Segment SEQuence 
11 QUAL Str ?:BA87554332211 ASCII of Phred-scaled base QUALity+33 
Table 2|Overview of the mandatory fields in the SAM format. Each column is associated with an 
explanatory example. ✶ Pe indicates the probability that mapping position is wrong. 
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Bit Binary Meaning 
1 000000000001 Template having multiple segments in sequencing → it is a mate 
2 000000000010 Each segment properly aligned according to the aligner 
4 000000000100 Segment unmapped 
8 000000001000 Next segment in the template unmapped 
16 000000010000 SEQ being reverse complemented 
32 000000100000 SEQ of the next segment in the template being reverse complemented 
64 000001000000 The first segment in the template 
128 000010000000 The last segment in the template 
256 000100000000 Secondary alignment 
512 001000000000 Not passing filters, such as platform/vendor quality controls 
1024 010000000000 PCR or optical duplicate 
2048 100000000000 Supplementary alignment 
Table 3|Explanation of bits used for composing the FLAG field. 
 
Box 2|Example of decodification of the FLAG meaning. 
163 = 000010100011 
● 000000000001 → it is a mate (1) 
● 000000000010 → both mates are properly aligned (2) 
● 000000100000 → its mate is reverse (32) 
● 000010000000 → it is the second mate (128) 
The SAM format can accept also optional fields, where the mapper shall provide more 
information regarding the alignment. Such column can often store also read features, when 
a uBAM is produced. Nevertheless, independently from what is contained, optional columns 
must follow the TAG:TYPE:VALUE format, where TAG is a two character string, while TYPE  is 
a single case-sensitive letter (A, Z, H, B, i, f) which defines the format of VALUE. 
The compressed form of SAM format is called BAM format, where B means binary. In fact, 
due to the large dimensions of the SAM files, they are almost always converted into BAM 
format, which promises a size reduction of 4-5 times, keeping the compatibility with the 
majority of post-mapping programs. Differently from SAM, BAM format contains 0-based 
coordinates and the letters used in CIGAR string are converted into number. Surely, other 
differences can be identified, but for the complete description of BAM format I suggest 
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referring to its online specification [130]. However, another important feature of BAM is the 
possibility of indexing. In this way, the alignments overlapping a determined region can be 
fastly retrieved without sliding the whole file. Before indexing, BAM must be sorted by 
reference ID and by the leftmost coordinate. The basic indexing algorithm is based on the 
UCSC binning scheme [131]. 
After mapping, the obtained BAM files are further processed in order to improve the quality 
of the information contained. In particular, optical and PCR duplicates are marked or 
removed, then initial alignments are refined by local realignment around known indels and 
finally base quality scores are recalibrated exploiting an empirically accurate per-base error 
model [132].  
Although all these processes are becoming standard for variant analysis, the correct 
parametrization of each single step is still difficult to perform as it requires a lot of testing. 
Indeed, the parameters chosen for a specific problem could not be the best for a different 
type of project, because for example the read length or the mean coverage can change. 
 
1.2.3 Variant calling and VCF format 
After the read alignment and the post-processing, the final BAM is ready to be handled in 
order to find all the differences between the base called and the reference. This process is 
known as variant calling (VC) and it is usually followed by genotype calling, where it is 
determined the genotype of the called variants [133].  
Essentially, two different types of variant can be discovered through the VC: germline or 
somatic. Although the software to detect variants, referred as variant callers, are often 
capable of performing both kind of calls, the basic processes are quite different. For defining 
germline variations, the comparison is made between the sequenced sample and the 
reference genome, which is a digital assembled sequence providing the best representation 
of the sequence of a particular specie [134]. On the other hand, instead, the detection of 
somatic variants is usually achieved finding the difference between the genome of a tumoral 
specimen and its normal counterpart, which works as a reference [135]. 
More than 40 tools for VC can be found in literature, able to determine both single 
nucleotide polymorphisms (SNPs) and short insertion deletion (indels). These tools are 
based on various algorithms, allowing the reaching of different values of sensitivity and 
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positive predictive value (PPV) [136]. The first methods for VC were based on the direct 
counting of alleles at each site, using simple base quality cutoff, typically QPHRED equal to 20, 
for determining either the variant or the genotype [137]. Further improvements regard the 
introduction of probabilistic approaches and local realignment for variant detection. In 
particular, GATK UnifiedGenotyper [132], FreeBayes [138], Strelka [135] and SAMtools [129] 
are based on Bayesian statistical approaches, while VarScan2 [139] detects variants applying 
an heuristic method and a statistical test. Moreover, LoFreq [140] relies on Poisson–
binomial distribution, instead SNVer [141] employs a binomial-binomial model for testing 
how significant is the difference between the observed allele frequency against sequencing 
error. The most advanced variant callers integrate more complex methods based on local 
realignment or de novo assembly for the haplotypes reconstruction. For example, GATK 
HaplotypeCaller [142] is designed for calling together SNPs and indels, exploiting a local de 
novo assembly of haplotypes in a region which displays sign of variation. On the other side, 
VarDict [143] carries out supervised and unsupervised realignment, for calling short and 
long indels, respectively. Last, Platypus [144] relies on a local de novo assembly using de 
bruijn graph, followed by a local realignment and by probabilistic haplotype estimation. 
Almost all tools give a set of parameters for a comprehensive description of the reported 
variants and also some suggestions for a proper filtration.  
Moreover, it has been proved that the use of multiple individuals triggers to an 
improvement in the genotype calling accuracy over using single samples, that is even 
increased if linkage disequilibrium (LD) information are used. Otherwise the gain in accuracy 
mediated by LD is great for variants with high-allele frequencies, while is not so significant in 
the calling of rare allele [133]. 
Nevertheless, several issues still afflict the VC process, as currently no software or pipeline 
succeeded in calling all mutations. In particular, it was pointed that sensitivity and precision 
seems to be inversely proportional, in sense that high sensitivity is always accompanied by 
the increasing of the false positives number [136]. Consequently, as the variant callers use 
various approaches to optimize sensitivity and PPV, the resulting variants concordance is 
usually quite poor, in particular when indels [145] or data from low coverage regions [146] 
are compared. For these reasons, some strategies using a consensus of data derived from 
different software [147, 148], in addition to a specific attention on variants falling in low 
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complexity regions allowed an increasing of accuracy [149], even if a lot of work is needed 
for getting reproducible results. 
The information obtained during the VC step are collected into a standardized format called 
variant call format (VCF). It is capable of storing the prevailing types of sequence variation, 
like SNPs, structural variants and indels, in addition to other kinds of annotation [150]. VCF 
is a tab-delimited text file format, containing at the beginning several meta-information 
lines preceded by two ‘#’ characters, a header line starting with only ‘#’ char, and then data 
rows each including information about a position in the genome [151]. The meta-data rows 
provide information regarding file format or associated with INFO, FILTER, FORMAT or 
sample IDs fields of the VCF file. The header line contains eight mandatory columns 
(#CHROM, POS, ID, REF, ALT, QUAL, FILTER, INFO), followed by a FORMAT field when 
genotype is present. The latter describes which features are shown into the following 
arbitrary number of sample IDs. The body of VCF, usually constituting by the variants even if 
in a slightly modified version of this format, referred as genomic VCF (gVCF), also non-
variant blocks are included, presents the same number of header columns, whose meaning 
is explained in Table 4. 
Col N  Field Type Example Description 
1 CHROM Str chr1, 1 Chromosome name 
2 POS Int 307058, 1274308 1-based position sorted numerically 
3 ID Str rs21589, COSM15, . Semi-colon separated list of unique identifier 
4 REF Str A, AT, AGN Reference base(s) included in A, C, G, T, N  
5 ALT Str AG, AGGG, * Comma separated list of alternative alleles 
6 QUAL Int 0, 22, 40, 365 Phred quality score for ALT [−10 log10 Pe✶] 
7 FILTER Str PASS, q10  Filter status; PASS → all filters passed 
8 INFO Str NS=3;AF=0.01 Additional information, semicolon-separated 
9 FORMAT Str GT:AD:DP Specification of the data types and order 
10 SampleID1 Str 0/1:28,32:60 Specific values of FORMAT keys in Sample1 
... ... ... ... ... 
N SampleIDN Str 1/1:0,44:44 Specific values of FORMAT keys in SampleN 
Table 4|Overview of the fields in the VCF format. Each column is associated with an explanatory example. 
Columns from 1 to 8 are mandatory, while the others are optional, even if they contain the information 
linked to the analyzed samples. ✶ Pe indicates the probability that call in ALT is wrong. 
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The variability in the keywords included in the various fields, in particular INFO, FORMAT 
and consequently Sample ID, is wider than what present in the other described formats and 
it mainly depends on the software used for making the VC process and on the type of 
mutation is going to be detected. 
 
1.2.4. Variant annotation and prioritization 
Once variants are called, researchers need to give them a meaning in order to understand 
their functional impact. This process of adding useful information on variants is called 
variant annotation. Two main level of annotations can be found: variant level and gene 
level.  
The first type of annotation includes features directly derived from the VC step, such as the 
variant and the genotype quality scores, or calculated after the localization of the mutation 
at genomic level or found in various external sources [152]. Among the latter, the 
predominantly used are the allele frequencies databases, including the 1000 genome 
project [153], dbSNP [70], the Exome Variant Server (EVS) [154] and the Exome Aggregation 
Consortium (ExAC) [68], the pathogenicity predictors, as for example SIFT [155], CADD [156] 
and DANN [157], and the conservation scores, such as PhyloP [158], PhastCons [159] and 
GERP++ [160]. Almost all these information, in addition to predictions of mutation affecting 
splicing sites, are collected into dbNSFP database [161], which is often exploited for adding 
such annotations on VCF files by the most famous variant annotators, including VEP [162] 
and ANNOVAR [163]. The most complex type of annotation seems to be related to the 
assign of the impact of the DNA mutation at the transcript and protein levels. In fact, several 
types and versions of genes and transcripts, which differ each other, can be used, even if the 
main ones are provided by the Ensembl [164], the UCSC [165], the NCBI RefSeq [166] and 
the GENCODE [167]. In this way, a variant can affect a coding region in a specific gene set 
while it can be intergenic in another one. For this reason, it is usually recommended to 
employ the consensus coding sequence (CCDS) in the case that protein coding genes should 
be annotated, as CCDS are normally characterized by all gene sets [168]. Moreover, another 
problematic point regards the proper using of the HGVS nomenclature [169]. The main 
discordances between variant annotators are found in the indels as they are not always 
correctly realigned to the most 3’ possible position of the reference sequence, thus causing 
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multiple depiction of the same variant. Furthermore, taking into account the annotation of a 
frameshift variant, which theoretically causes the creation of a premature stop codon and 
therefore a shorter protein, it has to be pointed that this is only a prediction, probably 
wrong, because the process is dominated by the nonsense-mediated RNA decay 
phenomenon [170].  
When variations lack of their intrinsic annotation, it is important to access data at the gene 
level. The Gene Ontology (GO) [171] is surely one of the most widely used, as it allows a 
characterization of the gene considering the cellular component, the biological process and 
the molecular function. Moreover, further information can be obtained accessing to the 
Disease Ontology (DO) [172], the Phenotype Ontology (PO) [173], the Genotype Tissue 
Expression (GTEx) [174] or the Gene Expression Atlas [175] data. Even pathway sources, 
such as KEGG [176] and Reactome [177], can be employed at this purpose. All these features 
are not usually integrated during a standard protocol of variant annotation, unless specific 
plugins have been used, constituting one of the main problem of the gene level annotation. 
The information added during the annotation step are handled for finding all the variant 
which could be associated to the disease or condition under study. This process can be 
performed through a subsequent application of filters, which eliminate variants no 
overtaking the imposed thresholds, or through a prioritization system, which allows to bring 
out the most feasible variants, ordering them for relevance exploiting a certain number of 
criteria. The latter approach is more powerful, as it does not suffer of the main problem of 
filtration which regards the risk of removing something that is just below the threshold for 
one of the criteria, while being well above the threshold for the other criteria [178]. The 
main typologies of criteria work directly on variants features, including the mode of 
inheritance (e.g. autosomal recessive), the genomic localization (e.g. CDS or UTR), the type 
(e.g. missense or nonsense), the frequency in the population (e.g. ExAC or dbSNP), the 
pathogenicity predictions (e.g. CADD) and the previous description in the databases (e.g. 
LOVD [179] or ClinVar [180]).  
Although several methods for annotating and prioritizing variants have been published, 
currently there is no gold standard able to clarify all the possible situations. Moreover, with 
the near switching from WES to WGS, new software will have to be implemented, allowing 
the interpretation of more kinds of variants, including those that nowadays are considered 
almost neutral such as the synonymous or the intronic ones [152]. 
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2. General aims and thesis structure
 
The typical bioinformatic workflow that is currently used for the identification of genetic 
variants is affected by several problems that make these analyses difficult and prone to 
errors. As extensively explained in the introductory paragraphs, there are some crucial steps 
which are particularly prone to errors due to their complexity or to intrinsic features of NGS 
data [20]. For example, read mappers fail to align short NGS reads when they match to 
duplicated regions, while variant callers need an extensive parametrization. Moreover, an 
accurate annotation of genes and variants is often difficult to achieve because there are no 
tools that can provide this information, in a direct and comprehensive way, using a standard 
format.  
With these premises, to keep up with the progress, in 2014 the University of Padua funded 
the BioInfoGen Strategic Project with the goal of developing technology and expertise in the 
area of bioinformatics and molecular biology applied to personal genomics.  
Since this field of research requires multidisciplinary expertise, five different groups of the 
University of Padua have been involved, including four departments and the 
Interdepartmental Research Center of Innovative Biotechnology (CRIBI) (Figure 5). Each unit 
owns specific expertise, which are shared with the other groups to reach common goals. In 
particular, the Department of Biology guarantees the support in molecular biology, 
genomics and bioinformatics, while the Department of Mathematics, through its top-level 
knowledge in the machine-learning approaches, including neural networks and kernel-based 
methods, supplies the informatics expertise, particularly suited to be applied to the 
information collected in the genomics research. Moreover, the two medical units 
(Department of Women's and Children's Health and Department of Medicine) supply 
excellent skills in the genetics of the lysosomal storage diseases (LSD) and the renal proximal 
tubulopathies respectively. The case-studies considered in this research, besides their 
inherent medical interest, are also very useful for the setting up of a robust bioinformatics 
platform for personal genome analysis. Last, the CRIBI center contributes with the DNA 
sequencing facility and the computing resources, accompanied by the decennial experience 
in genomics and bioinformatics fields. 
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However, although each research units needs to achieve specific objectives within their 
respective fields, the general aim of the project is even more important. In fact, the 
establishment of an advanced platform for personal genomic analysis can emerge only from 
the joint effort of the different units, as the cooperation and the transversal knowledge 
diffusion are two strongholds for reaching ambitious scientific target. 
 
Figure 5|Schematic representation of the two projects debated within the thesis. On the left, the five units 
involved in the BioInfoGen are depicted. The extensive interconnection among the various research groups is 
highlighted using the arrows. On the right, the two main branches of my PhD project are summarized, 
proposing at the same time a further division into the subsections discussed within the thesis. SDB: 
Department of Women’s and Children’s Health. 
My PhD has been funded by the BioInfoGen project (Figure 5), and many of the objectives of 
my research activity follow the general aims of the project. In particular, I was involved in 
the setting up and in the development of suitable software and solutions to overcome many 
of the problems associated with the NGS data analysis. 
To reach the purpose, I developed three main tools: I) a comprehensive pipeline for Illumina 
data analysis (§3.1), which grants a cutting-edge detection of nucleotide variants; II) a 
variant annotator, named VarPred (§3.2), to provide a quick and exhaustive transcript-level 
annotation; III) a web-platform for variant prioritization, referred to QueryOR (§3.3), which 
allows an easy investigation of mutations affecting patients with rare genetic diseases.  
Although the various programs have been specifically implemented for solving distinct 
problems, such as read alignment, variant calling, variant annotation and variant 
prioritization, these tools can be considered as part of a whole bioinformatics platform for 
high-throughput data analysis which should allow to get closer to personalized medicine. In 
fact, the proposed procedure can be applied not only to the two case studies involved in the 
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BioInfoGen, the lysosomal storage diseases (§4.1) and the renal proximal tubulopathies 
(§4.2) respectively, but also to other exome sequencing projects, where rare monogenic or 
oligogenic diseases need to be investigated. 
To provide an easy comprehension of the proposed thesis, I decided to split it into two main 
parts, each of them is further divided into subsections. In particular, the first part describes 
the three major bioinformatic tools that I developed, while the second one shows the 
application of such methods to investigate the two clinical cases and to perform a deep 
study of recurrent variants in human exomes (§4.3). 
I preferred to present the various subsections using a paper style format rather than 
organizing all the information in the usual material and methods (M&M), results and 
discussion (R&D), and conclusion blocks. In this way, I think the reader is facilitated in the 
interpretation of the discussed arguments. Nevertheless, each part is however subdivided 
using the common scheme based on introduction, M&M, R&D and conclusion paragraphs. A 
final paragraph (§5) summarizing all the obtained results is also proposed as conclusion of 
the manuscript. 
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3. Development of new bioinformatic tools 
 
3.1. Illumina data analysis pipeline 
3.1.1. Introduction 
The purchasing of a new Illumina sequencer at the CRIBI sequencing service triggered the 
need of developing new systems for data analysis, because quite different in terms of 
software from what applied for Ion Proton data. Considering that the Illumina systems are 
the most widely spread sequencing technologies and for this reason such company is the 
market leader, several data analysis pipeline have already been published in literature [94, 
181], in addition to specific suggestions proposed by the Broad Institute of Cambridge [103]. 
Commonly, after the base calling, reads are converted into FASTQ files, which are then 
aligned against the reference genome. A further processing involves the detection of 
duplicates derived from PCR or clusters misreading, followed by indel realignments and/or 
base quality score recalibration [182]. The last step requires the application of a variant 
caller in order to get somatic or germline variations.  
Although the choosing of the software to implement within a pipeline is quite easy when 
the Broad Institute best practices are followed, the selection of the best parameters is 
instead challenging as it depends on the type of variants to detect, the read length, the 
coverage and many other factors. Moreover, as often some tools have been designed to be 
precise and sensitive at the expense of the performances, another important issue to 
consider is the computation time. 
 
3.1.2. Materials and Methods   
The following pipeline (Figure 6) is a bash script able to create and launch job files, derived 
from specific templates suitably designed for the various steps employed into the analysis. 
The majority of the applied programs are included in the Picard tools (version 2.3.0) [183] or 
in the GATK suite [181], both developed by the Broad Institute, with the exception of the 
read aligner (BWA [126]), the somatic variant caller (VarDict [143]) and a binary to calculate 
statistics (SAMtools [129]).  
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Figure 6|Illumina data analysis pipeline. All the steps included within the pipeline, from raw reads up to 
variant detection, are summarized. The different backgrounds are used to distinguish the packages which 
the various tools refer to (yellow: Illumina, blue: Picard, green: BWA, red: GATK, grey: VarDict) 
The first step, called demultiplexing, is performed using the Illumina software bcl2fastq. It 
allows the separation of read clusters, depending on the information provided in the sample 
sheet, and the removal of residual portions of primers and/or indexes erroneously 
sequenced. The various lanes containing the sequenced reads are converted into the uBAM 
format using FastqToSam, and subsequently merged together through MergeSamFiles, for 
creating a unique uBAM file for each sample. A further step of sequence checking is 
performed applying MarkIlluminaAdapters. At this point, the resulting file is reconverted 
into an interleaved FASTQ file though SamToFastq, as the BWA mem aligner (version 0.7.15) 
cannot accept uBAM format. The obtained BWA output (SAM file) is then merged together 
with the previously processed uBAM using MergeBamAlignment, achieving the final aligned 
file with all the necessary information for the following manipulation. Optical and PCR 
duplicates are detected using MarkDuplicatesWithMateCigar and some statistics are then 
computed thanks to both CollectHSmetrics and SAMtools stats (version 1.3). The 
subsequent step is carried out applying a software included into the GATK suite (version 3.6-
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0), named IndelRealignment, which performs a local read realignment around known indels 
taken from dbSNP v144. The final stage of read manipulation is accomplished with GATK 
BaseRecalibrator, which performs the base quality score recalibration (BQSR); such method 
helps to achieve a really accurate variant calling process.  
When the read analysis is completed, a second block of instructions for variant calling is 
executed. It depends on the planned type of research, as somatic variants detection 
requires different parameters and tools from those used for the germline calling.  
Thus, for common exome studies, where germline variations have to be found, only GATK 
tools are essentially used. First of all, HaplotypeCaller is run against all the samples, 
obtaining a set of VCF files. These latter are then processed all together by the 
GenotypeGVCFs in order to get a joint genotype for the called variants. Concluding, to 
obtain a refined set of calls, the variant quality score recalibration (VQSR) is performed, 
leading to the exclusion of several false positives. Unfortunately, this sophisticated machine 
learning approach carries to high quality data only when a large batch of samples (at least 
30 exomes) and highly curated sets of known variants are available. Otherwise, the 
improvements are poor. 
On the other hand, for somatic variants detection I chose to integrate two different 
programs, VarDict (version February 2017) and MuTect2 (version 3.6-0) respectively. 
Depending on the conditions required for the analysis, it is possible to select one of the two 
callers, which allow various kinds of parametrization. 
 
3.1.3. Results and Discussion 
The automatization of the various software for Illumina data manipulation into a high-
performance pipeline allows an easy and rapid analysis of the NextSeq 500 output. In 
particular, the system has been thought to be handled not only by bioinformaticians, but 
also by biologists with a minimal knowledge of the Linux shell, allowing a wide usability 
among the people of the CRIBI sequencing center. Indeed, a single command with few 
required inputs including the sequencing run name, the folder on which FASTQ data are 
stored, the interval file with the coordinates of the enriched regions, the reference genome 
which should be used and the applied sequencing type (paired-end or single-end), is enough 
for performing the whole analysis. The last two options are really useful as they improve the 
 
36 
 
overall versatility of the system: in fact, both kinds of reads can be accepted and, more 
interestingly, almost all species with a known reference sequence can be processed and 
analyzed. Regarding the parameterization, an intensive critical reading accompanied with a 
lot of simulations using testing samples has been performed, in order to obtain reliable and 
reproducible results. 
However, the most time-expensive part of the pipeline implementation regarded the 
performance optimization. Indeed, special attention has been dedicated to the reduction of 
the pipeline wall time and to the saving of disk-space, as in the NGS field data storage has 
become a tricky problem to tackle [184].  
To face up the latter issue, I tried to use, where possible, compressed BAM files, rather than 
their extended SAM form, diminishing at the same time the number of intermediates. For 
example, the read alignment using BWA required a first step of read reconversion into 
FASTQ format, followed by the merging of the obtained BAM file with the previously 
prepared uBAM file. Thus, many temporary intermediates will be created and saved if this 
triptych of processes is performed separately. Instead, in the described system, the three 
commands have been concatenated into a unique instruction, where the output of a 
program is directly redirected into the input of the following one. This method allows to 
store only one file for each sample, simultaneously diminishing the wall time. The drawback 
of such approach is related to the need of repeating all the steps if an error arises when the 
whole block is not finished yet.  
On the other hand, the issue regarding the long wall time has been solved applying a wide 
parallelization, not only associated with the software used, which is not dependent on the 
pipeline implementation, but mainly over the various samples which are usually sequenced 
together into a single run. In fact, each specimen, from FASTQ conversion to the final 
recalibration, is processed independently and parallelly to the others thanks to a series of 
jobs which are automatically created and executed into the thirty blades of the CRIBI 
cluster. Furthermore, the step of somatic variant calling, which supports both VarDict and 
MuTect2 callers, has been found to constitute the most time-wasteful stage, as it can take 
more than one week to process a single matched pair of tumor-normal specimens. Surely 
VarDict offers a better performance than MuTect2, but the software parallelization is not so 
efficient to significantly reduce the time required for the analysis. Instead, for the system 
speeding up, the Broad Institute suggests the application of its pipeline, called Queue [185], 
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that is based on scatter-gather parallelism (Figure 7). Exploiting such method, the Queue 
engine will execute the same GATK command on separate portions of the input data 
(scatter step), storing results in temporary files. Then once all the runs will be completed, 
the engine will combine all the results into the final output files, simulating an event 
comparable to a single running command (gather step). The great advantage of such form of 
parallelism consists in the possibility to extend the programming at cluster level, allowing at 
the same time the multithreading parallelism within each single machine. However, as 
integrating a pipeline within another one is a difficult task, not always associated with such a 
great improvement to justify the effort, I decided to directly integrate an approach similar to 
the scatter-gather parallelism into my program.  
 
Figure 7|Scatter-gather parallelism. After the initial split of the input data, the same command is run on 
each of the previously created junk (scatter step). When the processing (single-threading or multi-threading) 
is completed, the partial outputs are merged together to obtain the final result (gather step). 
For this purpose, BAM files are splitted per chromosome, then the variant calling is linearly 
executed (tests on multithreading did not evidence substantial improvements) comparing 
case with control on each couple of chromosomes and finally partial VCF files are joined 
together producing the final output. This kind of implementation reduced the wall time of 
somatic calling by about twenty times, allowing to carry out the process in less than one 
day. A possible limitation of such method could be associated with the reduction of 
extension of the sample background, used by callers to determine variants. Nevertheless, 
the comparison of the results produced by MuTect2 applying or not the scatter-gather 
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parallelism on the same couple of samples did not show significant differences, taking into 
account also the heuristic component of the software. For this reason, such approach seems 
to be a very efficient form of parallelization, that can be moved and applied in many other 
bioinformatic tasks, as for example the variant annotation. Considering the whole pipeline, 
it can completely process a high coverage (~100X) case-control couple of exomes in nearly 
one day using the resources available for a single user in the CRIBI cluster. 
At the time of the thesis writing, the pipeline was already used to successfully analyze 
dozens of normal exomes for germline variants detection, in addition to more than thirty 
exomes of matched pairs of tumor-normal specimens derived from patients affected by 
various types of tumor, including gastric cancer [186].  
 
3.1.4. Conclusion 
The proposed pipeline is a good compromise to process and analyze Illumina data, in order 
to detect either germline or somatic variants. The easy command line should guarantee the 
usability also to non-bioinformatician personnel, while the application of a job scheduler 
system and the scatter-gather parallelization permit to widely reduce the analysis time, 
without losing the consistency of the obtained results. Indeed, the overall quality of the final 
output has already been proved by Di Bartolomeo and colleagues [186], but also in other 
internal controls, allowing thus to retain concluded this part of the work, even if further 
ameliorations are always possible following the development of the technology. 
 
3.2. VarPred: a flexible tool for genetic variant annotation 
3.2.1. Introduction  
As extensively explained in the previous paragraphs, the development of NGS sequencers 
has quickly moved the main bottleneck of the sequencing studies from the sequencing 
process linked to Sanger technology to the data analysis, which has become almost always 
the most cost-effective step of each project [88]. In fact, the big amount of the produced 
data raised novel tasks linked to the downstream steps, including the calling of the variants 
and lastly their annotation and prioritization. Several bioinformatic approaches have been 
proposed to solve the problems associated to each specific step, even if a lot of work is still 
ongoing to ameliorate the existing software or to implement new one. In particular, getting 
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back on specific issues related to short nucleotide variants (SNVs), once they are called and 
reported into a VCF file, they have to be annotated using various information including gene 
features, HGVS descriptions [187], allele frequencies, variant database identification codes 
and ontologies. The majority of variant annotators, including the most used VEP [162] and 
SnpEff [188], have chosen the Sequence Ontology (SO) [189] for describing the specific traits 
of biological sequence, while other tools such as VariOtator [190] adopt the Variation 
Ontology [191] to depict nature, outcomes, consequences and processes of variation. A 
comprehensive annotation is also necessary to carry out a deep prioritization process, which 
can exploit sequential filtering steps, as in wANNOVAR server [163], or more complex 
criteria selection, integrated for example in QueryOR platform [178].  
Although a lot of work has been recently made to standardize the VCF annotation, various 
standard formats have been proposed, including the clinical sequencing nomenclature (CSN) 
[170] which is mainly based on the principles of HGVS guidelines and the Variant 
annotations in VCF format [192] which instead takes into account both HGVS notation and 
SO terms, slightly modified in order to eliminate inconsistencies with VCF format. Surely, a 
standard annotation format is fundamental to facilitate benchmarking, to allow an easy 
integration of each annotator into common NGS data analysis pipelines, and to solve issues 
regarding particular cases, including indel realignment. 
Another task often unconsidered regards the various representations by which a single 
variant can be described. In fact, the lack of variant normalization can trigger misleading 
variant annotation as the same variant has not a unique VCF depiction. In particular it is 
possible to encounter this problem when multiple alleles, usually classified as indels or 
multiple nucleotide variants (MNVs), are detected in a specific position by variant callers. To 
prevent this ambiguity and to allow a consistent representation, a variant needs to be left 
normalized and parsimonious, which respectively mean that the position of the VCF entry is 
the smallest and the allele is the shortest between all alleles representing the same variant 
[193].  
Moreover, even if the introduction of recent variant callers, based on haplotype 
reconstruction, has partially solved such issue, in many cases adjacent variants, falling in the 
same reads, should be fused into a single feature, constituting a MNV. This event has to be 
treated with special attention when these variations are located in a single codon, as often 
their separate annotation leads to an incorrect interpretation of the real variant. To my 
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knowledge, none of the publicly available annotators integrates a system to perform such 
step of neighboring variants aggregation, exploiting only the information contained in the 
VCF file. Indeed, the main challenge of the methodology resides in the haplotype phasing, 
which requires the BAM file with the aligned reads. MAC software [194] has been specially 
implemented to correct potentially misannotated MNVs among the reported SNVs, getting 
in input both files, the VCF and the BAM, but then the real annotation is performed using 
ANNOVAR, SnpEff or VEP. 
It has been proved that also the gene-set employed for the annotation has a great impact 
on the variant prediction even if the main differences among GENCODE [167] and RefSeq 
[166] can be found in non-coding transcripts and UTR sequences [195]. This issue is directly 
linked to the need of annotating all the gene transcripts, not only the canonical isoform, as 
the same variant could have different impacts depending on the transcript in which it falls. 
Considering all these issues, together with the will to give the user the possibility to highly 
customize the version of the input databases required for the annotation, I implemented 
VarPred, a flexible and efficient variant annotator able to characterize all types of SNVs, 
including indels and complex rearrangements. Although its development is not yet 
completed, VarPred is available as stand-alone software, allowing its integration into variant 
discovery pipelines, and as web-platform, ensuring the opportunity to explore results in a 
simple, but at the same time accurate manner also to non-bioinformaticians.  
 
3.2.2. Materials and Methods 
VarPred is implemented in Python 3 and it requires the installation of Pandas library and its 
dependencies, tabix [196] and python3-tables module, which provides an efficient data 
storage, based on HDF5 and pickle formats. Pandas library has been chosen as it allows a 
simple and efficient management of tabular data, in which almost all genomic data can be 
converted, promising at the same time great computational performance, thanks to its 
compiled C core. Differently from the other variant annotators, which require an initial step 
of precomputed data downloading, VarPred directly works on the original annotation files, 
allowing an easy knowledge of the version of data used. The required inputs are very few: 
the VCF file to be annotated, a set of transcripts in GTF or GFF3 format and the indexed 
reference genome (Figure 8). Moreover, optional annotation data can be added to the 
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software, including three databases of allele frequency (ExAC [197], ESP6500 [69] and 
dbSNP [70]) and one linked to somatic mutations as the Catalogue Of Somatic Mutations In 
Cancer (COSMIC) [198]. Other options can be set to annotate not common organisms, 
mainly when the nuclear or the mitochondrial genetic codes are not the standard ones. Also 
variations in plants are supported thanks to a specific module which handles the plastid 
genetic code. Finally, to manage the memory required by the software, the number of 
variants which have to be annotated for each run can be selected, in addition to the 
possibility to declare how many processors can be employed. 
GENCODE, Ensembl and RefSeq transcripts can be used by VarPred as genomic scaffold for 
the annotation. During the first running on a specific gene set, the software carries out 
several computations in order to obtain the highest number of information on CDSs, exons, 
introns and UTRs, but also on whole transcripts. Moreover, the presence of common 
splicing sites within multi-exons transcript is checked and possible inconsistencies due to 
superimposed features are removed. For each gene, the various transcripts are sorted 
depending on the rules for the canonical transcript definition provided by Ensembl [199]. 
The tables obtained during the previously described processing are saved into a HDF5 file, 
while the computed searching structures are included into a pickle file. Both files allow a 
quick access to the stored data, which are employed to determine the annotation at gene, 
transcript and eventually protein level. 
During the annotation step, variants are firstly normalized following the method proposed 
by Tan et al [193] with slight modifications. Then, the information included into the selected 
databases is added, considering that in many cases such features need to be rearranged, 
and not simply copied and pasted. It happens, for example, with minor allele in reference 
(MAiR) variants where minor allele frequency (MAF) value, usually corresponding to the 
variant frequency, is not related to the variant itself, but to the frequency of the reference 
allele. Thus, the variant frequency has to be somehow calculated. In the following step, 
variants are divided depending on their type and each subgroup is annotated exploiting a 
dedicated function. The annotation format chosen is based on suggestions proposed by 
Cingolani and colleagues [192] and it includes the HGVS predictions, the sequence ontology 
annotation, in addition to the various IDs associated with the adopted gene-set and the 
position at transcript and protein level. The final output of the program is an annotated VCF, 
to which also a TSV file can be added. 
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Figure 8|VarPred annotation process. During the first run, the software employs the transcript data in GTF 
or GFF format and the reference genome to build some cache tables, containing genomic features, and a 
searching structure to provide a fast detection of the regions in which the variants fall. These files will be 
then used to complete the annotation of the input VCF file, after the association of the database related 
features (allele frequencies and IDs) to such variants. Before to undergo the main annotation procedure, 
variants are also splitted into a number of chunks equal to the declared CPUs. In this way, the parallelization 
process can be enabled. Then, special functions are applied to annotate SNPs, MNPs, indels and complex 
rearrangements contained in each chunk. Finally, the annotated variants are joined together into the final 
file. 
Even if not yet completed, VarPred owns also a web graphic interface, built using Django, a 
high-level Python web framework. The user can select one of the implemented species, 
which are the widest used in the scientific area, including Homo sapiens, Rattus norvegicus, 
Danio rerio and Mus musculus. Subsequently, one or more VCF files can be uploaded and 
the parameters for annotation, as for example the frequency databases, can be selected. 
With the collected knowledge, the system creates a job file containing the command line 
and all the accessory information for correctly executing the instruction. The job is 
submitted to the CRIBI cluster, while a progress bar shows the status of the processing. 
When it is completed, a notification email, containing the link to the results, should be sent 
to the address indicated during the file uploading (this part is not yet implemented). The 
managing of the results is performed using a plug-in for the JQuery JavaScript library, called 
DataTable, which allows easy pagination, instant search and multi-column ordering of the 
VCF table calculated during the annotation step. No database is employed to store the 
 
43 
 
results, which instead are saved into pickle files and then processed using Pandas before to 
be treated by the JavaScript. A basic filtering strategy is also integrated, similar to what 
proposed by wANNOVAR or the online Ensembl VEP, where user defined cut-offs are 
applied to reduce the searching space of the analysis. 
To evaluate the performance of VarPred, it has been compared with the state-of-art variant 
annotators, including ANNOVAR (release June 2017), SnpEff (v4.2) and VEP (v89). Various 
conditions have been tested on Intel(R) Xeon(R) CPU E5-2687W v2 @ 3.40GHz exploiting all 
the 16 CPUs, changing in particular the dimension of the input VCF (~45000 variants for a 
typical human exome and ~2900000 variants corresponding to a human genome-size 
dataset, even if in this case coding mutations of COSMIC v74 have been used) or adding 
common parameters, such as the dbSNP annotation. Moreover, to assess the accuracy of 
VarPred, always considering the other tools, a subset of near 2 million variants selected 
from coding mutations of COSMIC v74 have been analyzed. In particular, protein predictions 
contained in COSMIC and those computed by the annotators were compared, dividing them 
into SNPs (1964578), insertions (18015), deletions (47002), MNPs (10130) and complex 
rearrangements (819), similarly to what reported in other studies [200].   
 
3.2.3. Results and Discussion 
Software implementation 
VarPred is an easy-to-use and flexible software guaranteeing a comprehensive variant 
annotation of almost all species for which an assembled genome and a complete gene-set 
exist. 
Two different data formats for transcript data, GFF3 and GTF, are accepted by the annotator 
raising the possibility to choose among GENCODE, Ensembl and RefSeq gene annotations. 
This feature is really important as it has been proved in other studies that the selection of 
the reference transcripts is challenging for the functional annotation of the variants, as wide 
effects can be found on the outcome [195]. For solving this issue, it was developed also a 
consensus sequence among the various transcript sets which unfortunately are limited to 
protein coding regions [168]. Moreover, still considering the genomic features, VarPred has 
also been developed to annotate all the transcripts found within the provided gene-set, as 
different impacts could be linked to a certain variant depending on the transcript in which it 
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falls. In fact, the same variation could be intronic in a particular transcript, while it could 
affect the coding region in another one, constituting for example the disease-causing 
mutation, as such transcript is the most expressed isoform in the considered tissue. 
Nevertheless, as often researchers focus their attention on the canonical isoform, VarPred 
sorts transcripts following the rules supplied by Ensembl [199], based on the presence of 
CCDS, the length of the coding regions and the whole length of the transcript. Thus, the 
possibility to extend the analysis to different annotations, considering at the same time the 
whole plethora of transcripts, can give a wider comprehension of the genomic context 
associated with the variants under consideration.  
This possibility is supported also by the other annotators, which however require the 
downloading of several cache data related to the chosen gene set. Instead, VarPred 
calculates such files during the first running of the software, facilitating in this way also the 
using of user-created custom gene set, deriving for example from non-model organisms or 
from a re-annotation of common species. 
The reproducibility of the annotation is guaranteed by the normalization system based on 
the algorithm proposed by Tan et al [193]. Thus, a specific variant, even if depicted in 
various ways within the VCF, as it can happen for particular indels or MNPs, will be always 
associated with the same prediction, facilitating the evaluation of the results and avoiding 
possible misleading in variant interpretation. Moreover, such normalization system is also 
applied to correctly realigned variants to the most three prime position of the transcript, in 
order to compute an accurate HGVS prediction at transcript and protein level. Indeed, the 
exact characterization of HGVS notation was one of the main reason which promoted the 
development of VarPred, because in the late 2014 none of the available annotators had 
completely fixed the problem. Obviously, nowadays such issue has been predominantly 
solved by almost all the previously mentioned tools, even if some discrepancies can still be 
found when a variant falls near the boundaries of uncompleted protein coding transcripts, 
where the coordinates of the first or the last codon are not properly assigned. 
Regarding the annotation format, I chose what suggested by Cingolani and colleagues [192], 
as the proposed rules are based on the HGVS recommendations and on the SO terms, 
allowing a compact but exhaustive representation of all the information computed during 
the annotation process. The knowledge included into the VarPred annotation ranges from 
the HGVS notations at genome, transcript and eventually protein level, to the consequence 
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prediction using SO terms and a simple estimation of the putative impact, in addition to the 
various IDs associated with the adopted gene-set, the position at transcript and protein level 
and the transcript biotype. Moreover, errors, warnings or informative messages, regarding 
possible issues raised during the annotation, are reported. Although other formats, 
including CSN, have been proposed, such scheme has already been adopted by default by 
SnpEff, and selecting a specific option by VEP. This indicates the willingness of the 
developers to make a common effort to achieve a standard and easily handled format, 
favoring also the developing of new VCF parser which will facilitate the final data 
prioritization. 
 
Web-interface implementation 
The process of variant prioritization is not directly integrated in the stand-alone version of 
VarPred, as it was established since the beginning to develop a web interface of the 
software when its implementation was almost finished. Even if the platform is not still ready 
to be publicly released, its skeleton is essentially completed. Indeed, not only for testing, but 
also for convenience, the web version of VarPred was frequently used to annotate various 
type of VCF and to explore the obtained results. For using the platform, implemented 
through the Django Python framework, no registration is required, but only a valid email 
address where a message with a private URL for the results visualization will be sent. Firstly, 
the user has to choose among one of the integrated species (Figure 9A) which are 
essentially the most used in the biosciences including some model organisms, as the 
zebrafish and the mouse, and obviously the human. This initial selection is necessary for the 
following steps because the different species are associated to peculiar parameters and 
features (Figure 9C), such as which databases or genes sets are available. These latter are 
set up in the second step, where also several VCF files can be uploaded (Figure 9B). Once 
variants and the other information are submitted, a job file is properly modified and sent 
into a specific designed queue in the CRIBI cluster. The processing can be followed in the 
specific web page through a loading bar (Figure 9D). When the annotation is concluded, the 
user can begin to explore the results, which are presented as an interactive table, managed 
by the JQuery DataTable library. If more VCF files have been uploaded, the same number of 
pads will be clickable on the top of the web page. On the left, instead, it is located the menu 
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for the filtering, where the type of variant, the allele frequencies, the genomic context and 
the putative impact on protein can be selected (Figure 9E).  
Contrary to the majority of similar web tools, which save data into relational databases, the 
web interface of VarPred exploits pickle files, where annotated variants are stored. Once the 
user’s request for filtration or sorting is sent to the server, a Python Pandas script collects 
the information, loads the specific pickle file, executes the request and returns the final 
 
Figure 9|Web implementation of VarPred. A|The typical workflow, using the web implementation of 
VarPred, starts with the selection of the species to be annotated, among those implemented. B|Then, 
several VCF files can be easily uploaded in few seconds through a ‘drag and drop’ window. C|The analysis 
parameters including the project name, a valid email address and the expiration time, are set up in the 
following step, D|which triggers to the beginning of annotation process, notified by the loading bar 
appearance. E|Finally, the user can filter the annotated results exploiting the interactive menu on the left 
side of the page and refine the output using the controllers integrated into the table.  
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results. The whole operation usually takes few seconds, ensuring an almost real-time 
visualization of the final outcomes. Although not yet implemented, the results will be 
accompanied by several interactive charts, which will help the user in the comprehension of 
the managed data.   
As it is possible to understand, the VarPred web server is currently a work in progress, and 
for this reason it is probably the area in which more improvements could be introduced in 
the near future. In fact, in addition to the features which will be included into the stand-
alone software, the platform will be ameliorated in order to become widely usable, thanks 
to the development of a fully interactive user-friendly interface, but at the same time 
flexible and easily maintainable, to be kept always updated.  
 
Tool comparison 
To assay the performance in terms of speed and quality of annotation provided by VarPred, 
the software has been compared with the most widely spread variant annotators, including 
ANNOVAR, SnpEff and VEP, which collect respectively 3280, 1746 and 1160 citations in 
literature. The speed tests are quite simple to perform as it is enough to run multiple times 
all the tools on the same machine with identical or at least similar parameters in various 
conditions. The quality of annotation is instead really difficult to establish for several issues. 
First of all, no benchmark is available for such kind of testing, excluding the COSMIC 
database whose annotation is homemade, but almost all predictions do not follow the HGVS 
nomenclature. Moreover, the output of the different tools is quite various even if a great 
effort has been done to standardize it. Indeed, VarPred, SnpEff and VEP follow the rules 
provided by Cingolani and colleagues, but in many cases a rearrangement of protein 
predictions is necessary to efficiently compare them. Finally, also the choice of the gene-set 
selected for the annotation has a great impact on the comparison; unfortunately, it is not 
always possible to trace the version or the type of transcripts used, as it happens for 
COSMIC. 
Nowadays the annotation time is not so relevant, if compared with the whole time taken by 
a common analysis pipeline from raw data conversion to variant detection. Nevertheless, 
the time performance of the previously mentioned variant annotators has been tested in 
different conditions, changing in particular the number of variants to process (WES or WGS) 
or setting up a common parameter, such as the addition of rs codes and allele frequencies 
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obtained from dbSNP. For each test, five replicates have been performed and the final 
averages have been plotted with their matched standard deviations to facilitate the 
comparison. Moreover, SnpEff has been assayed twice, as the multithreading configuration 
has been considered separately from the common implementation, as previously reported 
in the work of McLaren and colleagues [162]. 
VarPred shows an overall good performance. In particular, considering the annotation of a 
VCF derived from a human WES project (~45000 variants), VarPred is really competitive, 
showing a higher computation time only when compared with ANNOVAR (Figure 10A). 
Moreover, VarPred is the quickest software for annotating the same VCF using also the 
dbSNP database. In such condition, all programs have significantly increased their running 
time from 2 to 15 times, with the exception of VarPred (Figure 10B). This evidence could be 
explained by the integration of tabix algorithm, which guarantees a high-level computing, 
within the function for associating the dbSNP information to the variants. At genome level, 
instead, VarPred seems to perform a little bit worse than the others even if its performance 
is quite similar to the Ensembl VEP (Figure 10C). A possible explanation could be associated 
to the fact that VarPred is the only software among the considered ones to display almost a 
linearity between the run-time and the variants number, while SnpEff is the tool whose 
processing is less affected by the increasing of variant number. Surely, the best performance 
of SnpEff, when the cohort to be annotated is wider, depends on the programming language 
used for the software implementation. In fact, Java thanks to its compiled nature is typically 
faster than the interpreted languages, such as Python or Perl, in which VarPred and VEP are 
respectively written. On the other hand, Java employs much more time to begin the 
processing, explaining in this way the low efficiency of SnpEff in annotating a strict group of 
variants. Instead, the multi-threading version of SnpEff has not be included in the 
comparison at the genome level as the run time reproducibility was really low, due to 
several random errors, including an out of memory in a 48gb RAM server. Nevertheless, the 
fastest tool in almost all the conditions is ANNOVAR (Figure 10D), that is implemented in 
Perl like VEP. Similarly to what reported by McLaren and colleagues [162], the shorter 
processing time of ANNOVAR is due to the reduced annotation depth of such tool. Indeed, 
the other applications perform the annotation at transcript level, while ANNOVAR reports a 
prediction at gene level, usually considering only the canonical transcript or at most a few 
number of them.   
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The performance of VarPred has also been tested using various species with different 
complexities such as the Mus musculus or the Saccharomyces cerevisiae. It was seen that 
the number and the complexity of genomic features used during the annotation highly 
impacts on the run time of the software. This behavior results in faster analyses for species 
scarcely characterized than those associated with a rich annotation such as the human and 
the mouse. 
A 
  
B 
C 
 
 
Tool WES 
WES 
dbSNP 
WGS 
ANNOVAR 20.3±0.1 179.1±1.2 624.1±28.1 
SnpEff 88.8±0.8 157.2±0.5 2454.9±13.6 
SnpEff MT 71.7±0.6 139.1±1.3 NA 
VEP 66.1±0.7 1142.2±16.1 2735.3±82.0 
VarPred 51.8±0.3 57.1±0.9 3066.5±28.1 
 
D 
Figure 10|Time comparison among variant annotators using bar plots. ANNOVAR June 2017, SnpEff v4.2 
(common and multi-threading), VEP v89 and VarPred have been assayed. Tests on human WES VCF file (45K) 
A|using common annotation features or B|adding the dbSNP annotation. C|Test on COSMIC Coding 
Mutations v74 (2.9M) using common annotation features. D|To summarize all the results reported in the bar 
plots, the average running times, expressed in seconds, with their standard deviation are also numerically 
detailed. Common annotation features include all HGVS predictions, gene, transcript and protein IDs, SO 
terms and position at transcript and protein level. The NA value for SnpEff MT is due to several errors raised 
during the software execution, which inhibited the possibility to get reliable results.  
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The COSMIC v74 dataset, previously filtered to eliminate variants falling out of the coding 
regions, has been chosen for testing the reliability of annotation provided by the software 
included in the comparison. The obtained group, including about two million of variant, 
constitutes a good benchmark for such kind of evaluation, even if, as explained above, the 
predictions have to be modified in order to be compared with those calculated by the 
annotators. Although most of the dataset is composed by SNPs, it shows also a wide 
variability in the incorporated data, including complex rearrangements, thus almost 
completely covering the whole landscape of the possible types of annotation. 
A 
 
B 
 
 VEP SnpEff ANNOVAR VarPred 
SNP 99.191 99.194 98.599 99.283 
MNP 98.667 94.413 NA 99.191 
DEL 94.583 93.279 41.215 94.583 
INS 93.589 91.918 32.312 93.667 
COMPDEL 87.052 85.259 3.984 88.048 
COMPINS 77.918 73.817 3.155 78.864 
TOTAL 99.027 98.962 96.165 99.118 
 
Figure 11|Consistency of annotation 
among variant annotators.  VEP v89, 
SnpEff v4.2, ANNOVAR June 2017 and 
VarPred have been tested. Consistency 
is displayed by the percentage of 
variants matching protein annotations 
in a filtered version of COSMIC Coding 
Mutations v74 based on 1964578 
SNPs, 10130 MNSs, 18015 INSs, 47002 
DELs, 502 Complex DELs and 317 
Complex INSs, for a total of 2040544 
variants. NA, protein level annotations 
not available. A|Graphical 
representation of the results using bar 
plots. B|Tabular format of the same 
values expressed in seconds. 
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VarPred essentially outperforms all other tools for the consistency of annotations (Figure 
11A), displaying however similar results to what obtained with the Ensembl VEP, as the 
differences are not significative (data not shown). Indeed, VEP is the software showing the 
best outcomes among the published tools, followed quite closely by SnpEff, while ANNOVAR 
is really far from giving an accurate annotation (Figure 11B). In fact, ANNOVAR has a very 
high error rate on insertions and deletions, mainly due to the lack of realignment, it 
performs even worse with the complex variations, and finally it is not able to analyze MNPs. 
This is surprising as ANNOVAR is the most widely used variant annotator counting more 
than twice the number of citations of VEP or SnpEff.  
VarPred is really competitive and precise, as it is able to correctly annotate more than 99% 
of variants, showing the lowest performance with the complex insertions which is however 
near to the 80% (Figure 11). It should be pointed that the overall annotation quality could 
be even better, as not always the COSMIC predictions seem to be corrected: in fact, in such 
situations VarPred and VEP often show concordance among their computed values, which 
instead differ from what reported in the benchmark. Another source of error is related to 
the different transcript set used for annotating COSMIC: in fact, a certain number of 
variations are defined as coding, when instead with the new release it has been shown their 
non-coding origin. Finally, the COSMIC annotations in some occasions are hardly convertible 
into the right HGVS codes, causing a slight decreasing of the performance rate, even if such 
difference is not significant. 
Taking into account all the issues discussed in the introduction, VarPred solved all of them 
with the exception of the correction of adjacent SNPs in order to create a MNP, without 
using the information contained into the BAM file. Theoretically the only case of difficult 
interpretation is when both variations are heterozygous, while in the other two cases, both 
homozygous and one heterozygous and one homozygous, are quite easy to analyze. The 
above problem can be assessed starting from the analysis of the genotypes and the 
coverage values of the two variants. In fact, unless the two positions are exactly covered by 
the same number of mutated and normal reads, through the analysis of linkage 
disequilibrium between variants coverage, it should be possible to assign a confidence for 
defining if the two variations fall in the same read or not. Another problem of such method 
derives from intrinsic difficult to extract the coverage information from VCF files: indeed, 
the fields for including the coverage values are not standardized among the VCF files 
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released by the various software, and furthermore some variant callers report only 
genotypes and the associated reliability of the computed values, without including the 
necessary data. In these last cases, it is not possible to fuse the SNPs into a unique MNP. 
However, the integration of this functionality within VarPred should allow to ensure the 
best level of annotation among the publicly available tools, although its consistency is 
already the highest one.  
 
3.2.4. Conclusion 
Thanks to its implementation, VarPred is a valuable tool for a fast and really accurate 
annotation of VCF files derived from NGS project. It can be employed not only in human or 
model organisms, but essentially in all species for which a reference genome and a gene 
annotation are available. This is possible as VarPred, in contrast with the other published 
tools, does not apply predigested files, produced by the developers, to perform the 
annotation, but it starts from the source files directly downloaded from the archives. 
Moreover, it is able to extend the annotation to all the transcripts included into the adopted 
gene-set, accepting data in both GTF and GFF3 format and from various repositories, 
including Ensembl, GENCODE and RefSeq. The reliability of annotation is guaranteed by the 
normalization system integrated into the software and by the choice of a standard output 
format. Also the web interface is almost completed, although some improvements and an 
extensive testing should be performed. Nevertheless, VarPred shows the highest 
consistency of annotation (>99%) among the published tools. Taking into account all these 
features, VarPred can be considered ready to be released to the scientific community.  
 
3.3. QueryOR: a comprehensive web platform for genetic variant 
analysis and prioritization 
This section contains a slightly modified version of the article that I published in April 2017 
on the BMC Bioinformatics journal [178]. The paper is accessible in its final format following 
the link https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-017-1654-
4. The figure numbers have been changed to be sequential with the enumeration of the 
thesis. 
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3.3.1. Introduction 
Over the past few years, the advances in DNA sequencing technology have opened new 
perspectives in many fields of Life Sciences. In particular, Whole Genome Sequencing (WGS) 
and Whole Exome Sequencing (WES) are contributing to the extraordinary progress in the 
study of genetic variants, improving the understanding of causative genes in human 
disorders. 
While “Next Generation Sequencing” (NGS) is making the production of sequencing data 
progressively easier, bioinformatic analysis is still a problem when dealing with genes and 
pathologies not well characterized at the molecular level. 
The initial bioinformatic steps for variant analysis are quite standard: the NGS reads are 
firstly aligned on the human reference genome [201], then the resulting SAM file [202] is 
parsed for the identification of genomic variants. As a result, a Variant Call Format (VCF) file 
with the list of variants is generated [182]. 
The selection of candidate variants responsible for the phenotype or disease under study 
remains a challenging task. Firstly, we need to functionally characterize and annotate the 
large number of variants that are typically detected: tens of thousands for WES and millions 
for WGS. Several approaches have been developed to accomplish this task. Programs like 
SIFT [203] and PolyPhen-2 [204] evaluate variants by focusing on the impact of amino acid 
changes on protein function, while ANNOVAR [163] extends the functional annotation 
considering other features such as phylogenetically conserved regions and allele frequency 
in populations. 
Once the variants have been annotated further action is required to choose the most 
effective criteria for “prioritizing” candidate causative variants. It is unfeasible to conceive 
an all-purpose protocol as the type of problems and the available data may be very 
disparate. Moreover, field-specific expertise may be essential both in the definition of the 
criteria and in the interpretation of the data. 
If the genetic disease is well characterized at the molecular level, then the obvious action to 
take is to focus on the variants occurring on known causative genes. Unfortunately, our 
knowledge is still limited as ~50% of Mendelian monogenic diseases have not yet been 
associated with causative genes [205], while most polygenic disorders remain 
uncharacterized at the molecular level. 
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Taking into consideration that the function of many genes is still unknown, bioinformatic 
approaches such as Endeavour [206] prioritize candidate genes on features shared with 
other genes that are involved in the same biological process or disease under study. Several 
phenotype-driven approaches have been implemented in programs like eXtasy [207], 
PhenIX [208], Phenolyzer [209], PHIVE [210], Exomiser [211] and Phevor [212], taking 
advantage of resources such as Gene Ontology (GO) [213], Human Phenotype Ontology 
(HPO) [214] and Disease Ontology (DO) [215]. 
As previously mentioned, the prioritization process usually requires the integration of a 
wide range of functional information about variants, genes and diseases as well as mode of 
inheritance when multiple individuals are considered. Currently, the standard strategy 
involves the application of filters with arbitrary thresholds that progressively remove 
variants not satisfying the criteria. As a result, there is the risk of removing something that is 
just below the threshold for one of the criteria, while being well above the threshold for the 
other criteria. 
Prioritization is not only confined to the problem of merging information on variants, genes 
and phenotypes. An issue that is often disregarded is that the clear majority of genes 
undergo alternative splicing [216]. As a result, the same variant may have very different 
functional outcomes, for instance it may generate a stop codon in a transcript and a silent 
variant in another isoform of the same gene. For this reason, the annotation of variants 
should refer to each alternative transcript rather than the putative major isoform. 
Recently, some web-servers [217] have been developed to analyze exome data, but they do 
not satisfy most of the above requirements, thus limiting the spectrum of possible analyses. 
Stand-alone programs such as VariantMaster are available [218], but they are driven by line-
commands that make their usage cumbersome and difficult for most users. An additional 
problem is that our knowledge on human genomics is changing very rapidly at all levels, 
needing continuous updates, implementations and integration of data, tools and ideas. 
Therefore, a platform for prioritization that combines usability and comprehensiveness has 
become a priority. 
With these premises in mind, QueryOR has been engineered as a user-friendly web-platform 
that integrates the most advanced prioritization criteria. Furthermore, QueryOR is built on a 
robust set of XML-defined rules that allows an easy implementation of new criteria without 
modifying the program code. Currently, 70 different criteria of prioritization have been 
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implemented in the platform and can be selected by users to build dynamic tailor-made 
queries and to facilitate expert-driven variant and gene prioritization.  
QueryOR is freely available for academic institutions at http://queryor.cribi.unipd.it/. 
 
3.3.2. Materials and Methods 
Web-interface implementation 
QueryOR has been implemented in CGI/Perl combined with Apache web-server. JavaScript, 
Jquery, AJAX and CSS properties are used to dynamically render some parts of HTML pages 
and to define their structures and layouts. The pages for criteria selection and transcript 
report are built on dedicated XML-files. For this reason, we have developed a XML-language 
that describes standard database queries and their web representation (layout, form 
elements, hyperlinks, highlighted columns). Thus, any selection criterion or transcript data 
table is completely specified in a XML node, making the system flexible and scalable. The 
XML language also allows the user to integrate custom databases into the QueryOR 
platform. This integration is easily obtained loading multicolumn files with information 
related to genes (one column must contain the ENSEMBL gene ID) or variants (four columns 
are mandatory: chromosome, position, reference allele and alternative allele). Once the file 
is loaded, the user can select the fields on which one or more filters have to be created. 
Then, the system automatically fills a new database associated with the project and builds 
specific XML-files containing the new queries, which will be available with all other criteria. 
 
Data processing implementation 
The data processing step is based on in-house scripts developed in Perl, Python and Bash; it 
runs on a blade cluster, managed by a PBS job resource manager (TORQUE). ANNOVAR 
software and dbNSFP database (v2.9) [219] are used for the annotation of variants, in 
addition to a homemade script. All project data are stored in a local database using 
MariaDB, a MySQL open-source fork, with the TokuDB® engine. The database is designed to 
contain both annotation tables and user data tables. The former host human gene 
annotations and known SNP information (global minor allele frequency, clinical significance, 
etc.) and are regularly updated every 6 months. The latter stores the data uploaded by the 
user and the associated meta-data produced during the “Data processing” step. 
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ENSEMBL data and variant annotation integration 
The hg19 release 81 of human gene and transcript data has been downloaded from 
ENSEMBL (http://grch37.ensembl.org/info/data/ftp/) [220]. Two different databases of 
known mutations have been integrated in the platform: dbSNP [71] version 144 
(http://www.ncbi.nlm.nih.gov/SNP/) [221], modified to recover old variants excluded from 
this last release but present in the online version, and Exome Variant Server version 
ESP6500SI-V2 (http://evs.gs.washington.edu/EVS/) [154] have been chosen to annotate 
allelic frequencies in the population. Disease information has been obtained from OMIM 
(http://www.omim.org/) [154, 222] and associated to gene and transcript data. Regarding 
somatic mutations, QueryOR incorporates COSMIC database [223] version 74, whose SQL 
table has been created starting from VCF files containing both coding and non-coding 
mutations and the complete export file of COSMIC. In case of new releases of gene 
annotations, dbSNP files or OMIM data, a custom set of Perl/Python scripts have been 
developed for the automatic update of all SQL tables. 
 
Integration of functional and phenotypic annotations 
QueryOR integrates several gene annotations derived from different public databases, 
which have been directly obtained from their respective websites or through ENSEMBL 
BioMart [243]. Within these annotations, QueryOR embeds Gene Ontology [171] and 
InterPro [224] data, as well as two different pathway repositories, KEGG (Kyoto 
Encyclopedia of Genes and Genomes) [225] and Reactome [177], which have been collected 
using the Graphite package [226] of Bioconductor [227]. QueryOR also makes available gene 
expression data derived from the GTEx portal (version 6) [174]. The information contained 
in this atlas has been processed to link Ensembl ID to tissues and sub-tissues in which the 
gene is expressed. The level of expression is measured in RPKM (Reads Per Kilobase per 
Million mapped reads) [228]. Moreover, regarding the phenotype annotation, the platform 
accommodates two main databases: DisGeNET version 3.0 [229] and Human Phenotype 
Ontology (HPO) release 98, whose entries have been further processed to be associated to 
ENSEMBL-ID. The updating of these functional annotations has been automatized through a 
set of Perl/Python scripts as described in the previous section.   
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Chromosome map tool implementation 
The “runs of homozygosity” (ROHs) are calculated by comparing the user-uploaded variants 
and the high-polymorphic dbSNP variants (GMAF higher than 0.3) falling into the target 
regions. The algorithm extracts those positions where only dbSNP variants, and no custom 
variants, are mapped. The resulting locations are those with a homozygous genotype for the 
reference allele (0/0) in the analyzed sample. 
Using these spots, the script finds all the ROHs, computes the length distribution and selects 
the stretches whose length exceeds the 95th percentile of the distribution. Then, the 
algorithm tries to extend all the ROH seeds in both directions as long as the homozygosity 
ratio (number of positions with 0/0 genotype divided by the sum of homozygous and 
heterozygous positions in the considered region) remains above 0.9. ROHs are used to build 
the “chromosome map” chart in association with the genes selected during the 
prioritization process. 
 
Case study dataset 
The exome data from the “Diagnostic Exome Sequencing in Persons with Severe Intellectual 
Disability” (study EGAS00001000287, 
https://www.ebi.ac.uk/ega/studies/EGAS00001000287) [230, 231] were obtained from the 
European Genome-Phenome Archive (EGA) website. 
 
3.3.3. Results 
We have implemented QueryOR dividing the process into three main steps as shown in 
Figure 12. Each step is further divided into different sub-steps and procedures, as detailed 
below. Users will spend most of their time at step 3, querying and browsing the system in 
the search of possible causative variants. To test the potential and features of the querying 
step, several sets of data have been made openly available on the platform, including some 
trio data from de Ligt et al. [230], as well as data produced by our own group. 
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Figure 12|The three main 
steps of QueryOR 
analysis. Step 1 and step 
3 require interaction with 
the user, whereas step 2, 
data processing, is 
automatically performed 
by the system after 
uploading VCF files. 
 
Uploading and updating VCF files 
All QueryOR’s activities are centered on projects that the users can create and possibly 
share with their collaborators. Projects can be related to single individuals, trios or families, 
as well as population or cohorts. Starting a project is very simple, but users must first 
register, both for privacy reasons and for permitting the retrieval of their data. 
The creation of a project requires the uploading of VCF files that must satisfy several 
requirements. Firstly, each individual sample should be labeled with a unique name that will 
be used as identifier in the subsequent steps. Secondly, the information about genotype, 
allelic depth and total read depth, which are usually found in the GT, AD and DP fields, must 
be available. Although VCF is a well-established format, not all variant callers implement the 
VCF fields in the same way; for instance, the Torrent Variant Caller does not fill the AD and 
DP fields. Therefore, we have developed specific scripts that calculate the allelic and total 
read depth from other parameters, such as Alternate allele Observations (AO) and 
Reference allele Observation count (RO). As a result, the platform accepts VCF files 
produced by all the commonly used variant callers. 
In the upload/update step the user can also upload BED files containing regions of interest. 
BED files should have four columns for each row: chromosome number, starting position, 
ending position and sample ID; the latter is used to associate the genomic coordinates to 
the right individual. These custom-defined regions will be shown in the graphical synopsis of 
variants and transcripts (Fig. 13-Q3) as yellow boxes. We usually exploit this feature to mark 
on each sample the regions with low coverage. 
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Once the files are uploaded, QueryOR takes some time, from minutes to hours, to process 
data, depending on the number of uploaded samples and variants. The user can check the 
job status while the processing is running. The beginning and the end of the process are 
notified by automatic emails to the user’s registered address. 
  
Data processing 
Data are processed by an automatic back-end procedure that provides a comprehensive 
annotation of the variants, linking them to genes, transcripts, encoded proteins and 
biological ontologies. QueryOR takes into consideration that alternative splicing may 
generate multiple transcripts from the same gene. As a result, a variant may have different 
effects depending on the transcript isoform. With this premise, we thought that the 
common practice of limiting variant annotation to the major transcript isoform is a coarse 
approximation. Therefore, to manage this problem QueryOR annotates variants on all the 
predicted ENSEMBL transcripts derived from alternative splicing events. Furthermore, the 
distribution of variants on the different splicing isoforms can be displayed and examined by 
the user as a part of the interactive result analysis described in the next paragraph. 
Besides QueryOR’s own procedures, a further double annotation is performed using both 
ANNOVAR [163] and dbNSFP [219], thus obtaining a wide set of measures, scores and 
constraints related to each variant, that among others include SIFT [155], PolyPhen [204], 
MutationAssessor [232] and GERP++ [160]. 
Data processing involves many other steps, including the association of variants to the 
available information in dbSNP, such as the allelic frequency in the global population and in 
ethnic groups, as well as the presence in the 1000 Human Genome Project [233]. Moreover, 
we discovered several thousand SNPs in the reference genome (both in GRCh37 and 
GRCh38) that do not correspond to the major allele in the population and as a consequence 
are found as “false positive” in most individuals. To overcome this problem, the reference 
positions characterized by a dbSNP frequency lower than 0.1 are annotated as MAiRs 
(Minor Allele in Reference). 
When a project involves the analysis of multiple patients such as trios and families, the 
platform runs a specific module that automatically computes how variants are shared 
between individuals. Moreover, possible Runs of Homozygosity are calculated for each 
sample, as explained in the Methods section. 
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All the retrieved and computed information obtained by the data processing step is stored 
in the QueryOR database. 
The overall time required for loading and processing data is approximately proportional to 
the number of variants. Typically, for ~100,000 unique variants (6-8 exomes) the time 
required is less than 20 minutes. A more detailed analysis of the loading time is given in 
Figure S1. 
 
Interactive queries and results analysis 
After the completion of data processing, the user can explore the information that has been 
associated to the project, following the general procedure shown in Figure 13. Queries can 
be formulated very easily and the resulting answers are typically delivered in a few seconds 
that can extend to minutes for very complex queries. Thus, it is possible to experiment 
different criteria and parameters, to perform a comprehensive investigation and to get 
progressively closer to possible causative genes. A detailed analysis of the querying time, as 
a function of the number of criteria and variants can be found in Figure S2.  
The complete route from query to variant takes five progressive steps that correspond to 
pages appearing on the web browser, labelled Q1 to Q5. At each step, some decisions must 
be taken: Q1 is for the query, Q2 is for choosing a gene from the resulting list, Q3 is for the 
selection of a specific transcript among the different isoforms, Q4 corresponds to the 
transcript report where a certain variant can be chosen and Q5 is the description of the 
variant. Like being in a maze, you may explore some paths and you can go back if the route 
leads to a dead end. In the web browser, Q1 to Q5 will open as independent pages making it 
easy to return to any of the previous steps. Some integrated QueryOR tools are associated 
to different points of this route, to make decisions easier. The main features of this process 
are described in the following paragraphs. 
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Figure 13|Common analysis in QueryOR. A typical route for a QueryOR investigation starts with the 
selection of criteria (Q1); a ranked list of genes and variants is returned in Q2. The selection of a gene, for 
instance FUCA2, leads to page Q3 where variants and affected transcripts in their genomic context are 
shown. The black track at the top of Q3 shows the target regions of exome capturing. The blue tracks just 
below show that the analysis was done on two samples named APN and APM, that share a heterozygous 
variant (white circles). The yellow boxes report the positions specified in the optionally uploaded BED file, 
indicating for instance low coverage regions. The bottom part of Q3 shows two alternative transcripts where 
the same variant in one case is located in an exon, generating a missense substitution (dark blue circle) while 
in the other case is located in an intron (gray circle). By clicking on a transcript of Q3, the system returns Q4, 
where several transcript features are directly linked to external resources, as well as to the variant overview 
page (Q5). For a full list of symbols used in Q3, see Figure 14. A more detailed description of the entire 
process is given in the main text. 
Query procedure (Q1) - Page Q1 allows the user to select the criteria for prioritization that 
are grouped into seven main sections. Three sections (ENSEMBL Features, Functional 
Annotation and Phenotype Annotation) are related to genes, pathways and phenotypes. In 
these sections, it is possible to select for specific lists of genes and transcripts as well as 
features like gene ontology, gene expression and associations to pathways, diseases or 
phenotypes. The remaining four sections are related to variants. These include Variants 
Annotation (for instance genomic context and functional prediction scores), Variants 
Databases (for instance dbSNP, EVS and COSMIC), Variants Sharing and Segregation 
(variants in homozygosity and/or heterozygosity present or absent in different individuals) 
and VCF User Data (for instance variant coverage, genotype and quality calls). 
Each section can be exploded to visualize sub-sections that can be further expanded to see 
the selectable criteria. Figure 13-Q1 shows a query page where the section Variants 
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Databases shows four sub-sections and where the last sub-section (dbSNP) shows six 
selectable criteria. The selected criteria are shown on the right side of frame Q1 where 
GMAF is under definition, while other 7 defined criteria are shown in their “collapsed” view. 
By default, all criteria have the same relevance in the ranking process, but this can be 
modified by assigning different weights to each criterion. There are no restrictions in the 
number of selected criteria, but very complex queries may take a longer processing time.   
Engine (Q2) - When a query is submitted, the system performs an independent search for 
each of the selected criteria; then, the score of each variant is calculated as the sum of the 
weights of the satisfied criteria. Finally, genes are ranked according to their highest-score 
variant. The results from the query are summarized in a score table (right part of Figure 13-
Q2) that shows the number of genes and variants associated to each score. The two top-
scores shown in the right side of Figure 13-Q2 were selected and expanded to produce the 
results matrix on the left, where each row reports a single gene combined with the number 
of variants satisfying the prioritization criteria. 
By clicking on a gene name in the results matrix, more details show up. For instance, the 
image in Figure 13-Q2 was taken after expanding FUCA2 and BPIFB3. This feature is useful 
to better understand the results. In fact, although the first six genes have positive variants in 
every column, as shown by the blue background, only 2 genes satisfy all the 8 selected 
criteria, resulting in an associated score of 8. This apparent incongruence can be explained 
by looking at the expanded data of BPIFB3, showing that although the gene has some 
variants satisfying all the criteria, the two best variants satisfy only 7 criteria. 
From the bottom line of Q2 (Total Number of Variants) it is possible to appreciate the depth 
and the stringency of each filter and to make a general evaluation of the prioritization. Thus, 
the user can reconsider some of the criteria and go back to Q1 to redefine the query. 
Gene overview (Q3) - This page is shown after a gene is selected by clicking on the Gene-ID, 
in the results matrix. The page displays a compact graphical representation of alternative 
transcripts associated to the selected gene, together with the position and type of each 
variant across all samples. In Figure 13-Q3, two samples named APM and APN are shown at 
the top of the frame. Both samples share a heterozygous variant, represented by the white 
dots. The bottom part of the Q3 frame shows two alternative transcripts in which the same 
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variant acts as a missense mutation (dark blue dot) in one transcript and as an intronic 
mutation (gray dot) in the other. 
In the case of trio studies, samples are differently tracked to highlight parental heritage of 
allelic variants (haplotype configuration), as shown in Figure 14. 
 
Figure 14|Trio analysis. In the Q3 section, the arrow points to a variant that is heterozygous in both parents 
and homozygous in the child (full green bar). At the end of the next exon, the child displays a heterozygous 
variant, shown as a small green bar, which was directly inherited from the father. A detailed description of 
the variants is given in the Q4 section where the user can also find a link to the IGV viewer, that will be 
conveniently opened on the appropriate genomic position. 
Transcript report (Q4) - Detailed information about the transcript selected in Q3 is shown in 
Q4 (Figure 13 and Figure 14), where various contents are briefly described and directly 
linked to their primary source on the web. The variants that emerged from the prioritization 
process are highlighted with a blue background. If the BAM file is available on the client 
side, the user can consider to launch IGV [234] that will automatically point to the position 
of the variant under analysis to view the alignment of the reads on the genome. By the 
“Varinfo” button the user can move to Q5. 
Variant overview (Q5) - This page allows the evaluation of the specific features of the 
candidate variant (Figure 13-Q5) where several pathogenicity scores are accessible, 
including the above mentioned PolyPhen and SIFT, as well as Mutation Taster [235], CADD 
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[156] and DANN [157]. Although these features are sometimes discordant, it is useful to 
have a global view to estimate the possible pathogenicity of the variant under analysis. 
Advanced analyses - From page Q2 it is possible to access other QueryOR’s tools such as the 
“Variants Report” that is a printable table summarizing the information on variants, genes 
and pathogenicity. Another link builds a “Chromosome map” reporting possible Runs Of 
Homozygosity, that can be important in the analysis of human disorders, as they represent a 
good clue for the presence of deleterious variants responsible for recessive diseases [236]. A 
further link takes the user to the “Gene Analysis tool” that allows the identification of genes 
carrying different mutations among a group of patients. With this tool, it is possible to 
investigate unrelated patients or to investigate diseases caused by de novo mutations, 
where it is more important to know if the same gene is mutated in different patients rather 
than if they share the same variant. This information comes as a summary table flanked by a 
distribution chart (data not shown). Each group of genes can be further investigated 
searching for shared biological terms, using DAVID [237], or for common pathways within 
Reactome [177] and KEGG [176]. 
 
Case study                     
To evaluate the performance of the platform we re-analyzed some of the data published by 
de Ligt et al. [230], (EGA study EGAS00001000287), concerning patients affected by 
recessive forms of cognitive impairment and mental retardation. Our prioritization strategy 
was achieved by applying several criteria on trio number 4 (VCF files EGAZ00001004509, 
EGAZ00001004510, EGAZ00001004511). In particular: 1) we selected high confidence 
variants with coverage level >60 and 2) with alternative allele coverage >30; 3) we only 
considered variants that changed the amino acid sequence; 4) as the disease is rare, we 
imposed a low frequency threshold with MAF<0.05; 5) the results were further fine-tuned 
by considering the “intellectual disability” Phenotype Ontology keyword; 6) taking into 
consideration the pattern of inheritance, we selected variants that are homozygous only in 
the child. QueryOR identified only two variants that could satisfy these six criteria. 
Interestingly, one of the two is a missense variant placed in the PDHA1 gene, in the X 
chromosome, corresponding to that proposed in the aforementioned work [230]. It is 
interesting to point out that with only six criteria it was possible to achieve a very effective 
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prioritization. The above case is fully explained in a tutorial available at 
http://queryor.cribi.unipd.it/cgi-bin/queryor/tutorial.pl. To prevent any incidental findings 
and to preserve patient’s privacy, the tutorial is based on the exome of a healthy patient, 
manually edited to insert the above variant. 
 
3.3.4. Discussion 
It is normal that when a new technology starts to produce novel types of data, the 
development of software analysis runs a little behind and eventually catches up. In the case 
of Whole Genome and Exome Sequencing this problem is particularly relevant because the 
scope of the prioritization process is not limited to the variants as such, but it extends also 
to a wide variety of data and information that is continuously updated and is often 
superseded by new discoveries. 
When we started the development of QueryOR, this context of generalized “work in 
progress” was one of our main concerns. Prioritization is essentially a process of data 
integration and to develop it using unstable datasets would be a vain effort. On the other 
hand, we thought that a user-friendly variant-prioritization platform, suitable for a wide 
range of analyses, could be of great utility. To overcome the problem of sustainability, 
QueryOR has been designed on a general schema rather than on predefined databases. A 
dedicated XML language permits the declaration of the datasets to be implemented in the 
platform. Each dataset is defined for its content, for the possible queries and for their web 
representation (layout, form elements, hyperlinks, highlighted columns), thus making the 
system flexible and scalable. 
Thanks to this flexibility many datasets are available in the platform while more will be 
added in the future. Although a query could be potentially made by selecting different 
features from all the available datasets, in a normal session only some of the data will be 
interrogated. Thus, there is a double level in which the information is organized: at the basal 
level, there are all the available datasets implemented by the QueryOR manager, while at 
the top there is the information emerging from the queries performed by the end-users.  
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Figure 15|Comparison of QueryOR with other platforms for variant prioritization. The platforms were 
tested using a VCF input file. The indicated number of available criteria is approximate due to different ways 
of implementation. 
In literature, several bioinformatic tools for whole exome analysis are reported, but only a 
few of them are suitable for a comprehensive and efficient exome investigation. In fact, 
while some platforms center their analyses on gene features found in biological ontologies, 
others focus primarily on variant annotations, disregarding gene function. In QueryOR we 
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combined the most useful features found in other tools, gathering and expanding them 
within a single platform. Moreover, to enhance the potential of the analyses, we 
implemented some important features such as the annotation of minor alleles in the 
reference genome, several prioritization criteria based on VCF information such as coverage, 
genotype and quality score, as well as criteria based on sharing variants and homozygosity 
in different individuals. Furthermore, we introduced the possibility to implement 
customized prioritization criteria based on databases supplied by the user. A detailed 
description of the procedure for submitting custom tables is given in the User Manual, 
available in the “Info” section of the web site. Figure 15 compares the main features of 
QueryOR with other available tools, including SeattleSeq [238], wANNOVAR [163], VEP 
[162], BierApp [217], PhenIX [208] and OVA [239]. 
To our knowledge, QueryOR is the open web tool with the widest spectrum of applicable 
criteria (currently 70) for exome data prioritization, spanning from gene and variant 
annotations, to intrinsic features of the VCF file. Another interesting peculiarity of QueryOR 
regards the opportunity to select a subset of samples within a multisample project, allowing 
focusing on attributes found only in the chosen group of samples. 
A major effort has been made to simplify the formulation of complex queries. To perform a 
query the user can select any combination of criteria and associated parameters. For 
instance, one of the criteria could be the minimal coverage of the locus where a SNP occurs 
and the associated parameter could be “30”. Criteria can be classified in three main 
categories. The first group is based on the knowledge of genes and diseases, exploiting the 
functional and phenotypical annotation integrated in QueryOR as well as lists of candidate 
disease genes when available. The second category discriminates variants on the basis of 
information contained in the VCF file including coverage, genotype and quality of calling. 
The third category is related to variant features, such as pathogenicity scores, effect on 
protein, population frequency and distribution among the project samples. In particular, it is 
possible to impose a specific inheritance model in trios as schematized in Figure 16, or 
families and cohorts, allowing for instance the selection of variants shared or not shared 
among different patients or that are homozygous in some patients and heterozygous in 
others. 
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Figure 16|Usage of the criteria for “shared” 
and “homozygous” variants in a trio case. 
Diamonds indicate different hypotheses that 
can be made. For instance, if we hypothesize a 
recessive homozygous variant in the child we 
should set two criteria: 1) shared variants by 
child and both parents and 2) homozygous 
variants only in the child. Whereas, for a 
compound heterozygosity we would expect 
that the child shares the variants, but we do 
not know which variant is in which parent; 
furthermore, the variant should not be 
homozygous in the parents. Compound 
heterozygosities are generally difficult to find 
and criteria based only on sharing and 
homozygosity would not be selective enough. 
In this case the “Gene Analysis tool” described 
in the text could help in the selection of genes 
carrying different mutations. Sometimes it 
may be useful to set criteria that may appear 
useless, like homozygosity on a X 
chromosome; however, this may help to 
reduce false positives. 
In the development of the graphical user interface, we dedicated a particular attention to 
user friendliness, both for setting the criteria and for interpreting the results. As an example, 
Figure 17 shows how de novo mutations can be searched and visualized in a trio of mother, 
father and child. 
 
Figure 17|Searching for de novo mutations in a trio. Q1: to set the criteria the user should select “Shared 
variants” and click the box beside each patient, selecting green, red or gray respectively for present, absent 
and ignore, while the sentence underneath will report in plain English the meaning of the settings; more 
criteria can be set by clicking the + symbol. Q3: the results include haplotype phasing. The yellow bar 
indicated by the arrow is a possible de novo mutation.  For the meaning of other symbols see Figure 14. 
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In contrast with other similar tools that return only the items that simultaneously satisfy all 
the query specifications, QueryOR sorts the results on the number and weight of satisfied 
criteria; thus, the user can have a global view of which criteria are or are not met for every 
gene and can decide whether to continue the investigation or modify the query. The 
integration of a wide range of heterogeneous information and the automated annotation 
procedure provides the end user with the ability to evaluate the information at various 
levels in order to establish the relationships between different data and to discriminate 
between causal and neutral variants. 
Several other innovative features of QueryOR make the process of prioritization thorough 
and at the same time easy. For instance, an important issue is that we annotated all the 
variants that in the reference genome are represented by rare alleles, that we named MAiRs 
(minor Allele in Reference). These variants can either be filtered off by the query 
specification or alternatively they will be automatically labelled as MAiR when seen on the 
selected genes. 
 
3.3.5. Conclusion 
Currently, QueryOR is primarily used to analyze exomes and gene panels, however it has 
been successfully employed also for whole genomes. In this respect, the main problem is 
the lack of functional information that can be associated to variants belonging to non-coding 
sequences. As this information will become available we will take advantage of the flexibility 
of QueryOR to implement datasets that may facilitate the prioritization of variants in whole 
genome analyses. 
In conclusion, the comprehensiveness of the implemented criteria and the aptness to add 
new features together with a user-friendly environment make QueryOR very suitable to 
support researchers, clinicians and geneticists engaged in variant analyses. 
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3.3.6. Supplementary Materials 
 
Figure S1|Time required 
for uploading and 
processing a project. The 
Figure shows the loading 
and processing time of 
about 200 projects, as a 
function of their number 
of unique variants. It can 
be seen that the 
required time is roughly 
proportional to the 
number of unique 
variants; however some 
discordance may be due 
to different ratios of 
novel/known variants, as 
well as to resource 
availability on the 
computer cluster. 
 
 
Figure S2|Time required 
for the processing of a 
query. The Figure shows 
the time required for the 
processing of queries 
with different number of 
criteria and with 
increasing number of 
variants. All the tests 
were repeated three 
times and the figure 
reports the mean and 
standard deviation of 
each point. 
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4. Data analysis: from clinical cases to recurrent 
nucleotide variants in WES studies 
 
4.1. A targeted sequencing panel for the analysis of the exons and 
the conserved intronic sequences of 50 lysosomal storage disease 
genes 
4.1.1. Introduction 
Lysosomal storage diseases (LSD) are a group of monogenic metabolic disorders, each one 
leading to the accumulation of specific substrates due to the deficit of a lysosomal 
hydrolase. Although individually rare, overall incidence of LSD is estimated around 1:5000-
1:8000 [240]. Affected children generally appear normal at birth and the first signs and 
symptoms develop during the first few months of life and progressively worsen; however, 
LSD can occur also as late-onset juvenile and adult forms. The diagnosis of LSD requires 
clinical expertise as most clinical features are not specific and could be shared by different 
LSD; in some cases, the diagnosis is very difficult and may take several years. The first 
diagnostic assessments performed are biochemical assays, useful to evaluate the 
accumulation of specific substrates and/or the enzymatic activity of one or more enzymes. 
Then molecular analysis of the suspected gene is performed to reveal the disease-causing 
genetic variants. This diagnostic route could be potentially reversed given the accessibility to 
NGS technologies which allow the simultaneous sequencing of several genes in a short time. 
An approach of targeting sequencing could be the primary screening tool in the diagnosis of 
LSD thus drastically shortening the time from the onset of first symptoms to the diagnosis 
formulation. In this study, we evaluated a LSD-genes targeted sequencing panel as a 
potential diagnostic tool for these disorders. The peculiarity of such panel derives from the 
inclusion of conserved intronic fragments (CIFs) within the design in order to detect 
mutations playing their pathogenetic role without directly affecting the coding region. 
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4.1.2. Materials and Methods 
Genes selection and panel design 
For genes selection we evaluated the Orphanet list of LSD, the SSIEM LSD list and the genes 
list reported by Fernandez-Marmiesse and colleagues for their panel design [80]. Genes 
associated with extremely rare disorders or disorders presenting with a very peculiar 
phenotype were removed from the list. The Ion AmpliSeq™ platform (Thermo Fisher 
Scientific®) [241] was used for the design of a custom panel including the selected genes. 
For each protein-coding transcript the exons, a 50 bp flanking sequence on each side and 
both UTRs were given to the Ion Ampliseq™ Designer software as target sequence. 
Moreover, we included the Conserved Intronic Fragments (CIF) obtained using a homemade 
pipeline developed ad hoc. To extract such regions, we used several kinds of data: a base-
wise conservation score (phastCons) calculated on the basis of multiple alignments of 33 
placental mammal genomes to the human genome [242], a list of common gene names and 
two gene annotations, RefSeq (version January 2015) and Ensembl GRCh37.75 [243]. 
Samples selection 
A total of 80 samples were collected from different European Clinical and Diagnostic Centers 
and from the Telethon “Cell Line and DNA Biobank from Patients Affected by Genetic 
Diseases” [244]. 59 were positive controls (PC); 12 of them belonged to patients who were 
diagnosed only through enzymatic analysis (biochemically diagnosed: BD). 9 out of 80 
samples came from suspected LSD patients for which a diagnosis had not been formulated 
yet (UD). 
Library construction, enrichment and sequencing 
DNA library preparation was performed according to the Ion AmpliSeq™ DNA Library 
Preparation protocol (Thermo Fisher Scientific) in combination with the Ion AmpliSeq™ 
Library kit, version 2.0. For the Ion Proton sequencing, libraries were loaded into a Ion PI 
chip and sequenced using the Ion PI HiQ Sequencing 200 kit. The produced reads were 
mapped using the Torrent Mapper (TMAP) and variants called by the Torrent Suite Variant 
Caller (TSVC). On a subset of BAM files (n=30), corresponding to the initial two sequencing 
runs (8+22), a coverage study has also been carried out to understand inter-runs and inter-
samples coverage variations, using principal component analysis (PCA) and density plots. 
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Variant analysis and prioritization 
Variant prioritization was performed by using QueryOR [178]. First an accurate selection of 
the most suitable criteria capable to choose in the positive controls the variants known to 
be associated with the pathology was done. Hence for each sample the analysis was splitted 
in three distinct queries aiming to prioritize: missense, nonsense and sense variants (query 
1), frameshift, inframe, stoploss and stopgain variants (query 2) and splicing-affecting 
variants (query 3). In case of no appreciable results obtained with the first three queries, an 
additional optional forth query was performed with the aim to prioritize the 5' UTR, 3' UTR 
and intronic variants (Table 5). Finally, in case of no results, the same queries were re-
launched removing the coverage filters to detect poorly covered variants. When the 
presence of long indels was suspected, a copy number variation (CNV) study using a in-
house software, specially designed to detect amplicons whose coverage significantly differs 
from what found in the same amplicons in the other samples of the same run, was carried 
out. All the variants identified were verified for coverage and chromosomal position through 
IGV [234] and annotated using the HGVS nomenclature through Ensembl VEP [162] or 
VarPred (§3.2).  
Filter Type Query 1 Query2 Query 3  Query 4 (optional) 
Allele frequency <0.01 <0.01 <0.01 <0.01 
MAiR no no no no 
Substitution type 
Missense, 
nonsense, sense 
Frameshift, 
inframe, stoploss, 
stopgain 
- - 
Transcript region - - 
Acceptor site, 
donor site 
5’UTR, 3’UTR, 
intron 
CADD phred score >10 - - - 
DANN score >0.8 - - - 
Alternative variant 
coverage 
>10 >10 >10 >10 
Table 5|Prioritization strategy for LSD samples. Description of the four queries and the relative criteria 
used for variants prioritization through QueryOR platform. 
Analysis of Conserved Intronic Fragments (CIF)  
The intronic variants located in the CIF included in the panel were filtered for frequency 
<0.01 by QueryOR and analyzed using different tools. SPANR (Splicing-based Analysis of 
 
74 
 
Variants) [245] was used to predict both intronic and exonic variants affecting RNA splicing. 
For each variant, which may be up to 300 nucleotides into an intron, the tool computes a 
score for how strongly genetic variant affects RNA splicing. Variants falling in regulatory 
regions and predicted to have a deleterious impact were obtained through Ensembl VEP. 
Variants validation 
The sequence variants identified in the BD patients and in the UD patients were checked in 
dbSNP [70], 1000 genomes [246] and ExAC [197] for frequency. Moreover, the variants were 
confirmed by Sanger sequencing in both directions duplicate PCR products. Obtained 
sequences were compared to the genomic reference sequence through BLAST. 
 
4.1.3. Results and Discussion 
Implementation of pipeline for CIF detection 
The pipeline for Conserved Intronic Fragments (CIF) detection is characterized by two steps, 
each of them implemented in Python. The first script allows to select from the phastCons 
scores the bases presenting a conservation value equal or higher than the threshold chosen 
by the user. Several tests have been performed to define an optimal threshold value which 
has been set up to 0.85. The output of the program is used as input of the second software, 
which contains the real core for designing the CIF; the other inputs are represented by two 
different gene annotations (Ensembl and RefSeq) and a simple gene list. First, all exons of 
the various transcripts assigned to the genes of interest included into the two annotations 
are extracted and merged together in order to collect all possible coding bases. This process 
allows to expand the region covered by common gene panels provided by the companies as 
they are usually based on the coordinates of the exons of the canonical transcript. In this 
way, not only exons, but also the intronic regions are identified. Within these latter, the 
conserved fragments are recognized and eventually fused into a unique feature when the 
gap among two of them is equal or lower than 2 bp. Then, CIF shorter than 20 bp are 
eliminated, while the rest are checked for the possible overlapping with exons of 
unconsidered genes, and in case discarded. Boundaries of the extended exons, the CIF and 
the UTRs are saved using a BED format with an extra column containing the gene name that 
the feature is associated with.  
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The file obtained running such pipeline over the selected LSD genes was submitted to the 
Ion AmpliSeq Designer™ platform to design specific enrichment primers. 
Panel design 
The total target sequence length is 202.59 kb and includes 50 LSD genes (Box 3) and 230 CIF 
with an average length of 40 bp. The panel design output is a 187.42 kb sequence covered 
by 1561 amplicons; the average amplicon length is 240 bp with 93% of the whole target 
sequence covered. Considering only exons, their flanking sequences and UTR, the target 
sequence coverage is 92.4%. The less covered genes result DNAJC5, CLN8, IDUA, NPC2, HYAL 
1 whose sequence is covered for a percentage between 55% to 80%. Considering only the 
coding sequence the most affected gene is IDUA with 8 exons being partially or totally 
uncovered. 
Box 3|List of lysosomal storage diseases genes included into the panel. 
AGA, ARSA, ARSB, ASAH1, CLN3, CLN5, CLN6, CLN8, CTNS, CTSA, CTSD, CTSK, DNAJC5, FUCA1, GAA, GALC, 
GALNS, GBA, GLA, GLB1, GM2A, GNE, GNPTAB, GNPTG, GNS, GUSB, HEXA, HEXB, HGSNAT, HYAL1, IDS, IDUA, 
LAMP2, LIPA, MAN2B1, MANBA, MCOLN1, MSFD8, NAGA, NAGLU, NEU1, NPC1, NPC2, PPT1, PSAP, SGSH, 
SLC17A5, SMPD1, SUMF1, TPP1. 
Sequencing 
Samples sequencing was performed in 4 separate runs having the following quality control 
metrics: 99% enrichment percentage, 22% polyclonal beads; 4% low-quality reads and 72% 
usable reads. Each library included about 300.000 reads with a mean length of 181 bp. The 
average coverage was at least 100X.  
On the first two runs, containing respectively 8 and 22 samples, a coverage study applying 
the principal component analysis (PCA) and analyzing the corresponding density plots was 
performed. The mean coverage of the two studies was 222.1±24.6 and 128.5±14.0 
respectively.  
Focusing on the results of the coverage study, the first run shows a quite uniform coverage 
distribution for 7 samples (Figure 18A), even if the corresponding PCA (Figure 18B), which 
represents the variation of the coverage distribution among the various amplicons, seems to 
identify three different groups of samples. Indeed, analyzing the mean coverage of the 
various target regions (data not reported), the clusterization reported in the PCA is quite 
easy to detect, as samples AWT and AWU display completely different behavior from the 5 
samples clustered on the top-left of figure 18B and from sample AXA (top-right, Figure 18B).  
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B 
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D 
E 
  
F 
Figure 18|Coverage study performed using density plots and PCA. A|Density plot and B|PCA on the first 
sequencing run including 8 samples. C|Density plot and D|PCA on the second sequencing run including 22 
samples. E|Density plot and F|PCA on all the samples of the two runs (30 samples). The comparison allows 
to establish intra-run and inter-runs differences.  
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Furthermore, this latter is the only specimen associated to a different coverage distribution 
(gray line, Figure 18A), indicating a higher number of bases with low coverage (pick at the 
beginning), but at the same time a slightly higher fraction of bases with really high coverage 
(>500X): in fact, its mean coverage (213.4X) is not significantly different from the others.  
Also the coverage distribution of the second run is almost homogeneous, with the exception 
of three samples (AZE, AZI and AZD) (Figure 18C), whose behaviors are similar to what found 
for AXA in the first experiment, even if in this case the coverage of the most unbalanced 
sample (AZE) is also the lowest of the whole run (105.1X). Moreover, for AZE and AZI, also a 
disequilibrium in the amplicon coverages can be observed. In fact, both PCA (Figure 18D) 
and CNV analysis (data not shown) allow to easily separate these two samples from all the 
others. 
Considering samples all together, with the exception of the previously discussed specimens, 
the coverage distributions have quite similar shapes, even if the first run shows a flattened 
trend due to the higher mean coverage (Figure 18E). The PCA confirms the results obtained 
using the density plots, as only AXA and AYX can be isolated from the main block of samples 
(Figure 18F). The behavior of AYX is difficulty explainable, while AXA was already widely 
disconnected in the first analysis.  
Thus, although the significative difference of the average coverage among the samples 
included in the two experiments (p-value=1.786×10-13), the reproducibility of amplicon 
coverage distribution between the different runs seems to be quite good. Indeed, the 
presence of outliers can be due to anomalous samples, which have met problems during 
library preparation or during sequencing or whose starting DNA quality was really low.   
 
Variant analysis 
Variant analysis has been carried out through a prioritization process performed by 
QueryOR platform. The total number of known variants per sample ranges from 63 to 359 
with an average of 253 variants; the average number of novel variants per sample is 7. To 
analyze the three groups of samples positive controls (PC), biochemically diagnosed (BD) and 
undiagnosed (UD), we used the same flowchart which consists in performing a set of 4 
queries, each capable of detecting a specific type of variant or group of variants (Table 5). If 
the output of a single query is greater than one variant, priority is given to alleles with the 
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lowest frequency or to not annotated alleles and to those presenting the most pathogenic 
scores. 
All 'pathogenic' variants but few have been detected applying the first 3 queries, being most 
variants located in the coding regions or in the nearest intron-exon boundaries. The analysis 
leads to the identification of pathogenic variants in 64% of the PC's alleles, if applying the 
coverage filters (>10X). Failed variants detection may be caused by: I) variants not covered 
by the amplicons due to panel design; II) low-covered variants due to poor amplification of 
specific amplicons; III) large deletions not detected by variant calling process. For analyzing 
this latter type of variations, we implemented a software able to discover amplicons with 
unbalanced coverage comparing to what found in the other similar samples, better if 
sequenced in the same run. This should allow to identify various types of CNVs. The 
program takes as input a table containing the mean coverage of each amplicon for the 
analyzed samples. Such values are normalized for the median coverage of the sample and 
then the average and the standard deviation of coverage within the amplicons are 
calculated. Two different approaches are thus applied for defining problematic amplicons: 
the ratio between normalized values and the median coverage over the amplicons, and the 
deviation from the mean amplicon coverage. The parametrization is left to the user, but by 
default the ratio is considered interesting if lower than ½ or higher than 2. Similarly, a 
variation from the mean of more than two standard deviations is worthy to be account. The 
output is a html table with a color code for an easy visualization of the obtained results.  
If the program detects a possible CNV, its trustworthiness is checked using IGV. For 
homozygous deletions, the evaluation of reliability is easier than the corresponding 
heterozygous case, as the amplicon is completely uncovered. Also for tandem repeats, the 
coverage should be twice or more times higher than the mean coverage in the other 
samples, facilitating the final interpretation. Surely, the efficiency of the software should be 
improved integrating more complex statistical methods or implementing new strategies 
based, for example, on Hidden Markov Models (HMM), as it happens in several tools for 
performing this kind of analysis, including CONDEX [247], XHMM [248] or CNAseg [249]. 
However, the detection of CNVs from genes panel data is still difficult and the using of one 
of the latest published tools, as HMZDelFinder [250], could help in such challenging task. 
Nevertheless, for some pathologies it has been proved that the increased benefit of exon 
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level deletion/duplication analysis is poor [251], leading to an improvement of the final 
efficacy that is not enough to completely justify the effort. 
 
Confirmation of biochemical diagnosis 
The panel analysis brought to confirmation of previous enzymatic diagnosis for 6 out of 12 
subjects in which we found both mutations. In two and three samples respectively we found 
only one mutation and no mutations. 
In one of the latter case, we found two mutations in GNPTAB gene in a patient 
biochemically reported as affected by galactosialidosis (CTSA). The patient carries a 
previously described mutation (c.3503_3504delTC) and a new variant presumably affecting 
a splicing donor site and potentially causing an exon skipping according to Human Splicing 
Finder [252] and SpanR [245]. Further cDNA analysis and the re-analysis of the clinical 
features of this patient for a better definition of his clinical picture should help in the 
confirmation of this hypothesis. 
 
New diagnoses achieved 
Two new diagnoses were achieved among the 9 undiagnosed patient (UD) analyzed. In a 
child suspected of mucopolysaccharidosis a novel hemizygous variant was found in the IDS 
gene (mucopolysaccharidosis type II); the same variant was detected in heterozygosis in the 
mother. In a girl suspected to be affected by mucolipidosis, we found two previously 
described mutations in GNPTAB gene (mucolipidosis II α/β, III α/β); the same mutations 
were detected in her parents. For the remaining 7 patients, a deeper analysis of the 
biochemical and clinical data is still undergoing in order to focus the panel analysis on 
specific genes whose gaps, if necessary, will be filled by Sanger sequencing. 
 
Analysis of Conserved Intronic Fragments (CIF) 
The analysis of CIF is performed to identify potentially dangerous variants located in intronic 
regions and is focused on those samples from undiagnosed patients in which no variants 
have been found through the previous analysis. 345 intronic variants with frequency <0.01 
or with no frequency (not annotated variants) filtered by QueryOR have been uploaded in 
SpanR and in Ensembl VEP. Nine variants have been selected by SPANR as potentially 
deleterious, but unfortunately none of them was carried by undiagnosed patients. The VEP 
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analysis instead revealed that 61 variants fall in regulatory regions, of which 6 can be found 
in promoters, enhancers or flanking regions of undiagnosed samples. The potential 
pathogenicity of these variants is currently under analysis, even if a final validation is 
possible only using “wet” approaches. 
 
Variant validation 
Sanger validations till now performed on BD samples confirmed the panel results with 
exception of one case in which a poor covered missense mutation was not confirmed. 
 
4.1.4. Conclusion 
Targeted sequencing is an appealing approach to implement routine diagnostic strategy, 
given its low sequencing costs and short sequencing time. However, a good coverage must 
be assured and validation by Sanger sequencing have to be carried out on the proband and 
on his parents as final step, also to exclude the presence of deletions in case of homozygous 
variants finding. Moreover, the possibility to fill the gaps in the panel design have to be 
guaranteed, especially in case of strong suspicion for a specific disease. 
 
4.2. LRP2 gene variants in Dent disease patients with no 
detectable mutation in CLCN5 and OCRL genes 
4.2.1.  Introduction 
The second case study has been investigated in collaboration with the group of Prof. Franca 
Anglani of the Department of Medicine. It regarded the evaluation of a small cohort of 
patients showing many signs recallable to Dent disease (DD) [253], but with no mutation in 
the previously identified disease-associated genes, CLCN5 [254] and OCRL [255]. These 
seven patients were classified as DD3. Globally, on the total cohort of DD patients, DD3 
constitute approximately the 25% of the cases. Considering our previously published work 
[256], we hypothesized that such group may represent unknown or unrecognized 
phenotypes of already known nephropathies, including the Donnai-Barrow (DB) syndrome, 
where mutations in LRP2 gene are typically associated with the onset of the disease [257]. 
The most interesting patient (BDA) affected by common symptoms of DD, but with 
pathogenic variations in LRP2 gene, has been further analyzed and described within a paper 
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submitted to Clinical Genetics, together with a second similar subject investigated by the 
group of Prof. Mauro Longoni of the Massachusetts General Hospital of Boston. A revisiting 
of such article will be presented as a final extended and deepen corollary (section §4.2.5) of 
the general analysis performed on the DD3 cases which constitutes the main topic of such 
part of BioInfoGen project.    
 
4.2.2. Materials and Methods 
To investigate the possible involvement of known disease-associated genes in the 
pathogenesis of DD3 patients, whole exome sequencing (WES) with the Ion Proton 
sequencer was conducted in all the seven collected subjects. The average read coverage for 
each sample was near 80X. The data analysis has been performed following the suggestions 
provided by the manufacturer: read alignment using TMAP and variant calling with TSVC. 
Variant prioritization has been achieved through QueryOR platform [178]. In particular, for 
missense variants, the prioritization strategy was based on query coverage, low MAF values 
and a possibly-probably damaging/deleterious prediction. Variants were finally validated by 
Sanger sequencing. 
 
4.2.3. Results and Discussion 
We identified in 4 patients 8 different variants of LRP2 gene which encodes for Megalin 
(Table 6). Two of them are novel predicted pathogenic variants.  
As explained in the article reported in a following section (§4.2.5), by deepening phenotypic 
features of BDA patient, we highlighted mild characteristics of Donnai-Barrow (DB)/FOAR 
syndrome, due to two non-conservative mutations in LRP2. A known LRP2 disease-causing 
mutation was detected in AMV, associated with a novel pathogenic mutation of CUBN gene 
encoding for Cubilin. This patient has no signs of DB syndrome, but presents an Alport-like 
glomerulopathy. No mutation in Alport disease genes was found by WES. A very rare 
pathogenic LRP2 missense variant was found in AMQ, in association with an OCRL disease-
causing mutation. Four different LRP2 missense variants were detected in AMT, two of them 
are common polymorphisms, while the remaining ones are low-frequency variants 
predicted to be pathogenic by MutationTaster [235]. No sign of DB syndrome was 
highlighted also in this patient, however an Alport-like glomerulopathy was reported. No 
 
82 
 
mutation in the Alport-causing genes was detected by WES. Notably, also in this patient an 
uncommon CUBN missense variant was observed. 
Patient Codon Substitution dbSNP code ExAC Frequency Pathogenicity 
BDA p.Arg2243Ter NA novel 
CV: NA  
MT: disease_causing (1.000) 
BDA p.Ile81Asn NA novel 
CV: NA 
MT: disease_causing (1.000) 
AMT p.Gly259Arg rs34693334 
TOT: 0.0632 
EUR: 0.0880 
CV: probable-non-pathogenic  
MT polymorphism (1.000) 
AMT p.Asn2632Asp rs17848169 
TOT: 0.0295 
EUR: 0.0426 
CV: probable-non-pathogenic  
MT disease_causing (1.000) 
AMT p.Gly669Asp rs34291900 
TOT: 0.0285 
EUR: 0.0430 
CV: probable-non-pathogenic 
MT: disease_causing (1.000) 
AMT p.Val3999Gly rs79723119 
TOT: 0.0089 
EUR: 0.0130 
CV: probable-non-pathogenic 
MT: polymorphism (1.000) 
AMQ p.Thr2086Ser rs146149181 
TOT: 0.0015 
EUR: 0.0010 
CV: NA 
MT: disease_causing (1.000) 
AMV p.Asp2054Asn rs138269726 
TOT: 0.0011 
EUR: 0.0016 
CV: pathogenic 
MT: disease_causing (1.000) 
Table 6|Interesting variants found into LRP2 gene of four patients (BDA, AMT, AMQ, AMV). Codon 
substitution is reported using HGVS protein code. Pathogenicity is expressed using information included into 
a public archive of clinically relevant variants (ClinVar, CV) [180], while the prediction scores are obtained 
from MutationTaster (MT) [235]. NA: Not Available.  
LRP2 and CUBN genes may be excellent candidates for DD3. They work in the same pathway 
of CLCN5 gene regulating the tubular reuptake of albumin and LMW proteins. However, 
mutations in these two genes are known to cause different monogenic diseases i.e. DB [257] 
and Imerslund-Gräsbeck [258] syndromes respectively. Both disorders show a DD-like renal 
phenotype.  
 
4.2.4. Conclusion 
Given our results, we can consider LRP2 variants as 1) causative of DB syndrome in BDA 
patient, 2) modifier of DD2 phenotype in AMQ, 3) possible disease-causing in association 
with CUBN mutation in AMV, and 4) difficult to interpret with unknown significance in AMT. 
Interestingly, in all patients glomerulopathy was present. 
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4.2.5. Hypercalciuria and nephrolithiasis: expanding the renal phenotype of 
Donnai-Barrow syndrome  
 
Introduction 
Donnai-Barrow/Facio-oculo-acustico-renal (DB/FOAR) syndrome (MIM #222448) is a rare 
inherited condition characterized by typical craniofacial features, agenesis/hypogenesis of 
the corpus callosum, high-grade myopia, sensorineural hearing loss, and low-molecular-
weight proteinuria (LMWP) (Figure 19). Congenital diaphragmatic hernia and omphalocele 
are frequent additional findings. Mutations in the LRP2 gene, encoding for Megalin, cause 
DB/FOAR syndrome. Proteinuria is a defining feature of this condition, as Megalin is 
expressed in the renal proximal tubule where it accounts for the uptake of retinol binding 
protein, vitamin D binding protein, and lipoproteins, among other ligands [259]. 
 
Figure 19|Graphical portrayal of different conditions in the tubular cells. Normal homeostasis is figured on 
the top-left, while Donnai-Barrow syndrome (DBS) (lack of megalin) and Dent disease (DD) (lack of ClC-5 
antiporter) are depicted on the right, at the top and at the bottom, respectively. LMWP: Low Molecular 
Weight Proteinuria; SNHL: SensoriNeural Hearing Loss; PTH: parathormone. 
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Dent disease (DD) identifies a group of X-linked renal tubulopathies characterized by the 
triad of symptoms LMWP, hypercalciuria, and nephrocalcinosis and/or nephrolithiasis 
(Figure 19) [260, 261]. Rickets and osteomalacia are also relevant features of DD phenotype. 
DD usually presents in childhood or early adult life. The most common genetic cause of DD 
is a mutation in the CLCN5 gene encoding the Cl-/H+ antiporter ClC-5, (Dent disease 1; 
MIM#300009) [254, 255, 262]. Mutations in the OCRL gene, encoding the 
phosphatidylinositol 4,5-bisphosphate-5-phosphatase OCRL1, usually associated with Lowe 
syndrome (MIM #309000), have been identified in about 10-15% of DD patients (Dent 
disease 2; MIM#300555) [254]. Whereas DD1 only affects the kidney, the spectrum of 
symptoms in DD2 can range from apparent exclusive kidney manifestations to the 
involvement of other organs, notably brain, muscles, and eyes in overlap with Lowe 
syndrome [255]. It remains an open question whether a third gene is responsible for DD in 
patients without identifiable mutations, or whether they represent atypical disease 
phenotypes of already known hereditary nephropathies [256]. 
In this study, we investigated two patients, an adult and a child with LMWP, hypercalciuria 
and nephrocalcinosis/nephrolithiasis without CLCN5 and OCRL variants. Exome sequencing 
revealed novel likely pathogenic variants in the LRP2 gene in both individuals.  
 
Materials and Methods 
Clinical cases 
Case 1 - The patient is a 69 years old male with a family history of increased urinary proteins 
(mother and sister) and nephrolithiasis (father). At the age of 14, he developed progressive 
bilateral hearing loss and left eye blindness. Moreover, at age 40 he developed glaucoma of 
his right eye. When he was 25 years old, he developed an acute kidney injury (AKI) with 
microhematuria, glomerular and LMW proteinuria, and granular casts in his urinary 
sediment. Urinary findings were presumed secondary to chronic tonsillitis and documented 
anti-streptolysin O (ASLO) positivity. AKI remitted completely after tonsillectomy but mixed 
proteinuria persisted (500 mg/day), with hyaline and granular casts, uric acid crystalluria, 
and incomplete Fanconi syndrome. This prompted a kidney biopsy which showed 1/23 
hyaline glomeruli, while in the other glomeruli there were mild PAS-positive mesangial 
hyperplasia, focal sclerosis of Bowman’s capsule, tubular cells with granular cytoplasm and 
few hyaline intraluminal casts. No specific therapy was administered. Bone biopsy was 
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performed when he was 30, and showed osteomalacia, consistent with a diagnosis of “renal 
rickets”. At age 40, he developed calcium oxalate kidney stones. By the age of 50, he 
developed hypertension and slow progressive chronic kidney disease (CKD) (creatinine 1.6-
1.7 mg/dL) with mixed proteinuria of 1-2 g/24h. At age 58, he developed also renal 
glycosuria. Since hypercalciuria (400 mg/day) was observed with normal calcemia and 
parathormone levels, therapy with amiloride-hydrochlorothiazide was started, reducing 
calcium excretion below normal levels. However, after 10 years he developed a new episode 
of nephrolithiasis.  
 
Case 2 - The patient is a boy of Senegalese origin with a negative family history for 
nephropathy. He was born weighing 3000 g at full term. The perinatal period was 
uneventful. Omphalocele repair surgery was performed at age of 6 months. Growth failure 
and a history of chronic constipation were reported in childhood. At the age of 5, he was 
hospitalized for clinical tests which documented marked growth failure (height -3/-4 DS, 
weight -2 DS), facial dysmorphisms (hypertelorism, flat and enlarged nasal bridge, broad 
forehead and prominent parietal bossing), and bilateral cryptorchidism. He displayed mild 
psychomotor retardation. Laboratory testing of the patient’s urine showed LMWP, 
hypercalciuria, and microhematuria, but no acidosis. Hypophosphatemia and 
hypovitaminoses D and A were also present. Ultrasound examination showed tiny 
calcifications in his left kidney compatible with the presence of nephrocalcinosis. After few 
months, the child was hospitalized for retinal detachment in his left eye, further 
complicated by ocular listeriosis and vitritis. His right eye demonstrated severe myopia with 
peripapillary atrophy. Shortly thereafter, the child underwent cataract surgery in the left 
eye. At age 12, he was hospitalized for an acute bowel obstruction with detection of 
hypokalemia (K 2.9 mmol/L); this was treated with intravenous potassium supplementation 
for few days, and then with oral supplementation. Currently, the patient is 16 years old and 
wears hearing aids.  
 
Whole Exome Sequencing 
Whole Exome Sequencing (WES) was performed using the Ion Proton System (Thermo 
Fisher Scientific, MA USA) in Case 1. The patient gave informed consent. We obtained an 
average read coverage near to 70X (Table S1). Alignment and variant calling were performed 
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using the software suggested by the company for Ion Proton data analysis. To annotate and 
prioritize the short nucleotide variants, we used QueryOR (http://queryor.cribi.unipd.it) 
[178]. 
WES of patient 2 was performed at the Broad Institute (Cambridge, MA) on the Illumina 
HiSeq 2000 after enrichment with Agilent SureSelect v.1.1. Mean coverage was 
approximately 100X (Table S1) with paired-end 76 bp reads. Data analysis was performed as 
previously described [263]. Briefly, sequence data was preprocessed with the Burrows–
Wheeler Aligner (BWA 0.7.5a) and SAMtools version 0.1.19. Variant calling was performed 
with the Genome Analysis Toolkit (GATK) (https://software.broadinstitute.org/gatk/) [264] 
according to GATK Best Practices [103], with minor adjustments. Mutation analysis was 
performed with Ingenuity Variant Analysis™ (Qiagen, MA USA) and seqr 
(https://seqr.broadinstitute.org/) [265]. Informed consent was obtained by the legal 
representatives of patient 2 (Partners Human Research Committee, Protocol Number: 
2009P001589). Variants that passed the in silico prioritization strategy (Table S2) were 
submitted for molecular validation by Sanger sequencing according to a previously 
published protocol [263]. 
 
Results 
The two patients received a provisional diagnosis Dent disease because their renal 
phenotypes were consistent with the triad of classical symptoms: LMWP, hypercalciuria, 
and nephrocalcinosis/nephrolithiasis. Both patients, however, also presented with 
extrarenal symptoms involving vision and hearing. Facial dysmorphisms were absent in the 
adult patient (case 1), but was present in case 2. Clinical DNA sequencing did not detect 
mutations in CLCN5 or OCRL; accordingly, WES was performed. 
Two alleles c.[242T>A];[6727C>T] of LRP2 (gene ID: ENSG00000081479, transcript ID 
ENST00000263816, reference sequence NM_004525.2) were detected in case 1 
(https://databases.lovd.nl/shared/individuals/00131892) [266]. One allele was predicted to 
cause the non-conservative amino acid substitution p.(Ile81Asn), while the other to 
introduce a premature stop codon at position 2243 of the aminoacidic chain p.(Arg2243Ter). 
Neither variant is reported in dbSNP, 1000 Genome, EVS, or ExAC. Parental DNA was not 
available for testing. 
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A homozygous missense variant c.7624C>T p.(Arg2542Cys) was identified in Patient 2 
(https://databases.lovd.nl/shared/individuals/00131950) [267]. Both parents were 
unaffected carriers. The variant is not reported in any of the SNV databases listed above. 
 
Discussion 
Pathogenic loss-of-function variants in LRP2 are associated with Donnai-Barrow/Facio-
oculo-acusticorenal (DB/FOAR, MIM#222448) syndrome [257, 268, 269], characterized by 
typical craniofacial features, and by high-grade myopia, congenital diaphragmatic hernia or 
omphalocele, sensorineural hearing loss, LMWP, brain anomalies, and intellectual disability 
[270]. The LRP2 gene encodes Megalin, a large single-spanning transmembrane multiligand 
endocytic receptor with a small intracellular region, expressed in the proximal tubule of the 
adult kidney where it works in the same pathway as the Dent disease-associated protein 
ClC-5 [271]. The extracellular domain has a modular structure with alternations of LDL-
receptor class A and class B domains, interspersed with EGF-like repeats and YWTD spacer 
regions [272]. 
Patient 1 is a compound heterozygote for a likely null nonsense mutation and the p.(I81N) 
missense variant at the N-terminus of the protein. The other missense Megalin variants 
reported in DB patients are instead localized to the C-terminal half of the protein (Figure 20) 
[257, 268, 273, 274], including one possibly pathogenic variant present in a patient with 
intellectual disability [275]. While we speculate that the p.(I81N) could act as a hypomorph, 
thus explaining the mild phenotype of patient 1, sequencing of larger cohorts will be needed 
to confirm this observation. 
In our patients, nephropathy was the presenting phenotype, characterized by incomplete 
Fanconi syndrome with LMWP, hypercalciuria, nephrocalcinosis/nephrolithiasis and rickets. 
The last three features are typical of DD phenotype but were never described before in 
DB/FOAR, although disturbances in systemic calcium homeostasis and bone metabolism can 
be observed in a mouse model with conditional inactivation of the LRP2 gene in the kidney 
[276]. Megalin is absent in the proximal tubular cells of patients with null LRP2 variants 
[277], while faint staining was detected in the cytosol of a DB/FOAR patient with two 
missense variants [268]. The latter had a LMWP pattern similar to Dent disease, yet without 
hypercalciuria and nephrocalcinosis/nephrolithiasis.  
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Figure 20|Diagram of LRP2 exons. Sequence variants identified in probands. p.(I81N) (pt1) is in a LDL-
receptor class A. p.(R2542C) (pt2) is in a LDL-receptor class B.  Missense (ID): homozygous missense variant 
in a patient with intellectual disability without signs of DBS/FOAR. Clinical testing: variants identified in 
clinical testing of patients and deemed pathogenic or likely pathogenic (ClinVar variant IDs 9450, 211391, 
374076); in these cases, the available clinical information is insufficient for phenotypic classification. 
References to the relevant papers are in the main text. Introns not in scale. 
In conclusion, we identified LRP2 mutation-positive patients with LMWP, hypercalciuria, and 
nephrocalcinosis/nephrolithiasis. We propose that a subset of patients presenting as DD 
may represent unrecognized cases or mild forms of DB/FOAR, or be on the phenotypic 
continuum between the two conditions.  
 
Supplementary materials 
Feature Case 1 Case 2 
Total number of reads 33051726 103331000 
On target reads 31708617 99817562 
On target bases 3887903103 3220721127 
Mean target coverage 67.33X 98.89X 
Percentage of target bases > 20X 73.78% 89.8% 
Table S1|Sequencing metrics of the two analyzed case studies. 
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Criteria for filtering Case 1 Case 2 
Total number of variants 49995 51858 
Variants with coverage > 30 39206 38876 
Variants with quality score > 50 38265 38591 
Number of variants with minor allele 
frequency ≤ 0.01 
3967 7171 
Exonic and splicing variants 1856 2385 
Exclusion of synonymous variants 1092 1361 
Pathogenic predicted variants (DANN > 
0.99) 
256 155 
Genes associated to kidney diseases✶ 9 8 
Clinically relevant variants 
LRP2: NM_004525.2, Exon 3, 
c.242T>A (p.Ile81Asn) 
LRP2: NM_004525.2, Exon 
39, c.6727C>T (p.Arg2243Ter) 
LRP2: NM_004525.2, Exon 
41, c.7624C>T (p.Arg2542Cys) 
Table S2|Prioritization strategy applied on the two analyzed case studies. ✶Genes associated to kidney 
diseases for conditions with matching DisGeNET term: Kidney Diseases (C0022658). 
 
4.3. Analysis of recurrent nucleotide variants reveals 
inconsistencies in the human reference genome 
4.3.1. Introduction 
Since its first draft release in 2001 [13, 14], the reference sequence of the human genome 
underwent several updates and improvements. Notably, in 2009 the Human Genome 
Reference Consortium made available the GRCh37 release (also known as hg19), that was 
followed by the GRCh38 release in 2013 and further updated in the form of “patches” in the 
following years [278]. 
Interestingly, many users are still adopting GRCh37 for their studies [134]. This is due to the 
many difficulties in updating tools and pipelines when a new version of the genome 
becomes available. Indeed, most commercially available exome kits, for instance the “Ion 
AmpliSeq Exome RDY Kit” from Thermo Fisher Scientific or the “Nextera Rapid Capture 
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Exome” from Illumina are still based on the old GRCh37 release. As a consequence, GRCh37 
is also recommended for bioinformatic analyses. 
This reluctance to update to the new release of the genome is unfortunate because GRCh38 
contains several important improvements [134]. It was derived from many donors instead of 
a few and led to the correction of 8248 bases; furthermore, GRCh38 supports the 
representation of complex haplotypes with the introduction of alternate loci, and includes 
many regions that were missing in the previous release, such as segmental duplications, 
centromeres and telomeres [134]. 
The problems derived from using the old reference genome for next generation data 
analysis have already been widely discussed in the literature. Two different studies 
demonstrated that the poor representation of repeated sequences in GRCh37 produces 
read misalignments and false-positive variants [279, 280]. To solve this problem, the authors 
propose the integration in standard pipelines of ‘decoy’ sequences [279] or ‘sponge’ 
databases [280] representing a collection of sequences omitted from the GRCh37 assembly 
that are supposed to result in mismapped reads. This integration allows an improvement in 
read mapping and in the resolution of false heterozygous calls [279]. 
More recent studies confirmed that the new sequences introduced in the updating of 
GRCh37 to GRCh38 improved the read mappability and lowered the number of false-
positive single-nucleotide variants [281, 282]. However, despite the above improvements, 
we observed that the problem of false-positive variants remains also in GRCh38. 
A large number of unexpected false-positive variants is certainly due to the inclusion of 
MAiRs, minor alleles in the reference genome, and can be easily filtered out with 
appropriate tools [178]. However, even after this filtering process, several thousand variants 
still remain. This is quite surprising because they are not reported as common variants in the 
databases and at the same time they are found in most exomes. Interestingly, exomes 
obtained with different technologies such as Ion-Proton, Illumina and SOLiD, exhibit a 
largely overlapping set of these false-positive variants, therefore they are not due to 
artifacts of a particular chemistry or sequencing platform. 
The study presented in this chapter was carried out in collaboration with other colleagues 
and has two main aims: firstly, we wanted to evaluate and classify the recurrent short-
nucleotide variants, both in GRCh37 and GRCh38. We believe that a clear repertoire of the 
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recurrent miscalls will help geneticists in analyzing exome data, facilitating the process of 
variant prioritization. 
A second, but not less important scope is to better understand the nature of this problem 
and to verify the hypothesis that sometimes these unexpected variants may originate from 
duplicated regions that are not reported in the reference genome. This can be 
experimentally verified because the “collapsed” repeated sequence of the reference 
genome would be the target for the alignment of reads derived from two or more real 
genomic regions, resulting in a disproportion between frequency, heterozygosity and 
homozygosity of the corresponding allele. 
With this premise, we analyzed a few hundred exomes from different platforms, using both 
GRCh37 and GRCh38. We found that the problem of collapsed repeats is indeed responsible 
for the call of many false-positive variants, several of which are still remaining in GRCh38. 
Furthermore, we suggest a few positions of the reference genome that require a revision in 
future updates. 
 
4.3.2. Materials and Methods 
Datasets 
In this study, we used three different datasets: one case study dataset, which has been 
extensively analyzed, and two control datasets. The study dataset was composed by all 
variants collected from 222 different exomes sequenced at the CRIBI facility of the 
University of Padua. These exomes were enriched with the Ion AmpliSeq Exome panel and 
sequenced with the Ion Proton system (Thermo Fisher scientific). Samples came from the 
most different research projects ranging from cohorts of individuals to trios (Table 7). 
The two other datasets are technological controls chosen to appraise platform-specific 
errors. One was composed by all variants found in 22 exomes belonging to two different 
projects and enriched with Illumina TruSeq Exome panel and then sequenced with Illumina 
NextSeq 550 platform at CRIBI. The other was composed by variants identified in 300 
exomes belonging to the study published by J. de Ligt et al [230]. It should be pointed out 
that these samples, enriched with SOLiD-optimized target enrichment and sequenced with 
SOLiD 4 System (Life Technologies), belong to 100 trios composed by patients with 
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unexplained severe intellectual disability and their unaffected parents (data deposited into 
The European Genome-phenome Archive under submission EGAS00001000287, [231]). 
 
Project Exomes number 
1 47 
2 45 
3 29 
4 22 
5 18 
6 17 
7 10 
8 9 
9 9 
10 6 
11 5 
12 2 
13 2 
14 1 
Total exomes 222 
Table 7|Number of exomes for each project. 
 
Alignment and variant calling on GRCh37 
All samples of study dataset and control datasets were aligned against the release GRCh37 
of the human reference genome. 
Study dataset - Each exome included into the study dataset was sequenced using the CRIBI 
Ion Proton system to reach a final mean coverage of 80x and a target uniformity higher than 
90%. Alignment and variant calling were carried out according to the Torrent Suite 5.0 
exome analysis pipeline, as suggested by the manufacturer.  Variants were merged into a 
unique file using CombineVariants of Genome Analysis Toolkit (GATK v. 3.6) and then 
normalized applying the method proposed by Tan and colleagues [193] in order to eliminate 
different representations of the same variant. Variant annotation, based on GRCh37.82 
version of Ensembl transcripts, was performed using VarPred (§3.2). 
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Illumina control dataset - Each sample was sequenced with 76 bp paired-end reads by using 
the CRIBI Illumina NextSeq 500 to reach a final mean coverage of at least 40x with an 
average of 103x. Alignment and variant calling were performed applying the Illumina data 
analysis pipeline discussed above (§3.1), following the suggestions reported in the GATK 
Best Practices [103]. The obtained variants were then normalized as previously described.   
SOLiD control dataset - VCF files were downloaded from The European Genome-phenome 
Archive (EGA). For alignment and variant calling procedures please refer to de Ligt et al 
paper [230]. Variant normalization was performed as indicated above. 
 
Alignment and variant calling of study dataset on GRCh38 
The 222 exomes of the study dataset were also aligned against GRCh38.p10 downloaded 
from Ensembl [283]. Alignment and variant calling were performed according to the Torrent 
Suite 5.0 exome analysis pipeline as described in the Alignment and Variant Calling on 
GRCh37 section. Variants from all samples were merged and processed as described above. 
Applying CrossMap [284] the coordinates of the resulting variants were converted to 
GRCh37 coordinates, allowing a comparison between such variants and those obtained 
using the release GRCh37 of the reference genome. 
Identification of Minor Allele in Reference positions 
We called Minor Allele in Reference (MAiR) those positions in the human reference genome 
that present an allele that is not the most frequent in the population. To identify if in our 
study dataset some variants fall in such positions, the allele frequencies in the total 
population reported in 3 databases including I) dbSNP [70] version 144 [221], modified to 
recover old variants excluded from this release but present in the online version, II) NHLBI 
ESP version ESP6500SI-V2 [154], III) ExAC version 0.3.1 [68], were analyzed. In particular, the 
reference allele frequencies were compared with the alternative allele frequencies. Thus, a 
genomic position was marked as MAiR if the reference allele frequency was lower than any 
alternative allele frequency in all databases. 
 
Confirmation of variants in MAiR positions at protein level 
Variants in GRCh37 MAiR positions confirmed in GRCh38 genome were annotated using 
both SnpEff [188] v4.2 and VEP [162] v84, employing respectively UCSC and RefSeq 
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transcripts. Two different annotations were chosen to avoid transcript-dependent biases. 
Missense variants were selected from the two annotated VCF files as associated to protein 
changing. These protein variations were independently compared with the Human 
polymorphisms and disease mutations release 2017_05 [285] of UniProt, in order to 
understand if these high frequency exomic variants have a known correspondence at 
protein level. Moreover, the presence of the mutated amino acid in the primary protein 
sequence was also evaluated. This analysis was performed using the reviewed Swiss-Prot 
human sequences [286]. The comparisons have been done using a in-house python script. 
 
Statistical test on heterozygous genotype frequencies 
Variants with a heterozygous genotype frequency significantly higher than the expected 
were investigated. This analysis was performed only for biallelic variants, defined as loci that 
have two observed alleles: the reference and one alternative allele. For each variant, the 
observed allele frequency was calculated as the number of times the specific allele was 
found divided by the total allele number (444 alleles). Then we calculated the observed 
frequency for the three possible genotypes of each variant as the number of times we found 
that genotype divided by the total number of exomes (222 exomes). Expected genotype 
frequencies were computed using the formula (p+q)2=1, where p and q are the observed 
frequencies of reference and variant allele respectively. We then performed a one-tailed 
binomial test for the heterozygous genotype. P-values were corrected for false discovery 
rate using the Benjamini-Hochberg procedure [287]. Observed genotype frequencies were 
considered significantly higher than the expected if the corrected p-value was lower than 
0.01. 
 
Realignment of reads containing interesting variants 
The analysis was focused on those reads belonging to amplicons containing more than one 
variant having an unbalanced heterozygous genotype and confirmed by Illumina and SOLiD. 
From three randomly chosen samples, we extracted for each amplicon those reads 
containing all the variants and reads with none of them. These two groups of reads were 
aligned against the GRCh37 and GRCh38 toplevel human reference genomes using BLAST. 
Toplevel genomes are defined as those assemblies containing chromosomes, regions not 
assembled into chromosomes and N padded haplotype and patch regions. Files were 
 
95 
 
downloaded from Ensembl ftp website [288, 289]. In this analysis, the identity percentage 
cutoff was set to 90%. 
 
Variant database creation 
All information collected on variants during the various analyses has been gathered into a 
unique tabular file using an in-house python script. The table contains one row for each 
variant and one or more columns for each analysis. 
 
4.3.3. Results 
Preliminary analysis of the study dataset 
After the normalization process, the obtained study dataset was composed by 264303 
variants, including 239255 SNPs and 25048 small INDELs (14075 deletions and 10973 
insertions). Among the total variants, 245088 were defined as biallelic while the remaining 
19215 variants occurred in positions in which more than one alternative allele was present. 
It was also observed that 9313 (3.52%) variants were shared by at least the 90% of exomes 
and even 2349 were identified in all the samples. Surprisingly, a consistent fraction of such 
variants cannot be explained by a high frequency in the population. Thus, although the 
subsequent analyses were performed on the total cohort of the 264303 variants, we mainly 
focused on these recurrent variants in order to find a feasible explanation about their 
presence.  
Comparison with Illumina and SOLiD datasets 
To understand if the 9313 variants shared by at least the 90% of exomes could derived from 
Ion Proton platform specific biases, they were searched for confirmation in two 
independent control datasets. These latter were produced by Illumina and SOLiD 
sequencing and analyzed with their corresponding pipelines, leading to collect 124935 and 
189512 variants respectively. Both datasets presented a lower number of variants in respect 
to the whole Ion Proton dataset. This event could be due to different causes: I) the Illumina 
samples were considerably fewer than the samples in our study dataset; II) despite the high 
number of samples in the SOLiD dataset, it should be pointed out that they belong to trios - 
that will implicitly share most of their variants - collected for the study of a particular mental 
disorder. 
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We considered variants as confirmed if they were present in at least the 50% of Illumina and 
SOLiD samples, separately. The number of confirmed variants is 6008 for Illumina, 5733 for 
SOLiD and 4607 considering both (Figure 21). The majority of not confirmed variants were 
localized in regions peculiar of Ion AmpliSeq Exome panel that were not enriched with the 
Illumina and SOLiD target. Only 41 variants localized in common target regions were not 
confirmed by both Illumina and SOLiD, so they could be platform specific systematic errors. 
A  
Ion Proton 
dataset 
Illumina control dataset SOLiD control dataset Both control dataset 
confirmed not confirmed confirmed not confirmed confirmed 
not 
confirmed 
9313 
6008 
(64.51%) 
3305 
(35.49%) 
5733 
(61.56%) 
3580 
(38.44%) 
4607 
(49.47%) 
4706 
(50.53%) 
OOT IT OOT IT 
3228 
(97.67%) 
77 
(2.33%) 
2267 
(63.32%) 
1313 
(36.68%) 
 
B 
 
Figure 21|Recurrent variants 
shared among Ion Proton, 
Illumina and SOLiD datasets. 
A|Paired comparisons are shown 
in the first two blocks where a 
distinction between not confirmed 
variants in target (IT) and out of 
target (OOT) is also appreciable. 
The last box considers all the three 
technologies together. B|Graphical 
representation of the comparison 
among the datasets.   
 
GRCh38 variant comparison 
Alignment and variant calling of the study dataset were performed also using GRCh38 as 
reference genome. We identified 255124 variants, a smaller number compared to the 
previous genome release. This was somehow expected as data published by Guo and 
colleagues [281] claimed a lower number of SNPs due to the improvements introduced in 
the latest release of the human reference genome, thus reducing the number of false 
positive variants. The number of variants shared between GRCh37 and GRCh38 was 242259 
(91.66% of the GRCh37 variants dataset). Similarly, the number of recurrent variants fell 
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from 9313 to 8132 (87.32%), indicating that the improvement of the latest human genome 
assembly allowed to sensibly diminish the number of false positives, as previously reported 
[134]. 
 
European and total population allele frequencies 
All the exomes of the study belong to European people. We wondered if variants in the 
dataset could present a higher alternative allele frequency in the European population 
compared to the general population (only ExAC database frequencies were considered). In 
fact, the high number of shared variants in our samples could be explained as European-
specific polymorphisms. The plot in Figure 22 shows the almost perfect correlation between 
the frequencies in the two populations, indicating that there is no evidence of a possible 
bias due to ethnic origin of the samples. 
 
Figure 22|Correlation of allele 
frequencies between European 
and Total populations. Red line 
shows the high correlation 
between the two datasets. 
 
Identification of Minor Allele in Reference positions 
It was estimated that erroneous reference bases, responsible also for incorrect variant calls, 
occur at a rate of 10-5 [15]. Consequently, several thousand positions of the reference 
genome do not carry the major allele of the population, as we previously reported [178]. In 
these positions, variant callers will identify an alternative allele that indeed should represent 
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the reference, thus increasing the number of false positives. We wondered if some variants 
in the dataset could be due to the presence of these erroneous reference positions. As 
explained in the Materials and Methods section, we partially revised our previous definition 
of Minor Allele in Reference (MAiR) positions. Thus, we marked 18839 (7.13%) variants as 
MAiRs. Interestingly, MAiR variants represent the majority (94.09%) of the variants shared 
by at least the 90% of the samples. Moreover, we checked if these erroneous reference 
positions have been corrected in the latest release of the reference genome. Only 1808 
(9.60%) MAiR positions have been solved in GRCh38, while the remaining 17031 (90.40%) 
MAiRs are still present, including 7876 highly recurrent variants.  
Furthermore, in order to understand if these MAiR variants were frequently found not only 
at genomic level but also at protein level, we investigated the UniProt protein variation 
database in search of correlation between predicted missense variants and known amino 
acid substitutions. In particular, the MAiR variants retained in GRCh38 were annotated using 
two different annotations (UCSC and RefSeq transcripts) thus avoiding transcript-dependent 
biases. After the selection of missense variants, we obtained a comparable number of 
mutations in the two databases: 3814 with RefSeq and 3761 with UCSC. When we compared 
these missense variants with the protein variation database, we found that ~74% of these 
variants were already known also at protein level as natural variants. More interestingly the 
2.6% of these mutated residues were included in the protein primary sequence, indicating 
that the alternative allele in MAiR position actually corresponds to the most frequent amino 
acid in the protein sequence. The remaining part of variants (~23%) were not confirmed at 
protein level: the main reason could derive from the fact that not all transcripts used during 
the annotation have a corresponding curated protein sequence in the Swiss-Prot database. 
 
Analysis of heterozygous genotype frequencies 
We proposed the presence of gene and region duplications not yet annotated in the 
reference genome as one of the possible causes for a misleading variant calling in the target 
regions: since these duplicated regions can be enriched and sequenced together with the 
original target gene, the corresponding reads will align to an improper position causing the 
identification of variants not really present in the gene. Consequently, we expected a 
heterozygous genotype for these variants, with the reference allele deriving from the 
original target gene and the alternative allele from the duplicated region. For each variant in 
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the study dataset we performed a statistical test to compare the observed and the expected 
heterozygous genotype frequency and we found that 767 variants had the heterozygous 
genotype frequency significantly higher than the expected one. These interesting variants 
were used in the following variants selection steps. 
Analysis of interesting variants and read realignment   
In order to identify possible duplicated regions accountable for the misleading variant 
calling, we analyzed those variants with the heterozygous genotype frequency significantly 
higher than expected. Among these we excluded from the subsequent analysis the 14 
variants not confirmed neither by Illumina and SOLiD control datasets, but localized in 
Illumina and SOLiD target regions, as they could be Ion Proton specific systematic errors. We 
obtained 753 variants that we believed to be very reliable. We then focused on enriched 
target regions containing more than one of the selected variant, collecting 145 different 
regions spanning over 45 genes. In the process of investigating these regions, we observed 
that two different groups of aligned reads were distinguishable: reads having all the 
selected variants or reads having none of them, thus suggesting a possible different 
genomic origin of these reads even if they aligned on the same region. This observation 
agreed with our hypothesis of duplicated regions not present in the human reference 
genome used for the analysis (Figure 23). 
 
A 
  
B 
Figure 23|Gene duplication hypothesis. A|Wrong assembly. Both kinds of reads align on the target gene. 
B|Correct assembly. Reads with no variants map on the original target gene, while reads affected by 
variations properly align on a paralog gene.  
 
We thus wondered if these duplicated regions had been identified and inserted in the most 
recent reference genome releases. In fact, the introduction of assembly patches in the latest 
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GRCh37 release and their resolution in the GRCh38 reference made possible to include 
segmental duplications and ‘missing’ sequences, such as paralogous sequences [134]. For 
this reason, we decided to realign both the two groups of reads against the GRCh37 and 
GRCh38 toplevel human reference genomes using BLAST. For each of the 45 analyzed genes, 
we compared the alignments of the two pools of reads in both the references. Assuming 
that the highest identity percentage indicates the real genomic origin of that read, BLAST 
results showed two possible scenarios: both groups of reads derived from the same region 
corresponding to the target gene or they derived from different regions. We realized that 
these different regions could be not only patches and other regions in the same or in a 
different chromosome, but also alternate loci scaffolds that provide more representation for 
population variation in the reference [134]. 
Among the 45 genes (Table 8), we classified 34 genes as solved in GRCh38 since reads with 
variants aligned to a position different from the original gene, indicating the presence of 
duplicated regions or haplotypes, whereas reads with none variant aligned to the original 
target gene. These new sequences added to the reference have been able to capture 
several reads that otherwise aligned to the original gene, thus preventing variants to be 
called. In fact, almost all variants localized in these solved genes were not identified using 
the GRCh38 toplevel reference, while the remaining variations could be real private 
variants. Most of these genes were solved because the toplevel references present different 
haplotypes that likely account for variants that we saw in the original gene. For example, the 
KIR2DL3 gene, coding the killer cell immunoglobulin like receptor, is known to be highly 
polymorphic [290, 291] and many alternate loci for this gene were introduced in the 
toplevel releases. Other solved genes are known to have paralogous genes that were not 
reported in the GRCh37 genome release. For instance, the PRIM2 paralog, missing in 
GRCh37 [292] is present in the modeled centromere for chromosome 3 in GRCh38 [134]. 
This paralog contains only exons 6-14 of the original transcripts [292], that actually are the 
exons covered by the enriched target regions we selected. 
We classified 6 genes as unsolved in GRCh38 since both the two pools of reads aligned only 
to the target gene, indicating that neither duplicated regions nor haplotypes are known. In 
fact, all variants localized in these unsolved genes were still present analyzing the dataset 
with the GRCh38 toplevel reference. For this reason, we suppose that also such genes could 
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present duplicated or haplotype sequences not yet reported even in the latest version of 
the human genome.  
We classified the remaining 5 genes as partially solved in GRCh38 since only a portion of the 
enriched target regions for these genes was solved by the introduction of new sequences in 
the references, whereas the reads aligning on the remaining target regions behave as those 
aligning on genes we classified as unsolved. Also in this group we found interesting genes 
worthy of being further investigated, as for example the MAP2K3 gene which is known to 
play an important role in tumor invasion and progression [293, 294].  
Solved genes Partially solved genes Unsolved genes 
BCLAF1 
CCDC144NL 
CES1 
CTBP2 
FRG1 
GPRIN2 
HLA-DQA2 
HNRNPCL1 
HYDIN 
KIR2DL3 
FAM194B 
TNXB 
KIR2DS4 
KRT6B 
KRTAP4-11 
KRTAP9-2 
MUC20 
NBPF10 
NBPF1 
NOTCH2NL 
OR1D5 
OR4C3 
MLL3 
OR4C45 
OR9G1 
PDE4DIP 
PPYR1 
PRIM2 
PRSS3 
SEC22B 
TPTE 
ZDHHC11 
LOC653486 
OR4M2 
FAM104B 
FRG2B 
FRG2C 
KCNJ12 
MAP2K3 
ALG1L2 
ANKRD36 
FAM131C 
PDPR 
PCDH11X 
PER3 
 
Table 8|Genes classification into solved, partially solved and unsolved cases.  
 
Variant database 
The results of the analyses, performed on all the variants included into the study dataset, 
have been gathered within an exhaustive database, which should help geneticists and 
clinicians to discriminate interesting variants from false positives. The process of database 
creation is shown in Figure 24, which also allows to summarize all the steps carried out 
during the study. 
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Figure 24|Variant database 
creation process. The 
building of the variant 
database passes through 
several analyses (red boxes) 
performed on the 264303 
variants of the study dataset. 
Each investigation can return 
one or more results which 
constitute the columns of the 
final table. 
 
4.3.4. Discussion 
Whole exome sequencing is a powerful tool for analyzing first and foremost human genetic 
variations and rare hereditary diseases. Nevertheless, finding the appropriate answer is a 
complex task while handling such a big amount of data as those obtained in exome 
sequencing projects. It is thus mandatory to perform the most reliable analysis as possible in 
order to reduce errors. In particular, during alignment and variant calling, a central role is 
played by the reference used, as it should be representative of the total possible variations 
in order to highlight known and unknown mutations. 
In this work, we presented a comprehensive study on a dataset composed by variants found 
in 222 exomes. Our investigations were targeted to find possible explanations about the 
presence of anomalous variants and to develop strategies able to individuate, characterize 
and filter them. For clarifying such strangeness, the existence of inconsistencies in the 
version GRCh37 of the human reference genome, which is suggested by the companies for 
alignment and variant calling steps, was put at the basis of our hypothesis. Following this 
assumption, we tried to achieve a feasible explanation for the 9313 variants that we found 
unexpectedly shared by at least the 90% of the samples. In particular, through a wide set of 
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analyses (Figure 24), ranging from allele and genotype frequencies comparison to read 
realignment on different reference genomes, we demonstrated that: I) 8680 variants are 
MAiR, meaning that the reference does not carry the most frequent allele in the population, 
II) 316 are possible indicators of gene or region duplications, III) 82 are both MAiR and with 
an unbalanced heterozygous genotype frequency, thus involving the issues of points I and II, 
IV) 16, among which 1 is also MAiR, could be Ion Proton specific errors as they are absent in 
Illumina and SOLiD samples, V) only 219 stand without a clear explanation. Among the 
latter, 41 variants have never been previously reported, while for the remaining we can 
hypothesize they could be population specific polymorphisms. In fact, although we did not 
detect any differences between the two populations for the whole set of variants (Figure 
22), the frequencies of these 178 variants are significantly higher for the Europeans 
compared to the total population as reported in Figure 25. 
 
 
Figure 25|European and Total frequencies of 
the 178 possible population specific 
polymorphisms. Contrary to what shown in 
Figure 22, the difference between allele 
frequencies in the two analyzed datasets is 
highly significant (p-value<0.0001). 
These findings strongly supported our theory regarding the presence of possible errors in 
the GRCh37 genome: in fact, the identification of MAiR variants can be essentially 
associated with uncorrected bases, while the detection of variants with an unbalanced 
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heterozygous genotype frequency showed that at least 45 genes were affected by assembly 
problems, mainly due to the presence of collapsed repeats within the primary sequence of 
the reference. 
Furthermore, since in 2013 a new version of human genome has been released, we also 
decided to investigate if the issues affecting the GRCh37 have been solved in the GRCh38. 
Indeed, important ameliorations in the latest version of the human reference have been 
declared in the works published by Guo [281] and Schneider [134].  
Nevertheless, our results indicated that although more than 8000 bases have been 
corrected in the most recent release of the human genome [134], other efforts are 
necessary to further reduce the base-pair-level errors, because more than 90% of MAiR 
found in GRCh37 are still kept in GRCh38. However, it is important to remember that the 
new definition of MAiR triggered the inclusion in such group of a higher number of variants 
than what we previously published [178]. So, to understand if these positions should be 
corrected in the reference, we planned to carry out in the near future a deeper analysis on 
the frequencies of variants associated to these positions, as only alternative alleles with a 
really high frequency in the population are worthy to be included within the primary 
sequence of the human genome.  
Regarding the problem of the collapsed repeats, many suspicious genes (34) marked as 
duplicate in GRCh37 have been solved in the most recent release of human reference, 
indicating a significant improvement of the assembly. Anyway, as happened for the previous 
task, even this question has not been completed answered, because 11 genes could present 
a partial or an entire duplication since they behave similarly to the “solved” genes when the 
GRCh37 is used. Thus, it is important to find these possible new regions and to correctly 
report them in the assembly as their absence leads to improper reads alignment and variant 
calling, complicating the discovery of the real disease-causing variations. 
 
4.3.5. Conclusion 
We believe that the human reference genome should be the best possible representation of 
the known global variation. GRCh38 clearly goes in this way and we encourage the usage of 
this latest release in whole exome and whole genome studies. However, our results indicate 
that some inconsistencies are still there. Duplications could be deeply investigated when 
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whole genome sequencing and analysis will be the regular practice in human genetic 
studies. Only with this kind of data it will be possible to have a thorough insight on gene 
duplication and gene copy number variation. However, we are aware that some genetic 
differences could be ascribed to natural polymorphisms. A possible solution could come 
from the development of regional variant databases more comprehensive of the allelic 
frequencies of specific populations than the global frequencies. An essential step in this 
path is the free access to human exome data: we have no doubt that these data contain 
sensitive information but they are also extremely useful to improve the knowledge on 
human genetic variability and hereditary diseases. In this view, we hope that the variant 
catalog produced with this study could represent a little step forward to the solution of this 
issue, helping researchers in discriminating between really interesting variants and those 
that could mislead their work. 
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5. Concluding remarks and future perspectives 
Since the middle of 2000s the development of high-throughput sequencing technologies led 
to a very fast decreasing of the sequencing cost, allowing nowadays to obtain a whole 
genome with less than $1000. This event shifted the main bottleneck of the workflow from 
the sequencing process to the data analysis [88], raising at the same time new issues 
regarding in particular the manipulation, the understanding and the storage of the produced 
data. Although various applications can be reached applying the NGS, one of the most 
widespread is surely the study of DNA variations for discovering the molecular basis of 
genetic diseases [45].  
As the interest in this sector has been growing steadily over the years, in 2014 the 
BioInfoGen Strategic Project was funded by the University of Padua, in order to establish 
new expertise in the areas of bioinformatics and molecular biology for approaching the 
personal genomics. My PhD project was framed within the BioInfoGen, with the goal to 
implement a series of tools for variant analysis and prioritization, easily applicable not only 
to the medical studies which I was involved on, but also to a wider spectrum of clinical 
cases. Obviously, the implementation of the various programs has required diversified 
developments, in order to adapt them to the state-of-the-art and to the specific needs and 
for this reason they have been separately described in the several chapters of the 
manuscript. Nevertheless, it is important to remember that such tools are not stand-alone 
software uniquely implemented to carry out a peculiar function, but they can be considered 
single step of a more complex pipeline specifically designed to approach to the personal 
genomics, which is finally the highest goal of the BioInfoGen project.  
The first problem I faced up derived from the purchase of a new sequencer, the Illumina 
NextSeq 500, which has been affixed at the CRIBI center to the already working Ion Proton 
machine. Since few Illumina exome/genome data had been processed by the bioinformatics 
unit before the advent of NextSeq, no pipeline for variant detection was available, raising 
the need to implement a new one. Initially a deep bibliographic research was performed to 
understand which were the mandatory steps for an accurate data analysis, giving particular 
importance to the software parameters. Then, thanks to the possibility of using a HPC 
cluster, various strategies to parallelize the pipeline were evaluated, finding in the scatter-
gather procedure, a performing and secure way to speed-up the process. The obtained 
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pipeline is able to process both paired-end and single-end reads and it can be used to detect 
germline and somatic mutations, exploiting two different variant calling suites, GATK 
HaplotypeCaller/MuTect2 and VarDict [143]. Another strength of the pipeline is the 
usability, as in its simple form it requires only few parameters, allowing also to the non-
bioinformatician personnel to execute it. The reliability of the final results is guaranteed by 
several internal controls which permit to check out if each step has been correctly 
concluded. Finally, such workflow has been applied for studying patients with poor 
prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-
S) trial, leading to the publication of a congress abstract [186]. 
Considering the issues raised during the pipeline development, one of the most challenging 
task was the selection of the best parameters for performing the variant calling step. 
Moreover, even if variant callers currently integrate many statistical and machine learning 
approaches useful to define quite affordable cohorts of variations, for obtaining the most 
reliable results, the starting material, including the reference genome, must be as precise as 
possible. Indeed, during our analyses of exome data produced by both Ion Proton and 
Illumina, it was surprising to notice that a group of variants was detected in more than 90% 
of the samples, even if not all of them were reported as common variants in the allele 
frequency databases. Excluding that such false-positives were due to platform specific 
errors, an extensive investigation of these variants was performed in order to create a clear 
repertoire of the recurrent miscalls for helping geneticists in analyzing exome data, but also 
to understand their origin, highlighting possible inconsistencies and errors of the reference 
genome. To validate our assumption, a lot of analyses were performed on the collected 
variants ranging from statistical tests on genotype frequencies, to read realignment on top-
level genomes, passing through the comparison between two different versions of the 
reference genome and an extensive evaluation of allele frequencies reported in widely used 
databases, such as dbSNP [70], ExAC [68] and ESP6500 [69]. We demonstrated that 
collapsed repeats could be responsible for the call of many false-positive variants, several of 
which still remain using the latest release of the human assembly as reference. However, 
the majority of them are due to the inclusion of MAIR positions in the reference genome, 
suggesting the needing of a revision in the future updates. Furthermore, we gathered all the 
results of the various investigations within an exhaustive variant database, which should 
help geneticists and clinicians to discriminate interesting variants from false positives. 
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Although the analysis is essentially completed and almost ready to be published, it was 
planned to extend the study to variants included into bigger cohorts such as the 2504 
individuals of the 1000 genomes project (http://www.internationalgenome.org/data) [86] 
and the 15496 genomes collected by gnomAD 
(http://gnomad.broadinstitute.org/downloads) [197]. This should allow to obtain a lot of 
information also on non-coding regions and not only on coding sequences analyzed by WES. 
In this way, it should be possible to have a really wide and complete overview of assembly 
problems along the whole genome sequence, thus identifying feasible assembly 
modifications which will ameliorate the final results of all sequencing projects. In fact, an 
improved reference will help the researchers to discriminate true variants, diminishing at 
the same time the number of false positives.  
The strategies proposed in the previous paragraph, together with the application of suitably 
defined parameters in the variant calling process, should allow the selection of the most 
affordable variants. With the following step of annotation, variations are enriched with a lot 
of information, such as the position at transcript and protein level, the impact on protein 
sequence, the pathogenicity and many more. Several programs are currently available for 
performing this analysis, but at the end of 2014, when my PhD project was at the beginning, 
these tools were afflicted by many troubles mainly regarding the indels realignment, the 
variant normalization and the annotation of complex rearrangements. To solve these issues 
and to improve the overall quality of the annotation step, a new variant annotator, referred 
as VarPred, was developed. From the comparison with state-of-the-art software, including 
VEP [162], ANNOVAR [163] and SnpEff [188], VarPred showed the best consistency in 
variant annotation (>99%), but also good performance in running times, in particular at 
exome level. Also a web interface for an easy data filtration has been implemented, even if 
it is not completed yet. Further developments of both the stand-alone software and the 
web platform will mainly regard the introduction of new sources of annotation, including 
dbNSFP [161] and ENCODE project [295] data, in order to extend the information provided 
by VarPred also to pathogenic prediction scores and non-coding features. 
The variant annotation process is fundamental for achieving a valuable prioritization, 
allowing to discover mutations which can be associated to the genetic disease under 
investigation. For this purpose, QueryOR [178] has been developed. QueryOR is the web-
platform with the highest number and the widest spectrum of selectable criteria. In 
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particular, differently from the other tools which apply arbitrary thresholds to filter out 
variants, QueryOR works on the whole cohort of variants, sorting them for the number of 
the satisfied criteria. In this way, variants with the highest score will be shown on the top of 
the list, even if they do not satisfy all the imposed criteria. In addition, the 
comprehensiveness of the implemented criteria and the aptness to add new features 
together with a user-friendly interface make QueryOR very suitable to support researchers, 
clinicians and geneticists engaged in variant analyses.  
So QueryOR has been successfully used in the case studies included within the BioInfoGen 
project. Although the objectives of the two investigations were different, the flexibility of 
the platform allowed to reach in both cases interesting results. Indeed, on one side it helped 
the detection of causative variants in LSD patients, pointing out also the good performance 
of the designed panel, while on the other hand QueryOR facilitated the identification of the 
LRP2 gene as possible candidate for explaining the phenotype of DD subjects with no 
mutation in the previously identified disease-associated genes, CLCN5 and OCRL. 
Concluding, the proposed thesis covers the various steps of variant analysis from the raw 
data manipulation to the final prioritization process, passing through the read alignment, 
the variant calling and the annotation. Many issues identified only a few years ago have 
been solved through the development of appropriate tools, such as VarPred and QueryOR, 
while others, raised during the PhD, have laid the groundwork for future projects. In fact, 
most of the work done during these three years was centered on the study of the coding 
regions, but thanks to the continuous decreasing of the sequencing cost, new scenarios over 
the non-coding side of genomics will be opened, leading to a continuous updating of all the 
bioinformatic programs including those I described in this manuscript.  
The road to personal genomics is still hard and long, but I will work for it!  
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